University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2018

Platelet Factor 4 And Von Willebrand Factor Form An
Immunogenic, Prothrombotic Complex In Heparin-Induced
Thrombocytopenia
Ian Johnston
University of Pennsylvania, IanJohnston32@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Pharmacology Commons

Recommended Citation
Johnston, Ian, "Platelet Factor 4 And Von Willebrand Factor Form An Immunogenic, Prothrombotic
Complex In Heparin-Induced Thrombocytopenia" (2018). Publicly Accessible Penn Dissertations. 2907.
https://repository.upenn.edu/edissertations/2907

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2907
For more information, please contact repository@pobox.upenn.edu.

Platelet Factor 4 And Von Willebrand Factor Form An Immunogenic,
Prothrombotic Complex In Heparin-Induced Thrombocytopenia
Abstract
Heparin-induced thrombocytopenia (HIT) is a prothrombotic, thrombocytopenic disorder that occurs in
patients exposed to heparin due to the development of antibodies directed against complexes of platelet
factor 4 (PF4) with heparin with other polyanions . We have recently shown that the perithrombus
endothelium is targeted in HIT. Using a photochemical injury model and an endothelialized microfluidic
system, we now show that PF4 binds to elongated strands of von Willebrand factor (VWF) released from
injured endothelium. This binding appears to be periodic along the VWF strand and to favor larger VWF
strands, suggesting formation of oligomers that may cross-link individual VWF subunits. KKO, a
monoclonal HIT-like antibody, and HIT patient plasma form PF4-VWF-HIT antibody complexes that may
stabilize the complexes which, in turn, avidly bind platelets, exacerbating thrombus growth in a human
whole blood microfluidic system. This increase in platelet binding is attenuated by blocking either the
platelet FcRIIA or the glycoprotein Ib/IX receptor. Charge-based as well as VWF-binding drugs can
disrupt the PF4-VWF-HIT complexes. Dynamic light scattering studies provide additional support for the
concept that PF4 and VWF form complexes in vitro. In vivo studies in a passive immunization model of
HIT indicate a potential role for VWF in the prothrombotic nature of HIT. Thus, these studies newly identify
VWF as a potentially important polymer involved in the formation of HIT antigenic complexes that
contribute to the prothrombotic nature of HIT and offer a potential new therapeutic target to mitigate the
thrombotic complications of affected patients.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Pharmacology

First Advisor
Mortimer Poncz

Second Advisor
Lawrence F. Brass

Subject Categories
Pharmacology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2907

PLATELET FACTOR 4 AND VON WILLEBRAND FACTOR FORM AN IMMUNOGENIC,
PROTHROMBOTIC COMPLEX IN HEPARIN-INDUCED THROMBOCYTOPENIA
Ian Johnston
A DISSERTATION
in
Pharmacology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2018

Supervisor of Dissertation

_________________________
Mortimer Poncz
M.D., Professor of Pharmacology and Pediatrics

Graduate Group Chairperson
_________________________
Julie A. Blendy, Ph.D., Professor of Pharmacology

Dissertation Committee
Lawrence F. Brass, M.D., PhD., Professor of Pharmacology and Medicine (Chair)
John W. Weisel, PhD., Professor of Cell and Developmental Biology
Doug B. Cines, M.D., Professor of Pathology and Laboratory Medicine
Robert J. Levy, M.D., Professor of Pediatric Cardiology

i

Dedication page
I dedicate this work to my wife, Courtney, whose love and support made all of this possible.

ii

ACKNOWLEDGMENT
I’d like to thank Dr. Mortimer Poncz for his guidance and support. He allowed me to integrate my
engineering background with the biology of the lab and venture into very interesting scientific
realms. This translated into various conference presentations and collaborations that weren’t
always available to other graduate students. So I thank him for these opportunities as I know they
will be valuable to my future career. I’d also like to thank my thesis committee members, Dr. Skip
Brass, Dr. Doug Cines, Dr. John Weisel, and Dr. Robert Levy. Their input provided the extra push
which helped me overcome the challenges of graduate school and helped me hone the skills I’ll
use for years to come.

I’d also like to thank Dr. Carlos Villa, Dr. Colin Greineder, and Dr. Jacob Myerson from the
Muzykantov Lab. Their collaborations helped broaden my view of science and research and were
essential to the development of the microfluidic model.

Lastly, I’d like to thank a few members of the Poncz lab. I’d like to thank Dr. Randy Lyde and
Vincent Hayes for their friendship and support during graduate school.

iii

ABSTRACT

PLATELET FACTOR 4 AND VON WILLEBRAND FACTOR FORM AN IMMUNOGENIC,
PROTHROMBOTIC COMPLEX IN HEPARIN-INDUCED THROMBOCYTOPENIA
Ian H. Johnston
Mortimer Poncz, M.D.
Heparin-induced thrombocytopenia (HIT) is a prothrombotic, thrombocytopenic disorder that
occurs in patients exposed to heparin due to the development of antibodies directed against
complexes of platelet factor 4 (PF4) with heparin with other polyanions . We have recently shown
that the perithrombus endothelium is targeted in HIT. Using a photochemical injury model and an
endothelialized microfluidic system, we now show that PF4 binds to elongated strands of von
Willebrand factor (VWF) released from injured endothelium. This binding appears to be periodic
along the VWF strand and to favor larger VWF strands, suggesting formation of oligomers that may
cross-link individual VWF subunits. KKO, a monoclonal HIT-like antibody, and HIT patient plasma
form PF4-VWF-HIT antibody complexes that may stabilize the complexes which, in turn, avidly bind
platelets, exacerbating thrombus growth in a human whole blood microfluidic system. This increase
in platelet binding is attenuated by blocking either the platelet FcRIIA or the glycoprotein Ib/IX
receptor. Charge-based as well as VWF-binding drugs can disrupt the PF4-VWF-HIT complexes.
Dynamic light scattering studies provide additional support for the concept that PF4 and VWF form
complexes in vitro. In vivo studies in a passive immunization model of HIT indicate a potential role
for VWF in the prothrombotic nature of HIT. Thus, these studies newly identify VWF as a potentially
important polymer involved in the formation of HIT antigenic complexes that contribute to the
prothrombotic nature of HIT and offer a potential new therapeutic target to mitigate the thrombotic
complications of affected patients.
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CHAPTER 1 - Introduction

1

Hemostasis: Pro-coagulative Factors
Hemostasis can be seen as the crucial balance between pro-coagulative and anticoagulative processes present on and within the vasculature. On the pro-coagulative side,
hemostasis assures that minor vascular injuries are sealed by platelets (platelets)
preventing unnecessary blood loss. On the anti-coagulative side, hemostasis assures that
excessive platelet accumulation or clot formation is mitigated to a level that sustains blood
flow through an injured vessel1,2. Pro-coagulative processes are driven in large part by the
serine protease thrombin (activated Factor (F) II, IIa or FIIa), a pivotal component of the
coagulation cascade. This cascade consists of a series of zymogens that when activated,
cleave and activate subsequent zymogens culminating in FIIa. The “intrinsic” pathway of
this cascade leading to IIa initiates with the activation of the plasma zymogen FXII bound
to a negatively-charged surface, e.g. a catheter, within the vascular lumen. Alternately,
the “extrinsic” pathway is activated via FVII binding the transmembrane receptor, tissue
factor (TF), which normally sequestered from the cell surface3–5. In either case, FIIa leads
to a positive feedback loop by activating FV, FVII and FXI, which generates additional FIIa
(Figure 1.1). FIIa ultimately promotes coagulation via direct and indirect pathways.
Directly, FIIa cleaves the plasma protein fibrinogen, which generates fibrin monomers that
polymerize and constitute most of the protein mass within fibrin clots. Indirectly, FIIa
activate platelets by cleaving protease-activated receptors (PAR) PAR-1 and PAR-4, and
activates endothelial cells (ECs) via PAR-1, generating inflammatory cytokines in addition
to promoting coagulation2,6,7.
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Hemostasis: Anti-coagulative Factors
ECs lining the vasculature have a major role in preventing undesirable clot
formation (Figure 1.2). ECs release prostacyclin (PGI2), nitric oxide (NO), and cluster of
differentiation (CD) 39 which down-regulate platelet activation within a healthy vascular
lumen8–11. Additionally, ECs are covered with a layer termed the glycocalyx, a negatively
charged meshwork composed of glycoproteins and glycolipids that provide a protective
coating to the vascular wall, by repelling inadvertent interactions of blood cells with the
vascular surface12–17. EC’s also express thrombomodulin (TM), a multidomain
transmembrane glycoprotein that binds FIIa, inhibiting its capacity to cleave fibrinogen and
activate platelets. Binding of FIIa of TM catalyzes (>1000-fold) the formation of activation
Protein C (APC) from Protein C (PC). When bound to its cofactor, Protein S, APC reduces
FIIa production indirectly by inactivating the upstream enzymes, FVa and FVIIIa. PC also
interacts with the PC binding receptor (EPCR) expressed on the EC surface that causes
a 20-fold increase in APC production. APC is capable of detaching from this complex and
imposing the previously mentioned anti-coagulative effects; alternatively, while still bound,
APC is capable of inducing cytoprotective effects including dampening inflammation and
improving endothelial barrier function via PAR-1. This improved EC barrier contributes to
APC’s anti-coagulative effects by reducing the production of pro-coagulative EC surfaces
and access to the pro-coagulative extracellular matrix (ECM)2,8,18–22. EC’s also produce
tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1); tPA
cleaves plasminogen into plasmin which is responsible for lysis of fibrin clots. On the other
hand, inhibition of tPA by PAI-1 prevents premature clot lysis. APC also inhibits PAI-1
allowing for greater tPA activation of plasmin23–25.
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Under physiological conditions, in which minor injuries or damage occurs,
hemostasis is maintained within the vasculature by a balance between these pro- and
anti-coagulative processes, allowing clot formation where and only as long as it is needed.

Thrombosis
Thrombosis is an imbalance of these pro- and anti-coagulative factors on a local
or systemic level favoring clot formation. An imbalance leading to thrombosis can be
caused by a variety of ailments which include, but are not limited to, significant vascular
damage, an excessive immune (antibody) or inflammatory response26–28. In any of these
scenarios, significant changes occur in the microenvironment of the blood vessel
promoting pro-coagulant processes (Figure 1.3).
When ECs are activated they shed or endocytose TM and suppress EPCR
expression19,22,29–33. This decreases APC production leading to an increase in FIIa with the
effects on coagulation mentioned above. Excess FIIa also enhances PAR 1 cleavage
leading to increased endothelial inflammatory responses and a decrease in EC barrier
function21. Moreover, the lack of APC minimizes the inhibition of PAI-1, while increased
FIIa increases PAI-1 production. Increased PAI-1 significantly inhibits tPA activity, leading
to greater fibrin clot stability. Additionally, activated ECs express intracellular adhesion
molecule 1 (ICAM-1) and vascular cell adhesion molecule (VCAM-1) adhesion proteins
that promote white blood cell binding which further enhance EC activation16,26,34.
Furthermore, ECs begin to develop additional pro-coagulative properties such as
expression of TF and release of VWF. TF contributes through its previously mentioned
function of binding FVIIa and increasing FIIa production. VWF, a multimeric glycoprotein,
is released from the Weibel-Palade bodies within ECs and helps to stabilize FVIII and
promote platelet adhesion under high shear stresses35–38. Lastly, the glycocalyx, which
4

normally provides a thick, negatively charged mesh can become damaged or partially
shed from the EC surface. This allows greater access to the EC surface and greater
interaction of plasma proteins and circulating cells with the glycosaminoglycan (GAG) that
make up the glycocalyx; both of these can contribute to pro-coagulative processes by colocalizing blood cells and cytokines to the EC wall leading to cell activation12,16,17.
Platelets play a significant role in hemostasis and, consequently, thrombosis. As
mentioned previously, platelets transiently bind VWF released from injured ECs via their
membrane receptor, GPIb-IX-V, which slows down platelet rolling along the vascular
surface. These transiently bound platelets then can undergo activation by interaction with
the receptor GPVI, commonly associated with collagen. Platelets also can link other
platelets via their integrin αIIbβ3, which can bind fibrin or collagen leading to platelet
activation. As mentioned previously, platelets are also activated by thrombin1,8. In any
setting, platelets an also be fully activated via their autocrine and paracrine signaling.
Activated platelets release agonists such as thrombin, TxA2, and ADP which amplify the
process by promoting the activation of surrounding platelets1,36,39,40. This creates a positive
feedback in which platelet activation leads to further platelet activation that contributes to
thrombus structure and stability. This amplification affect can be seen in the structure of
growing thombi in which platelets toward the center of a thrombi (core) are highly activated
and densely packed while the outer layers are less activated and loosely packed (Figure
1.4).

Heparin-Induced Thrombocytopenia (HIT): An Iatrogenic Prothrombotic Disease
HIT is an iatrogenic immune disorder that develops after treatment with heparin.
HIT is characterized by a fall in platelet count often accompanied by various thrombotic
complications, which include pulmonary emboli, myocardial infarction, and deep vein
5

thrombosis41–45. Recently, rare cases of HIT have been described where no prior heparin
exposure was identified46. HIT can be thought of as developing in three steps: initiation,
activation and propagation (Figure 1.5). Step 1, initiation of HIT is caused by the
introduction of heparin, a commonly used anticoagulant. Due to its highly negative charge,
heparin is able to bind the platelet-specific chemokine, platelet factor 4 (PF4, CXCL4) and
form soluble heparin/PF4 complexes. In some individuals this leads to the formation of
pathogenic HIT antibodies. This leads to the Step 2: activation, in which these HIT
antibodies bind to PF4/heparin complexes and cell surface PF4/GAGs complexes, leading
to cell activation via their surface FcIIA receptors (FcRIIA) and perhaps by complement
activation. Dermatan sulfate and heparin sulfate are among the GAGs with the highest
affinity for PF4 that can form complexes that are recognized by HIT antibodies47–49. Among
the cells expressing FcRIIA that are activated are platelets, likely accounting for the
observed thrombocytopenia, and monocytes that likely contribute to thrombosis by
expressing TF43,50,51. ECs are also activated though the lack FcRIIA, perhaps by adherent
activated platelets and leukocytes and via activation of complement42,43,52. In studies
described in Chapter 3, we demonstrate that the endothelium is an additional key target
in HIT. Thus, in Step 2, the activation of the vasculature and several intravascular lineages
can contribute to the prothrombotic nature of HIT. In Step 3, propagation of thrombosis
after discontinuation of heparin, we propose that PF4 interacts with other polymeric
molecules that allow thrombi to extend downstream of the initial thrombus. Among these
are polyphosphates released by injured/activated platelets and perhaps endothelial
cells53. Polyphosphates bind PF4 and become antigenic for the HIT-like monoclonal
antibody KKO. That they form large complexes in vitro demonstrated using dynamic light
scatter (DLS) technology.
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We have now observed while simulating HIT in a microfluidic system that PF4
bound to injured endothelium not only occurs in a diffuse fashion (likely to the glycocalyx),
but also along specific strand-like structures, which we identify in Chapter 4 as VWF. The
details of this in vitro and in vivo analysis are described as well as examining the effect of
targeted therapeutic intervention based on this approach. Another polymeric structure
identified by us to which PF4 binds are neutrophil extracellular traps (NETs) released by
activated neutrophils as described in Chapter 5. This effect appears to be more prominent
in the venous system in in vivo murine studies of HIT. Thus, the release of three polymeric
molecules will have been described that we propose as central to the propagation and the
prothrombotic nature of HIT.
The established treatments for HIT are the immediate cessation of any heparin
product and the use of direct thrombin inhibitors (DTIs), specifically lepirudin and
argatroban that bind and inhibit the prothrombotic actions of FIIa or inhibitors of FXa such
as fondaparinux, rivaraxoaban, or apixaban. These interventions are only partially
effective in decreasing morbidity and mortality from the thrombotic complications in HIT.
Such treatments also have limitations in that some require frequent monitoring, have
increased risk of bleeding, may accumulate with hepatic or renal insufficiency, and some
are associated with high cost and require hospitalization41,44,54. In Chapters 2-4 we
propose and test various novel therapeutics based on our observations on the novel new
mechanisms we describe in HIT.

HIT Modeling
The recognition that there was a clinical prothrombotic disorder in patients treated
with heparin took several decades to appreciate55. Progress was and is still limited by the
severity of illness and the complex clinical settings in which it often develops. Furthermore,
7

clinical diagnosis is challenging and the laboratory confirmation relies on functional assays
that are often limited to tertiary care centers41,44. To help gain better insight into the
pathogenesis of HIT, a passive immunization model was developed using double
transgenic mice that express human platelet IgG Fc receptor IIA FcγRIIA (present on
human but not on mouse platelets) and human PF4 (hPF4), often on a mouse PF4
knockout background43,47,56. HIT is induced by infusing KKO, a monoclonal antibody that
recognizes heparin/hPF4 and heparin-like/hPF4 complexes or HIT immunoglobulins
isolated from patients with a high likelihood of having HIT. When infused with KKO, mice
experience thrombocytopenia followed by fibrin-rich thrombi in multiple organs, including
the pulmonary vasculature. This model is used and elaborated on in the following sections
to investigate how thrombi develop in the setting of HIT. We recognize that these in vivo
studies suffer from being mostly based in the murine vasculature and coagulation system
and concerns arise over translatability to the clinic57,58. We therefore have focused on
developing an in vitro system that can be either human or murine based and that also
allows isolation and targeted manipulation of specific cellular components and combining
these components to obtain specific details of the mechanism of thrombosis in HIT. This
system, especially the use of the endothelial-lined Bioflux system where a targeted
hematoporphyrin-photochemical injury is induced in the lining, was key to many of the
observations on the role of the endothelium in HIT (Chapter 3), the prothrombotic nature
of PF4-VWF-HIT antibody complexes (Chapter 4), and the formation of PF4-NETs-HIT
antibody complexes (Chapter 5) in HIT.

Sepsis: An Immune-Based Systemic Disorder
Sepsis is a life-threatening condition characterized by impaired microclearance
combined with sustained excessive inflammation and activation of coagulation. The
8

dysregulated host response to infection leads activation of the complement system and
systemic thrombosis, among other adverse outcomes to the host. Through exposure to
the invading pathogen or the resulting inflammatory cytokine release, sepsis can interfere
with many of the previously mentioned EC-based anti-coagulant mechanisms that
normally prevent thrombosis. These include, but are not limited to, increasing TF-mediated
FIIa generation and impairing endogenous anticoagulant mechanisms and fibrin
removal33,59–62 (Figure 1.6.). During our studies into the progression of HIT, we became
interested in lessons that may be applicable to sepsis and other inflammatory thrombosis
models in which patients experienced thrombocytopenia and some develop disseminated
thrombosis. Patients often develop HIT in the setting of major surgery or widespread
inflammation as seen in the initial steps of sepsis. Moreover, sepsis and HIT each initiate
similar elaborate multicellular pathways leading to thrombosis that include activating ECs
with release of VWF, activation of neutrophils with the release of NETs, activation of
platelets and sustained progressive pathology that may worsen over the course of hours
to days33,59–62. Consequently, with collaborators, we developed a microfluidic model of
inflammatory thrombosis (Chapter 2) and investigated a novel ICAM-1 targeted TM
therapeutic to combat the formation of fibrin clots (Chapter 6). This allowed us to better
understand how ECs change in the setting of inflammation and determine if said changes
could be used to develop new approaches to therapy, especially those that could be used
in combination with currently employed approaches to treatment with maximally tolerated
anti-thrombotic drugs.

Summary
Our incomplete understanding of how thrombosis in HIT is propagated and
sustained even when heparin is withdrawn and even when maximally tolerated
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antithrombotic therapy is employed creates a need to see if potential avenues for
treatment have been overlooked. Furthermore, with only murine models available, there
are intricacies of the pathogenesis that are difficult to investigate without incorporating
human ECs. Consequently, this thesis aims to address these shortcomings in several
ways. First, we used an in vivo laser injury model of HIT in mice to inform the development
of a “humanized” in vitro microfluidic model (Chapter 2). Chapter 3 summarizes an in vivo
murine model of HIT that provided the framework for the questions then addressed in the
“humanized” setting. Chapter 3 describes the proclivity of PF4 and HIT antibody to interact
with the perithrombus ECs both upstream and downstream of an initial injury site. This
understanding of ECs involvement led to developing an in vitro microfluidic model using
human blood that demonstrated similar patterns of PF4 binding to the surface of ECs.
With this new understanding concerning the importance of ECs to the formation of PF4HIT antibody complexes, Chapter 4 and Chapter 5 summarize our understandings of how
vascular and intravasular cells and proteins contribute to the pathogenesis of HIT. Chapter
4 summarizes our finding that VWF released from injured ECs may contribute to HIT by
forming PF4-VWF-HIT antibody complexes. In vitro work displays how these complexes
induce greater platelet accumulation that is both FcRIIA and GPIb dependent. We also
showed that VWF targeted therapeutics disrupted these complexes and, in an in vivo
setting, attenuated thrombosis enhanced by HIT antibodies. Chapter 5 summarizes how
activated neutrophils release NETs that present an additional site on which PF4-HIT
antibody complexes form. In vitro microfluidic work in this chapter displays how the
presence of PF4 impacts NET conformation and causes resistance to deoxyribonuclease
I (DNase I). The work is translated in vivo showing a significant contribution of neutrophils
to venous thrombi in a model of HIT through increased neutrophil-EC adhesion and
neutrophil infiltrations of thrombi leading to even greater cell activation. Considering the
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impact of inflammation on HIT, Chapter 6 summarizes the use of the inflammatory
thrombosis model described in Chapter 2 to investigate EC activation as well as a novel
therapeutic. Chapter 6 presents data from a humanized microfluidic setting that help to
evaluate the changes in EC protein expression, fibrin deposition, and thrombi formation
that can occur in the inflammation that accompanies HIT or the similar pathology seen in
some cases of sepsis. Moreover, this chapter provides insight into the use of a novel
ICAM-1 targeted TM therapeutic. This thesis culminates with Chapter 7 presenting the
conclusions, clinical impacts, and future directions for the described studies.
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Figures

Figure 1.1. The coagulation cascade produces fibrin clots via production of FIIa and
various positive feedback loops.
Binding FXII to a negatively charged surface accelerates its autoactivation which
generates XIIa which cleaves FXI to FXIa, which initiates the intrinsic pathway. Highmolecular-weight kininogen (HMWK) and prekallikrein (Pre-K) accelerate these initial
activation steps. Kal =kallikrein. Binding of FVII/FVIIa to TF localizes FVIIa, initiating the
extrinsic pathway. Each of these contributes to the activation of subsequent zymogens,
including FXa, which is directly responsible for the activating FII. FIIa cleaves fibrinogen
into fibrin, while also activating FXIII which further assists in clot stability. FIIa indirectly
contributes by feeding back into the activation of FVIIIa and FVa. Image adapted from
drawing presented by Professor Dzung Le at UCSD Clinical Chemistry Conference,
October 2014.
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Figure 1.2. Quiescent ECs provide anti-thrombotic activity.
The antithrombotic effects of the TM/APC pathways and quiescent ECs. Quiescent ECs
release PGI2, NO, and CD39 to limit platelet activation. TM binds and lessens FIIa
mediated conversion of fibrinogen to fibrin by forming a complex which increases APC
production. APC can stay bound to EPCR and cleave PAR-1 on ECs leading to improved
cytoprotection and enhanced barrier function. APC can also inactivate FVa and FVIIIa and
also inhibit PAI-1 allowing for tPA to more effectively cleave fibrin clots. i-IIa/ i-Va/ i-VIIIa
= inactivated enzymes.
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Figure 1.3. EC activation promotes pro-thrombotic activity.
When ECs experience significant damage, they promote pro-coagulative effects that
contribute to thrombosis. ECs release VWF which bind platelets under high-shear stresses
and express TF, which promote additional FIIa production. FIIa can also cleave PAR-1
leading to increased inflammation and reduced cell-barrier function. Additionally, ECs
shed or endocytose their TM and suppress their EPCR in the setting of inflammation. This
allows for greater increases in FIIa and greatly relinquishes the anti-coagulative impact of
APC.
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Figure 1.4. The gradient of platelet activation that occurs within a clot.
(A) Displays the presence of a highly activated, densely packed platelet core that is
overlaid with a loosely packed shell of less activated platelets with an intermediate
transition zone. (B) As with the gradient of platelet activation, there is a gradient of agonists
with thrombin being focused at the sight of injury while ADP and TxA 2 persist in the
transition zone and outward to the thrombi shell. (C) Displays how the high density of
platelets in the thrombus core provide low transport and high solute retention while the
outer shells provide high transport with low solute retention. Image taken from Brass LF,
et al. 2016 Blood Advances.
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Figure 1.5. Proposed sequential steps in the development of prothrombotic
pathways in HIT.
Step 1. HIT is initiated by ultralarge immune complexes composed of heparin/PF4 and
HIT antibody (left). Step 2. PF4 also bind to GAGs on the surface of (intra)vascular and
cells leading to the activation of platelets, monocytes, ECs, and neutrophils via FcRIIa
and/or complement pathways. Step 3. ECs activated by immune complexes release VWF,
neutrophils release DNA in the form of NETs and diverse cell types release PPs, each of
which combines with PF4 to form antigenic complexes that amplify and propagate the
thrombus downstream. Studies of novel Step 3 pathways, focused on NETs, but especially
VWF, form the core of this thesis.
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Figure 1.6. Sepsis promotes thrombosis by disturbing the normal balance between
pro and anti-coagulant mechanisms.
Sepsis promotes thrombosis by activating various cells including ECs via inflammatory
cytokines such as TNF-α and IL-1β which results in the increase of TF expression. Sepsis
causes a decrease in PC and subsequently APC further bolstering TF production. The
activation of ECs under septic conditions causes a reduction in TM which furthers the lack
of APC production. Sepsis both directly and indirectly, through APC reduction, causes an
increase in PAI-1 which further promotes thrombosis. Image taken from Cohen J, 2002,
Nature.
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CHAPTER 2 – Microfluidic system modeling

This chapter presents work featured in the articles:
Hayes, et al., (2017) Journal of Clinical Investigation 127(3):1090-1098
Greineder, C., Johnston, I., et al. (2017) Blood Advances 1(18): 1452-1465
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Motivation for Developing an Endothelialized Microfluidic System
In the Introduction, I discussed the limitations of the passive immunization murine
model for mechanistic studies of HIT, including that it is limited to a mostly murine system
and the difficulties with manipulating individual lineages56–58. Although platelets and
monocytes have been shown to be significant contributors to the pathogenesis in HIT, the
contribution of ECs was less developed43,50,53,63. Consequently, the motivation for these
studies was to investigate avenues through which ECs, particularly following vascular
injury, contribute to HIT pathogenesis. Understanding these factors could provide valuable
insight into why thrombosis in HIT propagates in the vasculature, forming long, plateletrich “white clots”64–67. We posited that a major contributor is the injured endothelium in HIT
and that a model system that allowed either diffuse or local endothelial injuries was
deemed necessary. For diffuse injury, we utilized a tumor-necrosis factor alpha (TNFα)
injury, which we found leads to increased platelet and neutrophil binding to the
endothelium in the presence of PF4 and HIT antibodies26,51,68. We utilized a previously
described hematoporphyrin-induced photochemical endothelial injury to establish a
focused, localized injury69,70. Such an injury did not result in endothelial loss from the
microfluidic device or loss of apparent cell-cell contact. Pursuing these studies not only
provided greater insight into pathogenesis of HIT, but also novel therapeutic avenues
based on those mechanisms to limit HIT-associated thrombosis.

Microfluidic Device and Setup
This chapter will focus on the description and characterization of that microfluidic
model. The model used the Fluxion Bioflux 1000 microfluidic platform with micro-channels
connecting corresponding wells that allows for the infusion of reagents via an air pressure
mechanism. The walls of the vessel lumen are composed of the polymer
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polydimethylsiloxane while the bottom of the plate is a glass cover slip allowing for
visualization of the channel in real time. This additionally allows, in most cases, for coating
with an extracellular matrix alone or with subsequent ECs (Figure 2.1). Throughout the
following chapters, this model was used to provide a human cell-based in vitro system that
incorporated shear stress to better recapitulate the physiological conditions seen in the
vasculature. In some instances, the channels were only coated with fibronectin (50 µg/ml,
Sigma-Aldrich) in phosphate-buffered saline and incubated for 1 hour at 37°C. Once
coated, these channels were flowed with isolated cells, primarily neutrophils, re-calcified
human whole blood, or platelets for experimentation (Chapter 5). In other instances of
using this model, once coated with fibronectin, human umbilical vein ECs (HUVECS, 6-8
x 106 cells/ml, Lonza) were infused and allowed to grow to confluency (Figure 2.2).
At confluency (3-5 days), we characterized the monolayers to understand the
quality of our in vitro “vessel”. We stained the channels (Figure 2.3) for platelet endothelial
cell adhesion molecule (PECAM-1, CD31) (rabbit anti-human CD31, abcam), actin (Alexa
Fluor 488 Phalloidin, ThermoFisher Scientific), VWF (rabbit anti-human VWF polyclonal
antibody, Dako; alternatively, FITC-sheep anti-human VWF polyclonal antibody, abcam),
P-selectin (rabbit anti-human P-selectin polyclonal antibody, abcam). PECAM-1 verified
that proper junctions were forming between ECs and that minimal spacing was found
between adjacent cells, while actin showed that the cells grew with proper cytoskeletal
support71. VWF and P-selectin staining on uninjured channels showed that the internal
structure of the ECs where Weibel-Palade bodies would be located, were quiescent as
they were punctate in nature and not seen on the surface or released from the EC
monolayer34,36,72,73. Additionally, when uninjured channels were flowed with re-calcified
human whole blood, minimal to no platelet accumulation was observed.
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Injury Settings: Hematoporphyrin-Induced Endothelial Injury
Hematoporphyrin is a heme-pathway intermediate that in porphyria cutanea tarda
is present in excess due to the absence of uroporphyrinogen decarboxylase (UROD),
resulting in a light-dependent sclerosing of tissues. Prior studies by others in a microfluidic
device induced injury to ECs using changes in pressure74, γ radiation75, hypernatremia76,
physical vascular wall puncturing77, hypoxia78, lasers (405nm)79, and localized heat80.
However, many of these injuries lacked the ability to be localized, are limited in widespread
reproducibility, and/or cannot cause EC injury without also denuding them from the
microfluidic channel wall. In our microfluidic system, we added hematoporphyrin (50 µg/ml
final concentration, Sigma-Aldrich) and illuminated a localized area of the channel to
create a demarcated region of endothelial injury. We characterized this injury model by
showing localized activation of endothelialized microfluidic channels made as described
above and in Figure 2.4 as represented by localized VWF release detected using a rabbit
polyclonal anti-human VWF antibody (DAKO) in combination with a goat anti-rabbit Alexa
Fluor secondary antibody (ThermoFisher Scientific). Additionally, we showed that ECs
were not denuded by the injury as verified by nuclei stain using Hoescht staining. The
continued presence of the endothelial lining following injury is essential for our thrombosis
studies to distinguish from binding of platelets to the underlying fibronectin-coated
channels. Moreover, when recalcified human whole blood was introduced either during or
after the injury, platelet accumulation was localized to the injured ECs, but not to the
upstream or downstream uninjured ECs. Additionally, when looking at hPF4 binding, that
it was localized to the injury area and was present on the luminal surface of ECs, but not
in the subliminal space. By altering the shutter on the microscope, we were able to alter
the radius of this injury causing it to injure more or less of the channel.
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Injury Settings: TNFα-Induced Endothelial Injury
To study HIT and the patients vascular state prior to HITs initiation, we developed
an endothelial injury within our microfluidic system that utilized the inflammatory conditions
experienced during and post-surgery. TNFα is an inflammatory cytokine primarily released
by activated macrophages that induces changes in ECs that promote thrombosis. These
include the upregulation of ICAM-1, VCAM-1, TF and the down-regulation of TM26,51,68. In
our microfluidic model, we induced an inflammatory injury by incubating our
endothelialized microfluidic channels with basal media containing TNFα (0-10 ng/ml for 06 hours) at a variety of shear stresses (1-5 dynes/cm2) We characterized this injury model
by verifying increases in the surface expression of ICAM-1 (mouse anti-human
monoclonal ICAM-1 antibody, abcam) and VCAM-1 (rabbit anti-human monoclonal
VCAM-1 antibody, abcam) when endothelialized microfluidic channels were exposed to
TNFα (Figure 2.5). We saw increases in ICAM-1 and VCAM-1 as seen under
physiological conditions. Changes in TF and TM were only slightly detectable due to low
signal to background ratio (not shown). Additionally, we verified that when recalcified
human whole blood was flowed through TNFα-activated channels, fibrin clots formed in a
time, and TNFα concentration-dependent manner.

Discussion
This chapter describes two endothelialized microfluidic systems important for my
studies of Step 3 propagation in HIT. The photochemical injury model especially allowed
me to identify VWF strands as an important target binding PF4 and forming HIT antigenic
sites that have a high affinity for binding platelets that form the core of this thesis.
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Figures

Figure 2.1. Schematic of an endothelialized Fluxion Bioflux 1000 microfluidic plate.
This microfluidic platform consists of a microfluidic channel that connects two 1 ml wells.
Using filtered air pressure infused through a pressure sealing lid, the Bioflux is able to
perfuse reagents from one well, through the endothelialized microfluidic channel, into the
“outlet” well. The bottom of the microfluidic channel is formed by a glass coverslip allowing
for real time or post-experimental imaging. In most cases, the microfluidic system is coated
in extracellular matrix alone or with subsequent ECs. Orange spheres with purple center
= ECs with nuclei; Lilac solution = reagent solution representative of various reagents
used in experiments.
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Figure 2.2. EC growth to confluency in three dimensions of the microfluidic model.
Three-dimensional (3-D) renderings from confocal images of microfluidic channels coated
with ECs showing confluency along the top and bottom of channels. Looking down the
channel (left) and looking along the bottom of the channel (right) with EC nuclei (blue,
labeled with Hoescht) and cell membranes (white, Vybrant DiD cell labeling from
ThermoFisher Scientific) microfluidic channels showing the connectivity of cell
membranes covering the underlying fibronectin coating.
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Figure 2.3. Characterization of the endothelialized microfluidic channel by
identifying key protein structures and displaying quiescence by introducing human
whole blood.
(A) Confocal images that show PECAM-1 signal around the periphery of cells indicative
of junctions forming between neighboring ECs and (B) actin throughout the cell body
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showing the forming of internal cytoskeletons as expected of healthy cells based on
previous publications. (C) P-selectin and (D) VWF are localized to the nuclei where they
are presumably stored within the Weibel-Palade Bodies of the ECs as oppose to being
released or dispersed across the EC monolayer. Nuclei stained with Hoescht (blue) are
presented in all images. (E) Fluorescently imaged stills from a 40-minute video of whole
blood being flowed through an endothelialized microfluidic channel taken at 10x. The
whole blood was labeled with calcein AM which labels platelets and white blood cells. The
stills show that after 40 minutes of blood flow, there is no significant accumulation of
platelets within the channel which is indicative of the ECs being quiescent.
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B

Figure 2.4. Hematoporphyrin injury causes a localized release of VWF leading to
localized platelet accumulation and hPF4 deposition.
(A) Endothelialized channels after an hematoporphyrin injury showing the localized
release of VWF (cyan) in the channels with minimal to no VWF release downstream.
Additionally, ECs indicated by their nuclei (blue) are shown to persist throughout the
channel after injury showing no denudation. (B) Shows that the platelet accumulation
(white) and hPF4 (green) deposited during injury of re-calcified human whole blood is
localized to the injury area in which VWF is released.
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C

Figure 2.5. Inflammatory thrombosis model displays changes in surface proteins
and fibrin deposition dependent on TNFα concentration and time of exposure.
(A) Displays fluorescent confocal images showing increases in ICAM-1 (left, green signal)
and VCAM-1 (right, red signal) in a TNFα (1-10 ng/ml) and time dependent (2-6 hours)
manner. (B and C) Displays how the accumulation of fibrin varies with (B) increasing
concentration of TNFα (1 versus 10 ng/ml, each for 6 hours) and (C) duration (4 hours
versus 6 hours, each 1 ng/ml) of TNFα preactivation; fibrin deposition occurs more quickly
with increased TNFα or prolonged channel exposure. Top panels show representative
fluorescent images at various time points. Left panels show mean fluorescent intensity
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versus time, with mean ± standard error of the mean (SEM) shown for N = 2 channels for
control (no TNF) groups and N = 3 channels for each experimental group. Right panels
shows AUC analyses. *P < 0.05 versus control; **P < 0.05 versus each other condition; #,
not significant (P = 0.14). Fibrin deposition was monitored via red fluorescent anti-fibrin
monoclonal antibody during perfusion of whole blood through TNFα-activated
endothelialized channels at shear stress of 5 dynes/cm2. Video stills taken at 10x
magnification.
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Chapter 3 – Endothelial antigen assembly leads to thrombotic complications in
heparin-induced thrombocytopenia

This chapter presents work featured in the article:
Hayes, et al., (2017) Journal of Clinical Investigation 127(3):1090-1098
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Abstract
HIT is a prothrombotic disorder initiated by antibodies against complexes between
hPF4 and heparin. A better understanding of the events in Steps 2 and 3 of HIT that start
and propagate the prothrombotic state may improve approaches to antithrombotic
management. Here, we visualized thrombus formation in an in vivo murine model and an
endothelialized microfluidic system that simulate the pathogenesis of HIT. hPF4 released
from platelets predominantly bound to peri-injury endothelium and formed HIT antigenic
complexes that were dissociated by heparin. In mice expressing both hPF4 and human
FcRIIA, infusion of KKO increased fibrin and platelet deposition at sites of injury, followed
immediately by antigen formation on proximate ECs. After a few minutes, HIT antigen was
detected within the thrombus itself at the interface between the platelet core and the
surrounding shell. We observed similar results in the humanized, endothelialized
microfluidic system. hPF4 and KKO bound preferentially to photochemically-injured
endothelium at sites where surface glycocalyx was reduced. These studies support the
concept that the perithrombus endothelium is a key site of HIT antigen assembly in Steps
2 and 3. This suggests that disrupting antigen formation along the endothelium or
protecting the endothelium may provide a therapeutic opportunity to prevent thrombotic
complications of HIT, while sparing systemic hemostatic pathways.

32

Introduction
HIT is an iatrogenic disorder initiated by antibodies directed against a complex
between a positively charged chemokine, hPF4, and heparin81 that can lead to limb- and
life-threatening arterial or venous thrombi82, which often occur at sites of vascular injury83.
HIT remains a common and serious disorder, even though the use of unfractionated
heparin has been restricted to settings such as cardiopulmonary surgery84,85, where it
remains the anticoagulant of choice86. Present-day management with intense
anticoagulation has not reduced the incidence of death or amputation, provides
substantial, but incomplete, protection against recurrent thromboembolism, and is
associated with a risk of bleeding for which antidotes are not available87. A better
understanding of the pathobiology of HIT might lead to novel disease-specific approaches
that prevent immune complex–mediated thrombus formation and propagation, with less
reliance on intense systemic anticoagulation.
We have proposed a model to help explain the inordinate risk of thrombosis in
patients with HIT compared with the thrombosis risk with other antibody-induced
thrombocytopenias50,88: PF4 released from activated platelets binds to surface GAGs on
intravascular and vascular cells. Infused heparin, which has a higher affinity for PF4 than
for other GAGs, removes surface-bound PF4, forming circulating antigenic PF4-heparin
complexes that fix complement and bind to CD21 on circulating antigen-presenting B
cells89. PF4 also forms antigenic complexes with GAGs on the surface of platelets88,
monocytes50, and neutrophils90, leading to cell activation via Fc receptors91, which
promotes the generation of thrombin and other prothrombotic pathways92.
ECs are targeted by HIT antibodies, at least in vitro93–95, but the mechanism and
in vivo relevance are unclear. The endothelium is covered by a complex surface layer
termed the glycocalyx, which contains heparan sulfate–rich proteoglycans, glycoproteins,
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and associated plasma proteins17,96 that would be predicted to bind PF4 with greater
affinity than the platelet surface. Binding of HIT antibody to cultured ECs induces platelet
adhesion and expression of TF94, but there is little direct evidence that HIT antibodies
impair the natural antithrombotic properties of the endothelium in more biologically
relevant models.
The spatial and temporal events that initiate thrombus development in HIT are not
well delineated, but are potentially of considerable import. Studies of platelet degranulation
in the cremaster arteriole laser injury model by our group and others 97–99 showed that the
release of PF4 from platelets activated within a growing thrombus is likely to develop within
the compacted core after a 2- to 3-minute delay and then expand outward99. This would
suggest that this high local concentration and sequestration of PF4 would lead to antigen
formation on platelets within the core and the surrounding shell in preference to circulating
leukocytes or endothelium and that HIT-associated antibodies must penetrate the core to
propagate platelet-mediated thrombus extension. However, in HIT, we posit that antigen
assembly occurs on multiple cell surfaces including monocytes, neutrophils, and ECs. This
difference is important, because one places the emphasis on interrupting platelet-platelet
interactions, while the other suggests the value of therapies targeted to ECs, among other
cell types.
In this study, we used a previously described passive immunization model of HIT
in mice double-transgenic for human PF4 and FcRIIA (referred to hereafter as
hPF4+/FcRIIA+)50,56 and the cremaster arteriole laser injury model100 to study in situ
thrombus development in HIT. We extended these in vivo findings by using endothelialized
microfluidic chambers, which allowed us to introduce localized hematoporphyrin-based
photochemical injury to study the contribution of activated endothelium in a humanized
system. Our data show that the perithrombus endothelium is a predominant site of HIT
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antigen formation, surprisingly at sites where the glycocalyx is depleted, followed by lower
levels of antigen expression at the interface between the thrombus core and shell. These
studies shift the focus of studies on HIT pathogenesis and intervention to factors that
regulate antigen assembly and the thrombotic consequences of antibody binding to the
endothelium, which is the core of this thesis and addressed in the subsequent chapter.

Methods
Mice and human samples.
Transgenic mice expressing platelet-specific hPF4101 (hPF4+) and/or human
FcRIIA expressing its R131 isoform102 (FcRIIA+) were studied. All transgenic mice were
on a Cxcl4–/– background103, as murine PF4 is not targeted by HIT-associated antibodies47.
This knockout setting, common to all the mice studied, is not specified hereafter. Genetic
alterations were confirmed by the appropriate PCR analyses101,102. Mice were studied at 6
to 10 weeks of age. Only male mice were studied for the cremaster vessel injuries;
however, we have not noted any prior sex difference in thrombosis in the passive
immunization HIT murine model using a photochemical injury model50.
Human blood (10–25 ml) from healthy volunteers for in vitro studies was drawn by
gravity through a 19-gauge butterfly into sodium citrate (Sigma-Aldrich; 0.38% final
concentration). Blood samples were stored at room temperature and used within 1 hour
of being drawn. Deidentified plasma samples were obtained from patients who had a high
pre-test probability of HIT on the basis of their clinical history104, a positive PF4/heparin
ELISA, and a positive serotonin release assay105. For plasma samples from healthy
donors, whole blood was centrifuged (200 g, 15 minutes), followed by centrifugation (2,000
g, 15 minutes) of the resultant platelet-rich plasma.
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Heparins, antibodies, pooled IgGs, and other labeled probes.
Unfractionated porcine heparin (BD Biosciences) and low-molecular-weight
heparin (enoxaparin; Novaplus) were used in this study. KKO, a mouse IgG 2bK antihPF4/heparin monoclonal antibody, and TRA, a monoclonal IgG isotype control antibody
47

, were purified from hybridoma supernatants. F(ab′)2 fragments of the monoclonal anti-

mouse CD41 antibody MWReg30 (BD Biosciences) were used to detect murine platelets
in the cremaster laser injury model. Anti–fibrin 59D8 monoclonal antibody was provided
by Hartmut Weiler of the BloodCenter of Wisconsin (Milwaukee, Wisconsin, USA) 106.
Annexin V labeled with Alexa Fluor 647 was purchased from ThermoFisher Scientific.
Recombinant FXa labeled with Alexa Fluor 488 was provided by Rodney Camire of the
Children’s Hospital of Philadelphia (CHOP). Mouse anti-human P-selectin antibody (clone
CTB201) was purchased from Santa Cruz Biotechnology. Polyclonal rabbit anti-human
VWF antibody was purchased from Dako. hPF4 was visualized using polyclonal rabbit
anti-hPF4 antibody (abcam). All antibodies were either labeled using Alexa Fluor
antibody–labeling kits according to the manufacturer’s instructions or species-appropriate
Alexa Fluor–conjugated secondary antibodies (all from ThermoFisher Scientific). IgG was
isolated from plasma from HIT patients and healthy donors using protein G agarose
(Pierce, ThermoFisher Scientific).

Cremaster laser injury studies.
Intravital microscopy was performed as previously described107. Vascular injury
was induced with an SRS NL100 pulsed nitrogen dye laser (440 nm) focused on the vessel
wall through the microscope objective. Arterioles of 20 to 40 μm diameter were selected,
and the laser was pulsed until the vessels were perforated and a small number of red
blood cells escaped. Antibodies and unfractionated porcine heparin were infused as 10036

μL boluses via a catheter placed into the jugular vein. Widefield and confocal microscopy
were performed as described previously98. Data were collected and widefield time-lapsed
images of platelet and fibrin accumulation were analyzed using Slidebook 6.0 (Intelligent
Imaging Innovations). Confocal Z-stacks were analyzed using Volocity 6.3 (PerkinElmer).
hPF4+, FcRIIA +, and hPF4+/ FcRIIA + mice were studied. We studied 1–10 injuries per
mouse during a maximum experimental time of 1 hour.

Endothelialized microfluidic studies.
Microfluidic studies were performed using a BioFlux 1000 Controller (Fluxion) with
an attached heating stage set to 37°C as described previously108. The BioFlux controller
was used in conjunction with a Zeiss Axio Observer Z1 inverted microscope equipped with
a motorized stage and an HXP-120 C metal halide illumination source. The microscope
and acquisition were controlled using BioFlux Montage software with a MetaMorph-based
platform (Molecular Devices). HUVECs and adult human aortic endothelial cells (both from
Lonza), at passage 3–4 (5 × 106 cells), were seeded onto fibronectin-coated (50 μg/ml,
Sigma-Aldrich) channels of 48-well BioFlux plates allowed to adhere, then cultured at 37°C
under 5% CO2 in EC growth media (Lonza) until they reached confluency.
A HIT-like state was induced by adding KKO (10 μg/ml) to sodium citrate–
anticoagulated whole blood from healthy donors immediately before infusion. Platelets in
the whole blood were labeled by incubating the blood with 2 mM calcein AM (Thermo
Fisher Scientific) for 20 minutes prior to infusion. To cause photochemical injury without
disrupting the EC lining, hematoporphyrin (50 μg/ml final concentration; Sigma-Aldrich)
was also added to the whole blood prior to infusion69. Channels were exposed to blue light
using the HXP-120 C light source with 475-nm excitation and 530-nm emission filters,
allowing real-time, concurrent visualization of calcein AM-loaded platelets and reactive
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oxygen species (ROS) generation from hematoporphyrin. An exposure time of 50 msec
at the highest intensity setting on the light source was used for all experiments. The blood
was recalcified immediately before infusion with calcium chloride (11 mM final
concentration). Infusion into endothelialized channels was done at a rate of 10 dynes/cm2.
Following injury, channels were washed with PBS and fixed with 2% paraformaldehyde
(BD Biosciences) for confocal studies of P-selectin, PF4, and KKO. To measure the
glycocalyx thickness, HUVECs lining the channels were stained with 1 μg/ml DyLight 488–
labeled Lycospersicon esculentum lectin (Vector Laboratories) for 20 minutes prior to
fixation109. EC nuclei were visualized after staining with 5 μg/ml Hoescht 33342
(ThermoFisher Scientific) for 20 minutes. Stained channels were imaged with a Zeiss LSM
710 laser scanning confocal microscope. Data were analyzed using Slidebook 6.0 for
photochemical injuries or Volocity 6.3 (PerkinElmer) for confocal images acquired after
fixation.

Statistics and human and animal Institutional permission.
Differences between 2 groups were compared using a 2-sided Student’s t test or
a Mann-Whitney U test. Differences between more than 2 groups were determined by 2way ANOVA with Sidak’s correction for multiple comparisons. Occlusion studies were
compared using a 2-sided Fisher’s exact test. Statistical analyses were performed using
Microsoft Excel 2011 and GraphPad Prism 6.0 (GraphPad Software). Differences were
considered significant when P values were less than or equal to 0.05.
All animal procedures were approved by the IACUC of the CHOP and in
accordance with NIH guidelines (Guide for the Care and Use of Laboratory Animals.
National Academies Press. 2011.) and the Animal Welfare Act. Human blood was
collected after signed, informed consent was provided by healthy donors, and approval
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for studies using human blood was obtained from the CHOP Institutional Human Review
Board in accordance with Declaration of Helsinki principles.

Results
Distribution of HIT antigen after nonimmune vascular injury in hPF4+ mice.
We previously proposed that a key step in the development HIT was the formation
of antigen that occurs when positively charged hPF4 binds to negatively charged GAGs
found on many cell surfaces88. This model predicts that HIT antigen will form at sites of
vascular injury, even in the absence of HIT-associated antibodies. We tested this
hypothesis in vivo using a cremaster arteriole laser injury model in hPF4+ mice. Following
injury, hPF4, detected using a polyclonal anti-hPF4 antibody, and HIT antigen, detected
using the HIT-like monoclonal antibody KKO47, were present almost immediately on
widefield microscopy, and the involved area expanded over the ensuing 3 minutes (Figure
3.1, A and B, respectively). This result demonstrates that hPF4 released from hPF4+
platelets as a result of thrombus formation accumulates locally in the form of PF4containing complexes that can be recognized by HIT antibody prior to the development of
HIT.
We had reported that high doses of heparin attenuated the severity of
thrombocytopenia in hPF4+/ FcRIIA + mice

88

. We postulated that this occurred because

heparin can dissociate antigenic complexes from platelet surfaces at these
concentrations88, given its higher affinity for hPF4 than for surface GAGs 110. In turn, this
generates the circulating hPF4-heparin complexes needed to induce an immune
response110,111. Therefore, we asked whether infusing unfractionated or low-molecularweight heparin into hPF4+ mice would mobilize prebound PF4 and decrease retention of
the HIT antigen at the site of thrombus formation. Binding of KKO to the site of thrombus
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formation decreased proportionally with the dose of either unfractionated heparin (Figure
3.1C) or low-molecular-weight heparin (Figure 3.2) infused into hPF4+ mice. Importantly,
however, even when mice were given 1,000 U/kg unfractionated heparin – a dose
approximately 10-fold higher than therapeutic doses
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– about 25% of the HIT antigen

remained, suggesting that the vasculature continues to be a potential target for immune
injury. Also of note, mice that did not receive heparin had the highest level of local HIT
antigenicity, with an approximate 2-fold increase in HIT antigen compared with mice
receiving a dose in the range normally given clinically (100 U/kg)113.

Study of the prothrombotic state in a murine HIT model.
We have previously shown that infusion of KKO or HIT-associated IgG (HIT-IgG)
induces thrombocytopenia and a prothrombotic state in hPF4+/ FcRIIA + mice50,56,88. We
recapitulated the prothrombotic state in the cremaster arteriole laser injury model. Injection
of KKO into hPF4+/FcRIIA+ mice enhanced platelet and fibrin accumulation in
hPF4+/FcRIIA+ mice, but not in hPF4+ mice or in hPF4+/FcRIIA+ mice exposed to the
isotype control monoclonal antibody TRA47 (Figure 3.3A).
Patients with HIT may be predisposed to develop thrombi at sites where vessels
have been injured by catheters83. To simulate this sequence in the cremaster model, we
induced a thrombus in hPF4+/FcRIIA + mice, followed 5 minutes later by infusion of KKO
or HIT-IgG. Preexisting thrombi expanded in mice given KKO or HIT-IgG, but not control
antibodies (Figure 3.3B). These data may underestimate the severity of the prothrombotic
state because virtually all the vessels became occluded, limiting further thrombus
expansion (Table 3.1). Neither TRA nor normal IgG control infusions led to renewed
growth of thrombi or vascular occlusion (Figure 3.3B and Table 3.1). Of note, thrombus
regrowth began immediately after KKO was infused, and accelerated with time,
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demonstrating that a preexisting thrombus provides a potent nidus for expansion, leading
to vascular occlusion in the setting of HIT antibodies.

Analysis of thrombus development in HIT by confocal microscopy.
To begin to understand why thrombus regrowth was enhanced in HIT, we used
confocal microscopy to examine the initial steps in thrombus formation following laserinduced arteriole injury in animals preinfused with KKO. Remarkably, the predominant site
of KKO binding was the endothelium underlying and surrounding the thrombus, extending
both upstream and downstream from the site of thrombosis (Figure 3.4A). The upstream
binding appeared to be related to turbulent blood flow in this area. By 5 minutes after
injury, KKO began to appear on platelets within the clot, which intensified over time at the
boundary between the tightly packed core and surrounding looser shell of the thrombus99
(enlarged image in Figure 3.4A and Figure 3.4B). We posit that this hemispheric zone of
antigen was formed by the slow spread of α-granule release outward within the core until
reaching the core-shell interface99. Our studies suggest that more loosely bound platelets
on the surface of the thrombus or caught in turbulent flow around the thrombus may make
a more immediate and more significant contribution to the detectable PF4 in the thrombus.
Moreover, the PF4 released from surface-bound platelets probably adheres better to the
peri-injury endothelium, with its glycocalyx, which is rich in high-affinity heparan sulfate
and dermatan sulfate96, rather than to the platelets within the thrombus that express
chondroitin sulfate on the surface, which has lower affinity for heparin114,115. The plateletbound PF4 is likely swept downstream. The overlap of injured endothelium and KKO
binding for annexin V is shown in Figure 3.4B and for FXa in Figure 3.5
Infusion of KKO prior to laser injury in hPF4+/ FcRIIA + mice further increased the
size of the platelet-rich clot, and the total amount of HIT antigen in the perithrombus
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endothelium increased by approximately 3-fold compared with that detected in controls
(Figure 3.4C). We observed similar increases in binding of annexin V and FXa to the
perithrombus endothelium, suggesting that HIT antibodies exacerbated endothelial injury
that could potentially cause a feed-forward cycle involving PF4-antigen formation,
antibody binding, new injured endothelium, and spreading thrombosis.

Microfluidic studies of thrombosis in HIT.
The in situ cremaster laser injury model enabled us to study the details of thrombus
formation. However, the model is not fully humanized, and it is difficult to deduce the
separate contributions from individual cellular components. To examine the role of the
endothelium in HIT in a fully humanized context, we utilized the endothelialized
microfluidic set up described in Chapter 2. In these studies, we utilized the microfluidic
model with the hematoporphyrin injury to induce an upstream localized injury during the
perfusion of human blood containing hematoporphyrin (Figure 3.6A). As described in
Chapter 2 and expanded on here, platelets adhered to the injured part of the channel, but
not downstream (Figure 3.6B). Released PF4 was found surrounding platelet clumps and
along the endothelium within the injured area. A decreasing gradient of PF4 binding to
“uninjured” endothelium downstream of the injury was also in evidence (Figure 3.6, B–D).
PF4 did not escape between injured ECs to the abluminal surface (Figure 3.6D), a finding
that was consistent with retention of cell-cell contact.
HIT was induced by adding KKO and hematoporphyrin to infused human whole
blood prior to photochemical injury. KKO induced a significant increase in platelet
adherence to HUVECs in the injured area compared with that observed with TRA (Figure
3.7A) and had a similar effect on similarly prepared adult human aortic endothelium
(Figure 3.8). Downstream of the injury, no difference was noted between KKO and TRA
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exposure in the uninjured endothelium (Figure 3.7B). KKO also caused an increase of
approximately 7-fold in PF4 binding to the injured endothelium compared with binding to
the uninjured area, which was accompanied by an increase of approximately 16-fold in
KKO binding to the injured endothelium compared with uninjured endothelium (Figure
3.7C). The injured endothelium showed an increase of approximately 50-fold in P-selectin
surface expression (P < 0.0001, Figure 3.7D) and a decrease of approximately 55% in
glycocalyx staining by lectin compared with uninjured endothelium (P < 0.01, Figure
3.7D). Thus, the increase in binding of PF4 to the endothelium correlated with the loss of
glycocalyx and its associated GAGs, as had been seen following other EC injuries17,116.
Consistent with the results obtained with infusion of KKO, infusion of HIT-associated IgG
(300 μg/ml) along with whole blood led to occlusion of 6 of the 6 channels studied
compared with 1 of 6 channels exposed to control IgG (P= 0.02, Table 3.1).

Discussion
HIT differs from other antibody-mediated thrombocytopenias by its propensity for
significant thromboembolism82,117. We have attributed the prothrombotic state to the
concurrent activation of multiple cell types by immune complexes. Platelets are dually
activated by immune complexes through FcRIIA91 and by monocyte-generated
thrombin108; however, to date, the proposed involvement of the endothelium is based
entirely on in vitro findings using cultured cells.
To better understand the prothrombotic nature of HIT in Steps 2 and 3 of the
proposed pathogenic pathway, we performed video examination of thrombus formation in
HIT both in vivo and in vitro. These in vivo cremaster studies involved laser-induced
thrombi rather than spontaneous thrombi, but they allowed a detailed temporal analysis of
events. We anticipate that the results of future similar studies of spontaneous thrombi in
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HIT mice would be consistent with our findings. Our in vivo studies showed that released
PF4 was associated with formation of the HIT antigen, as identified using KKO and by the
binding of HIT-IgG to every thrombus. Infused heparin stripped this bound and antigenic
PF4 away from the thrombus, decreasing surface antigenic complexes. These findings
suggest that the pathogenic contribution of heparin to the development of HIT is solely the
presentation of antigenic sites on PF4 to immunogenic cells and not enhancing the
targeting of HIT antibodies onto thrombi. Indeed, stopping heparin may pose an increased
risk of thrombosis that must be countered by instituting alternative anticoagulants118.
Our in vivo findings also showed that soon after laser injury and thrombus
formation, PF4 was localized predominantly on ECs underlying and in the immediate
vicinity of the clot. It is likely that endothelium-bound PF4 originated from transiently
adherent platelets within the thrombus “shell”99 or by platelets that had undergone
activation within areas of turbulent blood flow. Only minutes later did PF4 begin to appear
at the core-shell interface within the platelet-rich thrombus as a result of spreading
degranulation, consistent with the appearance of surface P-selectin described by several
groups98,99,119 and perhaps due to less flow-induced dissociation within the core and
transition zone within the shell of the clot99. Our studies suggest that most α-granule
proteins are released from outer layers or the exterior of the thrombus by transiently
adherent platelets. Proteins that do not have a high affinity for surrounding cell surfaces
are probably rapidly washed away, while those like PF4 may adhere to cells within or
surrounding the thrombus.
The studies in this chapter support a scenario describing the pathogenesis of HIT,
in which binding of PF4 leads to the formation of immune complexes on the endothelium,
which may enhance platelet adhesion, enhance thrombin generation, and cause the
release of additional PF4, which would sensitize the downstream endothelium and lead to
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a feed-forward pathway that propagates thrombosis. This role would implicate ECs as a
key contributor to both Steps 2 and 3 in the pathogenesis of HIT (Figure 1.5), which has
not been previously suggested. Such a phenomenon could contribute to the vessel
occlusion we observed in the HIT cremaster arteriole model (Figure 3.3B) and, as
observed by others, to the presence of platelet-rich thrombi, resulting in the alternative
name for this disorder of “white clot syndrome”65. Whether these extended clots are related
to a recruitment of undamaged endothelium in HIT needs to be examined. If this model is
correct, it will be important to identify as potential therapeutic targets the biophysical and
biochemical changes in the endothelium that promote antigen and antibody binding.
Moreover, these studies suggest that EC–targeted anti-inflammatory and antithrombotic
drugs120,121 might provide a rational intervention focused on the primary vortex of
prothrombotic reactions that lead to thrombotic vascular occlusion.
The microfluidic photochemical injury studies, while involving a more diffuse
vascular injury than did the cremaster injuries, support the conclusion that the endothelium
is a predominant initial harbor for PF4 released from activated platelets and a target for
HIT antibodies. While PF4 and KKO bind directly to platelets88, monocytes50, and
neutrophils122, we found that binding was more intense on injured ECs. This is surprising,
given that the glycocalyx is highly enriched for negatively charged side chains on its
constituent proteoglycans, syndecans, and glypicans96. These are candidate receptors for
binding PF4, and one would have expected that with their loss, PF4 binding would have
decreased. The loss of the glycocalyx involves multiple glycosidases or sheddases123. We
posited that the enhanced binding to injured glycocalyx may be due to the unveiling of a
novel high-affinity binding site in the glycocalyx or the release of novel binding molecules
from the injured endothelium that then reside in the remaining glycocalyx. Surprisingly,
when we began these studies for a specific PF4-binding target in the next chapter, we
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discovered that it was VWF that was a prime target and this novel finding serves as the
central focus of this thesis.
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Figure 3.1. Widefield cremaster laser injury in a non-HIT hPF4+ murine model: In
situ studies of hPF4 and HIT antigen distribution in thrombi.
(A) Representative widefield study of more than 10 cremaster laser injuries in hPF4+
mice, with time 0 indicating the onset of injury. Images from a video of a laser injury;
platelets are indicated in red, hPF4 is indicated in green, and the direction of blood flow
in the vessel is denoted by blue arrows. Graph shows the accumulation of platelets and
hPF4 over the study in relative value units (RVU) compared with time 0. (B) Same as in
(A), but with green showing binding of KKO to indicate the appearance of the HIT
antigen. (C) Representative images from an experimental video beginning 5 minutes
after injury, the point at which 103 U/kg heparin was infused intravenously (IV). Platelets
are indicated in red and KKO binding in green. The graph indicates that various doses
of heparin were infused beginning 5 minutes after the cremaster injury. Percent mean ±
1 SEM for binding of KKO after heparin relative to the 5-minute time point is shown. The
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dashed line represents no change in KKO binding after heparin infusion compared with
the 5-minute heparin time point. Original magnification, ×60.
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Figure 3.2. Effect of low molecular weight heparin on KKO binding to a thrombus.
Effect of various doses of low molecular weight heparin infused beginning 5 minutes
after the cremaster injury. Mean ± 1 SEM for binding of KKO after low molecular weight
heparin was infused relative to the 5-minute time point is shown. The dashed line
indicates the value of KKO binding if there were no change in KKO binding after heparin
infusion compared to the 5-minute heparin time point.
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Figure 3.3. Widefield in situ studies of the prothrombotic state in a murine HIT
model.
(A) Widefield cremaster arteriole laser injuries were performed in hPF4+/FcRIIA+ and
hPF4+ mice infused with KKO or control TRA prior to injury. Platelet accumulation is
shown on the left and fibrin on the right. Six mice from each arm were studied, and each
mouse had five to six injuries. The AUC was calculated for each injury, then compared
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between groups by a 2-tailed Mann-Whitney U test. Data represent the mean ± 1 SEM.
*P < 0.05 comparing hPF4+/FcRIIA+ plus KKO versus either other group. (B) An
experiment similar to the one depicted in (A), but the injury was performed at time 0,
and KKO (1 μg/g, IV) was infused 5 minutes later. Images are from an experimental
video, in which platelets (red) were incorporated into a thrombus 0-4 minutes before or
5-15 minutes after the infusion of KKO. Blue arrows indicate the direction of blood flow
in the arteriole; black arrow denotes the growing platelet thrombus. Graph shows the
mean values for platelet incorporation into thrombi, with a break in the data just before
5 minutes, when antibodies were infused (vertical arrow). Three injuries were studied in
each arm. Original magnification, ×60. Ctl, control.
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Figure 3.4 Confocal microscopic studies of a growing thrombus in HIT showing
perithrombotic events.
(A) Confocal microscopic images showing events in a representative cremaster arteriole
injury in an hPF4+/FcRIIA+ mouse infused with KKO. Platelets are shown in red. KKO
binding is shown in green. Images on the left are from a real time experimental video
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and include blue arrows showing the direction of blood flow. The image in the middle is
an enlargement of the 5-minute time point, clearly showing a yellow semi-circle at the
interface between the core and shell of the growing thrombus just becoming visible at 4
minutes. Images on the right show 3 different views of a 3-D reconstruction of a
thrombus, with the yellow arrow indicating the direction of blood flow. The dashed white
circle indicates the outline of the vessel. (B) Confocal microscopic images, as in (A), of
another thrombus showing platelet accumulation (red) and binding of KKO (green) as
well as staining with annexin V shown in purple as an indication of endothelial injury
(50) and overlap with KKO binding shown in white. (C) Mice were preinfused with either
KKO or TRA prior to creation of a thrombus. Binding of platelets, KKO, annexin V, and
FXa to sites of vascular injury is shown. Data from the individual studies are shown as
well as the mean ± 1 SEM (wide and narrow horizontal lines, respectively). The number
of injuries studied for each parameter is indicated. *P < 0.001 and **P < 0.0001, by 2way ANOVA. Original magnification, ×60.
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Figure 3.5. Overlap in binding of KKO and FXa as an indicator of activated
endothelium at the site of thrombosis.
(A) and (B) are confocal images of a representative cremaster laser injury thrombus in a
HIT mouse done as in Figure 3.4. (A) is the reconstructed image shown from the top/front
with KKO binding in green (top left image), FXa binding in white (top right), accumulated
platelets in red (bottom left) and a merged image (bottom right). The direction of blood
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flow is indicated by the arrows in the KKO alone image as is the magnification. A dotted
white outline of the vessel is also included in this image for better visualization. (B) is a
more lateral single cut through the same thrombus as in (A), further showing that the KKO
binding and FXa binding are at the base of the clot and overlap with directional arrows
and magnification in the top left image.
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Figure 3.6. Studies of endothelialized microfluidic channel after photochemical
injury.
(A) Schematic of microfluidic chamber with whole blood containing hematoporphyrin
flowing into an EC–lined channel, with a light source to injure the endothelium. (B)
Adhesion of platelets (red, top) and PF4 (white, bottom) at the junction between the injured
and uninjured area from a representative study with infused blood, as in (A). (C) and (D)
Confocal images of the injured endothelium. (C) Top-down image of adherent platelets
and released PF4 in the photochemically injured area. (D) Same image as in (C), in a
sagittal view. Original magnification, ×10 (B) and ×40 (C) and (D).
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Figure 3.7. Studies of HIT in the endothelialized microfluidic channel photochemical
injury system.
(A) Platelet accumulation along HUVECs after photochemical injury perfused for 15
minutes with whole human blood containing either KKO or TRA. Data represent the mean
± 1 SEM. *P < 0.0001, for KKO versus TRA exposure by 2-tailed Student t test. (B) Images
demonstrate platelets bound to representative fields of photochemically injured and
uninjured areas of the channels shown in (A) from whole blood containing TRA or KKO.
(C) Images of representative uninjured and injured areas and graphs of overall
comparative measurements showing enhanced binding in injured versus uninjured areas
of PF4 (white) and KKO binding (green) after infusion of whole blood, as in (A). The mean
relative binding for injured versus uninjured endothelium ± 1 SEM is shown. *P < 0.01 and
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**P < 0.001, by 2-sided Student’s t test for injured versus uninjured areas, with an
expectation of 1 and no change in binding (dashed line). (D) Same as in (C), except for Pselectin staining (yellow) and lectin binding (yellow) in injured endothelium versus the
downstream uninjured area. Lectin staining of the endothelium was decreased after injury.
Original magnification, ×20.
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Figure 3.8. Thrombus growth during photochemical injury in the presence of KKO.
Similar studies as in Figure 5A, but microfluidic chamber coated with adult human aortic
ECs. Platelet accumulation along endothelium after photochemical injury perfused with
whole human blood containing either KKO or TRA for 10 minutes. Mean ± 1 SEM are
shown.*P<0.01.
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Tables

Table 3.1. Secondary growth of thrombi in hPF4+/FcRIIA+ mice leading to an
occluded vessel.
Cremaster arterioles were injured by laser, and the accumulation of platelets was
assessed. Five minutes later, KKO or TRA or HIT IgG was infused IV at the indicated
dose, and the site of injury was observed. The number of injured and occluded vessels
with cessation of blood flow is indicated. ^P < 0.0001, comparing the outcome after KKO
versus TRA by 2-tailed Fisher’s exact test. BP < 0.001, comparing the outcome after HIT
IgG versus control IgG by 2-tailed Fisher’s exact test.
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CHAPTER 4 – Platelet factor 4 and von Willebrand factor form an immunogenic,
prothrombotic complex in heparin-induced thrombocytopenia

This chapter presents work featured in the article to be submitted:
Johnston, et al., (2018).
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Abstract
HIT is a prothrombotic, thrombocytopenic disorder that occurs in patients exposed
to heparin due to the development of antibodies directed against complexes of PF4 and
heparin and other polymeric molecules. We have recently shown that the perithrombus
endothelium is especially targeted in HIT. Using a photochemical injury, endothelialized
microfluidic system, we now show that PF4 selectively binds to released VWF strands on
injured endothelium. This binding appears to be periodic along the VWF strand and to
favor larger VWF strands, raising the possibility that binding of PF4 crosslinks VWF
polymers. KKO and HIT patient plasma recognize these complexes, forming PF4-VWFHIT antibody complexes, which, in turn, avidly bind platelets, exacerbating thrombus
growth in a human whole blood microfluidic system. This increase in platelet binding can
be attenuated by that blocking either the platelet FcγRIIa or the GPIb/IX receptor. HIT
antibodies may stabilize PF4-VWF complexes but charge-based approaches as well as
drugs that disrupt VWF oligomerization can disrupt PF4-VWF-HIT complexes. In vitro
studies using dynamic light scattering further support the formation of PF4-VWF
complexes. Strategies directed at blocking formation PF4-VWF complexes reduce the
prothrombotic state in a passive immunization murine model of HIT. Thus, these studies
identify VWF as a newly described and potentially important polymer on which HIT
antigenic complexes form and propagate the risk of thrombosis in HIT even when heparin
has been discontinued (Step 3). The PF4-VWF complexes contribute to the prothrombotic
nature of HIT and may provide a new therapeutic target.
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Introduction
HIT is initiated by antibodies targeted to complexes of PF4 and heparin48. HIT
antibodies, through activation of various cell types such as platelets88, monocytes50, and
ECs43,93–95 promote the limb and life-threatening pro-thrombotic environment experienced
by HIT patients. Although initiated with heparin, other polymeric molecules are capable of
binding PF4 and then being recognized by HIT antibodies, including cell surface GAGs88,
DNA124, polyphosphates53, and bacterial wall components125. Notwithstanding the recent
identification of these additional potentially antigenic sites, a more complete
understanding of their contribution to thrombosis is needed to develop alternative
treatments options for patients with or at risk for HIT41,118.
The endothelium has been recognized to bind PF4 and become activated in the
presence of HIT antibodies over thirty years ago94. We recently showed that both in vitro
in an endothelialized microfluidic chamber and in vivo in HIT cremaster laser injury studies
in a murine HIT model that HIT-like antibodies predominantly bound to peri-thrombotic
endothelium that had undergone vascular injury43. When injured, the endothelium retracts
or denudes and exposes collagen within the basal membrane52,126–128. The endothelium
also exhibits changes to its glycocalyx, including a decrease in its thickness that may
enhance access to proteins on the endothelial luminal surface14–17. Injured, activated
endothelium also may express a diverse range of new or activated receptors and ligands,
and procoagulant factors such as TF and P-selectin on their vascular luminal
surface7,34,100,129–131.
In this study, we focus on binding of PF4 to VWF, which are, in part, stored within
Weibel-Palade bodies in resting endothelial cells and which are released following EC
activation or injury40,72,132. Initial studies focused on our previously described
endothelialized microfluidic model wherein we induced a localized photochemical injury
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using hematoporphyrin69,70. Prior studies have shown that these injured endothelial cells
release VWF as elongated strands under the influence of shear induced by flow43. We
now find that these VWF strands bind PF4 and subsequently HIT antibodies. We show
that in this model, platelets bind to these PF4-VWF-HIT antibody complexes and that this
binding could be reduced by the FcRIIA-blocking antibody IV.388,122,133 as well as the
GPIb-blocking antibody AK236,134,135. In vitro studies using dynamic light scattering
confirms the formation of PF4-VWF complexes. In a passive immunization murine model
of HIT, photochemical injury to the carotid affirms the development of PF4-VWF-HIT
antibody complexes and their contribution to thrombosis. These studies provide new
insights into the prothrombotic pathways activated in HIT and extend the number of
pathobiological polymeric molecules that can contribute to Step 3 in the propagation of
thrombi in HIT. The clinical implications of these findings are discussed.

Methods
Human blood samples.
Deidentified samples of whole blood from healthy human volunteers with no history
of a bleeding diathesis or known use of medications with anticoagulant effects was drawn
by gravity through 19-gauge butterfly needles into sodium citrate (0.38% final
concentration, ThermoFisher Scientific). Blood samples were maintained at room
temperature and used within 1 hour of being drawn. Deidentified plasma samples were
also obtained from patients determined to have HIT based on a combination of clinical
assessment, HIT ELISA positivity, and positive serotonin-release assay (SRA) as
described previously44,104,105. Similar samples from patients with low probability of HIT
based on history and negative ELISA and SRA results were used as negative controls.
Deidentified HUVEC (referred to ECs) were purchased (Lonza). Human blood samples
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were collected after signed, informed consent from healthy donors. Approval for these
studies was obtained from the CHOP Institutional Human Review Board in accord with the
Helsinki Principles.

Mice and mouse blood samples.
Wildtype C57Bl6 mice and transgenic mice on a Cxcr4 gene knockout
background103, were studied. These double-transgenic mice, previously termed “HIT
mice”, develop thrombocytopenia and a prothrombotic state when injected with the HITlike antibody murine monoclonal antibody KKO or IgG isolated from patients with HIT in a
passive immunization model of HIT56,88.

Recombinant proteins and antibodies.
Recombinant hPF4 was isolated from S2 cell media using the Drosophila
Expression System (Invitrogen), purified, and characterized as described47,136. Final
protein concentrations were determined using the bicinchoninic acid protein assay
(Pierce) using bovine serum albumin (BSA) as the standard. KKO, the mouse anti-hPF4heparin HIT-like monoclonal antibody, and TRA, a monoclonal IgG isotype control
antibody, were purified from hybridoma supernatants47. Antibodies used in these studies
also included a polyclonal rabbit anti-hPF4 antibody (Abcam), a polyclonal rabbit antihuman VWF (hVWF) antibody (DAKO) or a FITC-prelabeled polyclonal sheep anti-hVWF
antibody (Abcam). Bound HIT-patient IgG was detected using a rabbit polyclonal, antihuman IgG antibody (Jackson Immuno Research Laboratories). All antibodies were either
labeled using Alexa Fluor antibody-labeling kits (ThermoFisher Scientific) or were
detected using species-appropriate Alexa Fluor-conjugated secondary antibodies (all from
ThermoFisher Scientific). The FcRIIA-blocking monoclonal antibody IV.388,122,133 was
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produced in hybridoma cells and purified on Protein G (Invitrogen). The mouse anti-human
CD42b monoclonal antibody AK2 was purchased from Biorad.

Endothelialized microfluidic setting.
Endothelialized microfluidic studies were performed as we described previously43
and in Chapter 2. Briefly, studies were performed using the Bioflux 1000 Controller system
with an attached 37°C heating stage. The microscope was equipped with a motorized
stage and an HXP 120 C metal halide illumination source. 48-well Bioflux plates were
coated with fibronectin (50 µg/ml, Sigma-Aldrich), seeded with HUVECs (passage 3-4, 68 x 106 cells) that were allowed to adhere and cultured at 37°C under 5% CO2 in EC growth
media (Lonza; basal culture medium (BCM) bovine brain extract with heparin, human
endothelial growth factor, hydrocortisone, ascorbic acid, gentamicin, amphotericin B, fetal
bovine serum) until confluent. To induce a photochemical injury, hematoporphyrin (50
µg/ml final concentration, Sigma-Aldrich) was added to samples and exposed to a blue
light using the HXP-120 C light source with a 475-nm excitation and 530-nm emission filter
for 20-30 seconds during perfusion causing a reactive oxygen species injury43,70. PF4 and
VWF were detected using Alexa Fluor-labeled antibodies. Endothelial cell nuclei were
labeled with Hoescht 33342 (ThermoFisher Scientific) for 15 minutes at room temperature.
On the day of experimentation, BCM (described above) was flowed over the channels for
3-4 hours prior to the experiment. All imaging was performed on a Zeiss Axio Observer
Z1 inverted microscope or a Zeiss LSM 710 laser scanning confocal microscope as
described43. Data was analyzed using Imagej or, for confocal images, using Volocity 6.3.
Colocalization of fluorescent signals was analyzed using a built-in function of Volocity 6.3
providing Coste’s colocalization coefficients.
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Analysis of PF4-VWF-HIT antibody complexes.
All experimental solutions were made in BCM. A localized photochemical injury
was induced using hematoporphyrin and then the channels were washed with BCM and
then infused with hPF4 (0-25 µg/ml) in BCM for 10 minutes. In some experiments, at the
10-minute mark, KKO or TRA (each at 10 µg/ml) or plasma from HIT patients (1:100
dilution) or a polyclonal rabbit anti-hPF4 antibody (at 2 µg/ml final concentration,
PeproTech) was added to the PF4 solution and allowed to flow continuously for an
additional 10 minutes. After a total flow time of 20 minutes, channels were briefly washed
with BCM, and then fixed for 15 minutes at room temperature with Cytofix Fixation Buffer
(BD).
Experiments were performed to determine if PF4 bound primarily to VWF released
from injured ECs or to plasma VWF. Once VWF-PF4-KKO complexes were formed, a
BCM solution containing BSA (equimolar to 10 µg/ml of VWF, Sigma-Aldrich) or purified
human VWF (10 µg/ml final concentration, Haematologic Technologies, Inc.), was flowed
through the channels. Channels were fixed, labeled for VWF, PF4, and KKO, and binding
was quantified via confocal imaging to determine how the protein solutions flowed through
the channels affected formation of VWF-PF4-KKO complexes.
To examine the effects of drugs known to cleave strands of VWF or drugs known
to strip PF4 from vascular surfaces, channels with formed PF4-VWF-HIT antibody
complexes were exposed to various interventions; channels were flowed at 10 dynes/cm2
for 10 minutes with therapeutics including unfractionated porcine heparin (0-50 units/ml
final concentration, Novaplus), ADAMTS13 (0-7 nM, R&D Systems), and N-acetylcysteine
(NAC, 0-10 mg/ml final concentration, Auromedics). In some experiments, heparin (0-0.4
units/ml) was added to a PF4 (25 µg/ml) and KKO (10 µg/ml)-containing solution and then
introduced to channels containing PF4-VWF-HIT antibody complexes. After the 10-minute
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infusion, channels were washed with BCM, fixed with Cytofix Fixation Buffer (BD
Biosciences), and imaged to observe the presence of PF4, KKO, and/or large VWF
strands.

Platelet accumulation on PF4-VWF-HIT antibody complexes.
To track platelet accumulation by PF4-VWF-HIT antibody complexes, whole blood
from healthy volunteers was collected and labeled with calcein AM (2 µg/ml final
concentration, ThermoFisher Scientific) at room temperature for 15 minutes. Whole blood
was recalcified immediately before infusion using 2M CaCl2 (final concentration of 12 mM,
Sigma-Aldrich), and flowed through the channels at 10 dynes/cm2. Platelet accumulation
was quantified via total fluorescent intensity within the localized injury area. To test the
impact of blocking specific receptor/ligands on platelet accumulation on PF4-VWF-HIT
antibody complexes, IV.388,122,133 (20 µg/ml) and/or AK236,39,135 (60 µg/ml) were added to
whole blood and allowed to incubated for 30 minutes prior to running the experiment.

Biophysical interaction between VWF and PF4.
To further examine the physical interaction between VWF and PF4, we utilize
dynamic light scattering (DLS) analysis. Sample solutions are prepared and allowed to
mix at room temperature for 15-20 minutes. Samples (500 µL) are then transferred to zeta
disposable cuvettes (Fisherbrand) and measured in a Zetasizer Nano ZS (Malvern). In
these experiments, solutions containing hPF4 (10 µg/ml) alone, hVWF alone (0-10 µg/ml),
and solutions containing hPF4 (10 µg/ml) with various concentrations of hVWF (0-10
µg/ml) were studied. The size distribution of the resultant soluble particles was measured
as described previously53,110.
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Role of VWF in thrombosis in HIT in vivo.
Thrombosis was induced using a previously described murine model of HIT56,88 by
infusing KKO following rose bengal photochemical injury to the carotid artery25,50. HIT mice
were anesthetized using nembutal (80 mg/kg, CHOP animal facilities). Using standard
surgical methods, the left jugular vein was exposed and mice were infused with either TRA
(2 mg/kg), KKO (2 mg/kg), or KKO (2 mg/kg) + NAC (0.8 mg/g, Auromedic Pharma) in a
PBS (220 µL total volume). The injected materials were allowed to circulate for 10-15
minutes during which time the right common carotid artery was surgically exposed. Rose
Bengal (50 mg/kg, Sigma-Aldrich) was then infused and a miniature Doppler flow probe
(Model 0.5VB; Transonic Systems) was positioned around the artery. After 5 minutes of
measuring flow to assure sufficient signal, a green laser (540 nm) was targeted to the
carotid artery to induce an occlusive thrombus. Using the data points from Doppler flow
probe, we evaluated the time to occlusion (blood flow <10% of original and stable for 10
minutes), and the relative area under the curve (AUC) as measure of clot mass. When
clots were formed and stable for greater than 10 minutes, measurements were stopped
and mice euthanized; if vessel occlusion did not occur, experiments were ceased at a 2hour time point. When mice were euthanized prior to the 2-hour time point, the final flow
measurements were extrapolated to estimate AUC.

Statistics.
Differences between 2 groups were compared using a 2-sided Student’s t-test.
Differences between more than 2 groups were determined by 1-way ANOVA. All analyses
were performed on GraphPad Prism 6.0 (GraphPad Software). Differences were
considered significant when the P values were less than or equal to 0.05.
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Results
PF4 binds to elongated strands of VWF released from injured endothelial cells in a
microfluidic system.
We described how PF4 released from activated platelets bound predominantly to
peri-injured endothelium in both the endothelialized microfluidic and in an vivo murine
model of HIT43 in Chapter 3; however, the target(s) to which the PF4 bound and
subsequently HIT-like antibodies bound, was not identified. To begin to explore the
potential PF4-binding sites on injured endothelium, we utilized the hematoporphyrin injury
model in a HUVEC endothelialized microfluidic model. This model enables us to explore
a human endothelial surface, to control the composition of the thrombus, and to contrast
binding to injured and adjacent uninjured endothelium (Figure 4.1A). As previously
described, this photochemical injury model does not cause the endothelium to detach or
to lose cell-cell contact43. VWF was clearly released within the injured zone (Figure 4.1B).
Post-injury, solutions containing recombinant hPF4 were flowed across channels. The
most extensive binding of hPF4 was restricted to the injured area, less so in the immediate
downstream region, and was at near-background levels further downstream (Figures
4.1C and 4.1D). Binding of PF4 within these regions typically followed a linear pattern,
remarkably similar to the pattern of VWF following release from endothelial cells.
Therefore, we asked whether the PF4 was indeed binding to the released VWF. Costaining for VWF and PF4 showed significant (P=0.02) co-incidental binding as seen in
enlarged images (Figure 4.2A). PF4 bound preferentially to the most elongated strands
of VWF (Figure 4.2B and 4.2C).

A HIT-like monoclonal antibody and HIT patient IgGs bind PF4-VWF complexes in vitro.
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PF4 binds to polymeric molecules other than heparin, including various
glycoasminoglycans (GAGs)47, DNA and RNA aptamers124, and polyphosphates53. All of
these complexes are also antigenic for HIT-like antibodies, at least in vitro. Binding of PF4
to heparin leads to the formation of high molecular weight oligomers that increase antibody
avidity47,137. To determine if PF4-VWF complexes are antigenic for HIT-like antibodies, we
induced injury in the microfluidic chambers and introduced PF4 and the HIT-like mouse
monoclonal antibody KKO, known to replicate key features of patient-derived HIT-like
antibodies47. Binding of KKO followed the same distribution seen with PF4, with both colocalizing with the strands of VWF strands released by the injured endothelium (Figure
4.3A). Binding of KKO was localized primarily to the area of endothelial injury and to the
immediately downstream region (Figure 4.3B). An enlarged image of this field (Figure
4.4A) shows that the binding of the KKO to the VWF strands follows a periodic pattern
with little KKO seen in association with smaller VWF deposits. Detailed analysis of colocalization confirmed that KKO showed significantly more binding to elongated strands of
VWF (Figure 4.4B and 4.4C).
We then asked whether plasma from patients with positive clinical histories,
ELISAs, and SRAs for HIT IgG would also bind to the PF4-VWF complexes. A
representative field of IgG binding from one HIT patient compared to a control patient with
low probability of having HIT is shown (Figure 4.3C). Three of 6 samples from patients
with HIT caused significant binding of IgG to the VWF released from injured endothelium
in the presence of added PF4 that was not seen with the control patient sample with low
probability of HIT (Figure 4.3D).

Physical characterization of the PF4-VWF complexes in vitro.
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We used DLS as an independent method to study the binding of PF4 to VWF. We
first examined the particle size of PF4 and VWF alone. PF4 followed a Gaussian-size
distribution (all less than 10 nm), while VWF displayed a more complex size distribution
consistent with its polymeric nature and tendency to polymerize138 (Figure 4.5A).
When PF4 was added to VWF (PF4:VWF = 10 µg:5 µg), particles with a single
narrow range of masses that followed a Gaussian distribution was seen. The mean mass
of PF4 ~6-fold higher than the of mass PF4 alone, clearly establishing binding between
the reactants (Figure 4.5B). When more PF4 was added (PF4:VWF = 10 µg:1 µg), the
mass of the complex increased to ~40-fold higher than PF4 alone. If using masses of PF4
tetramers and VWF monomers, it can be estimated that the molar ratio in this scenario is
about 84:1 (PF4:VWF=316 nM:3.84nM). The molar ratio of reactants cannot be more
definitively estimated, as we do not know the number of VWF monomers present in the
starting VWF, the number of molecules in an “open” (permissive) conformation (see
below) or whether PF4 enhances oligomerization of VWF in vitro. However, of possible
relevance to this issue, at the highest concentration of PF4 studied (PF4:VWF = 10 µg:10
µg), the apparent mean mass of the PF4-VWF complexes widened with an appearance
similar to that of VWF alone. One possible interpretation of these data are that over a
limited molar ratio of reactants, binding of PF4 cause reorganization of VWF multimers,
consistent with the appearance of extended strands containing PF4-VWF-KKO observed
in the microfluidic model. At higher concentrations, PF4 may bind to smaller VWF
multimers, albeit with lower affinity, which are not cross-linked in the process. This
parabolic outcome recapitulates the growth and disappearance of PF4/heparin complexes
in solution and PF4/GAG complexes on cell surfaces as the PF4/polyanion ratio
increases47,53.
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The appearance of PF4 is predominantly along elongated strands of VWF released
by activated ECs. Shear stress alters the 3-dimensional conformation of VWF exposing
its “A” domains138–140. However, we next wanted to determine if PF4 also binds to plasma
VWF or to other plasma proteins. To test this, we injured the endothelium as describe
previously and introduced PF4 and KKO to form PF4-VWF-KKO complexes. Then
channels were exposed to flowing solutions that contain BSA or purified human VWF.
Purified human VWF was used at plasma concentrations (10 µg/ml) and BSA was used
an equimolar concentration. PF4 and KKO binding was assessed by confocal microscopy
to determine if soluble VWF or BSA would remove complexes formed on released VWF
compared with buffer alone (Figure 4.5C). Heparin, which removes PF4-HIT antibody
complexes from other vascular surfaces43,141, was used as the positive control. Heparin,
at 10x therapeutic concentrations (4 U/ml), removed PF4-VWF-HIT antibody complexes
from the injured endothelium (Figure 4.8A). In contrast, infused BSA had minimal effect
on PF4 and KKO binding (Figure 4.5D). Soluble VWF did not elute PF4 and KKO and, in
some experiments, appeared to increase PF4 and KKO binding. This might be due to
binding of soluble VWF to unoccupied sites on PF4 and becoming incorporated within preexisting EC-VWF strands. VWF self-association has been shown to be homotypic as
soluble VWF – but not BSA – is known to associate with immobilized VWF under
flow142,143; moreover, the self-association of VWF has been shown to assemble
hemostatically active filamentous networks and induce platelet activation under
shear17,39,144–146. These findings and recent studies suggest that tethered VWF strands
released from ECs are preferentially form PF4-VWF-KKO complexes that are not removed
by soluble VWF, which may actually enhance antigen formation.
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PF4-VWF-HIT antibody complexes are prothrombotic in vitro.
Do the PF4-VWF-HIT antibody complexes contribute to the prothrombotic state
seen in HIT? Using the microfluidic system described in Figure 4.1, we show that the
endothelium needed to be injured to cause platelet accumulation upon infusion of whole
human blood (Figure 4.6A). Platelet accumulation was greatest when both PF4 and KKO
are included and coat the VWF strands (Figure 4.6B and 4.6C). Neither KKO alone nor
PF4 plus the isotype control monoclonal antibody TRA47 enhanced platelet accumulation.
Platelet accumulation in the presence of PF4- and KKO-coated VWF became more
pronounced the longer blood was infused into the channels.

We were interested in understanding which components contribute to platelet
accumulation on VWF strands. Platelets bind to shear-activated VWF via the GPIb/IX
complex, in a pathway that can be blocked by the anti-GPIb monoclonal antibody AK2.
The PF4-VWF-KKO complexes could also enhance platelet activation and adherence via
their FcRIIA, a process that can be blocked by the anti-FcRIIA monoclonal antibody IV.3.
We demonstrate that both antibodies blocked the enhanced adherence of platelets in
whole blood to the VWF strands (Figure 4.7A and 4.7B), though by 40 minutes postinfusion, blocking the GPIb/IX-VWF axis appears to be more effective. AK2 plus IV.3 was
not more effective than AK2 alone, suggesting the GPIb/IX-VWF axis plays a crucial role
in supporting the binding of platelets to the PF4-VWF-HIT antibody complex.

Drug interactions with the PF4-VWF-HIT antibody complexes in vitro.
Patients who develop HIT are often on therapeutic heparin when they develop
thrombi41,43,44. Heparin binds to PF4 with high affinity. Therapeutic heparin levels range
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from 0.1-0.4U/ml147. Therefore, we asked whether PF4-VWF-HIT antibody complexes are
stable and would persist bound to the endothelium at pharmacologic levels of heparin.
Heparin at ≥0.4 U/ml reduced PF4 and subsequent KKO binding to the VWF released
from injured endothelium in the microfluidic system within 10 minutes (Figure 4.8A).
However, during thrombus development, PF4 levels are estimated to exceed 100 µg/ml122
and are likely to be persistently released from platelets trapped with thrombi as well. To
recapitulate this setting, we tested the effect of a flowing a solution containing increasing
PF4 concentrations (0-100 µg/ml) at a fixed pharmacologic concentration of heparin (0.4
U/ml) as well as HIT antibody. As PF4 levels increased, both bound PF4 and KKO levels
increased in the presence of heparin, consistent with the known risk of continuing this
anticoagulant in patients with clinically active HIT (Figure 4.8B).
Therapeutic strategies to prevent VWF-related pathobiology have included the use
of the metalloproteinase ADAMTS13 to lyse WVF strands38,148,149 or NAC to prevent their
assembly69,150. We asked whether PF4 and or HIT antibody would cause resistance to the
effect of ADAMTS13 or NAC on reducing the number and length of extruded VWF strands
after endothelial injury in the microfluidic system. PF4 alone did not protect VWF strands
from digestion by ADAMTS13 (7 nM) when looking at the number of strands present after
flow. PF4 plus KKO showed a trend towards protection from ADAMTS13 but the effect did
not reach statistical significance in the 10 minute time frame in which experiments were
performed (Figure 4.9A and 4.9B). Neither PF4 with nor PF4 plus KKO protected VWF
from the effects of NAC (Figure 4.9A and 4.9B). There was no significant differences
between the length of VWF strands after exposure ADAMTS13 or NAC in the presence of
PF4 or PF4 plus KKO (Figure 4.9A and 4.9C).

The role of VWF in the prothrombotic HIT murine model.
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The data shown in Figure 4.9 suggest that PF4 and HIT antibody binding do not
protect released VWF strands and therefore that both VWF-targeted therapeutics have
the potential to remove PF4-VWF-KKO targets in vivo. However, we could not test this
hypothesis by imaging intra-thrombi VWF, which show diffuse staining and cannot be used
to follow the resolution of elongated strands of multimeric VWF151,152. Consequently, we
used a functional evaluation to assess the effect of NAC on thrombosis in the HIT mouse
using the rose bengal photochemical carotid arterial injury model50. We confirmed our
prior findings in this model and showed that NAC both prolonged the time to full occlusion
induced by KKO and the relative AUC (Figure 4.10A and 4.10B). Thus, it appears that
VWF contributes to arterial thrombosis in this model of HIT and suggests the utility of VWF
targeted therapeutics.

Discussion
HIT is an unusually prothrombotic disorder that can have devastating
consequences even with the withdrawal of heparin and the institution of present-day
anticoagulants41,43,44,67. While the disease clearly involves the induction of antibodies that
oligomerize PF4 with heparin and with surface GAGs on the surface of platelets, its
prothrombotic nature now is clearly recognized to be in part due to the fact that PF4 also
forms antigenic complexes with GAGs on other cells including monocytes, endothelial
cells and neutrophils, leading to the induction of prothrombotic processes43,48,50,88,93,95, e.g.
the elaboration of tissue factor94. More recent finding indicate that additional polyanions
induced by HIT antibodies can bind PF4 and serve as antigenic targets that promote
thrombus extension64–67 and propagate the disorder even when heparin has been stopped
(Step 3) (Figure 1.5). These include polyphosphates released from platelets and perhaps
endothelial cells53 DNA found in neutrophil extracellular traps (NETs) released by
77

activated neutrophils122, which appear to be especially important in the growth of venous
thrombi.
We now show that PF4 also forms antigenic complexes with VWF strands released
from activated endothelial cells, most likely localized primarily to the arterial side of the
circulation. The PF4 appears to bind periodically along the elongated strands of VWF.
Binding of HIT antibodies to PF4-VWF complexes along the vasculature likely offer an Fcrich surface that permit binding intravascular cells that express FcRIIA, including
platelets, neutrophils and monocytes47,50 and provide a surface for activating
complement89. Our result appear initially differ from a prior study showing PF4 did not
enhance binding of VWF to platelets153 but did not address whether PF4 can bind to VWF
as examined in our system. This negative result is, however, consistent with what we
report: PF4 binds selective to large VWF strands that form under flow in preference to
VWF in solution. Binding of platelets to PF4-VWF strands was markedly enhanced when
a HIT-like antibody was also present. We propose that PF4-VWF-HIT antibody complexes
activate platelets through FcRIIA which stabilizes platelet adhesion to the EC-VWF
strands under flow. (Figure 4.6 and 4.7).
Of interest, unlike other polymeric molecules like heparin and polyphosphates,
VWF is not a polyanion. The mechanism by which VWF becomes a binding site for PF4
will require additional study. We hypothesize that the binding sites within vWF are exposed
by shear forces which may also enhance their proximity and thereby enhance their avidity
for PF4. This is similar to what has been postulated for the effect of unfractionated heparin
compared with low molecular weigh heparins and fondaparinux.
NAC, which prevents VWF oligomerization150 attenuated carotid arterial occlusion
induced by HIT antibody. Unfortunately, attempts to directly visualize the released VWF
and its complex with PF4 and HIT antibodies were unsuccessful because of intense
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diffuse staining which impeded identification of individual VWF strands. Studies using
confocal microscopy are in progress in an attempt to circumvent this problem.
In summary, PF4 binds to VWF strands extruded from injured endothelial cells and
forms HIT antigenic complexes. Such targets are periodically distributed along the VWF
strands under flow conditions, but binding to soluble VWF was not observed. These
complexes bind platelets through a pathway that involves both FcRIIA- and GPIb/IXbased pathways. We propose that the release of VWF strands expose a high-density
epitope that fosters binding of PF4 and HIT antibodies and promotes binding and
activation of platelets, monocytes and neurtrophils through by their surface FcRIIA and/or
by activating complement. Depolymerization of VWF strands by NAC attenuates
thrombotic arterial occlusion induced by HIT antibodies in a mouse model. These findings
suggest that VWF may play a significant role in the propagation of HIT in space and in
time (Step 3) (Figure 1.5. VWF may thereby play a role on the arterial side of the
circulation analogous to the effect of NETs in the propagation of venular injuries, which is
addressed in Chapter 5. Drugs targeting VWF biology may be an effective new approach
to therapy in HIT, especially for arteriolar thrombi.
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Figure 4.1. PF4 binds to elongated strands of VWF released from injured ECs in a
microfluidic system.
(A) Schematic of the endothelialized microfluidic system used for photochemical injury
studies to targeted regions of the endothelium. (B) Comparison of a representative area
of uninjured endothelium and hematoporphyrin-injured inured area showing pyknotic
nuclei and released VWF strands that are only seen after injury. (C) and (D) are stained
for PF4 using a polyclonal anti-PF4 antibody as well as staining for nuclei and released
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VWF. (C) shows representative microfluidic channel injured and downstream uninjured
(DU) areas designated as DU #1 of the first 150µ downstream. Direction of flow is
indicated by arrows. (D) shows relative binding of PF4 to either an area of 250µ X 150µ
of the upstream uninjured (UU) region, the injured region, or the DU #1 and DU #2 regions.
Mean ± 1 SEM are shown with N ≥ 3 with n signifying separate microfluidic channels. P
values were determined using a one-way ANOVA analysis to compare relative binding to
the uninjured upstream area of the channel.
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Figure 4.2. PF4 preferentially binds elongated VWF strands over not-elongated.
(A) Displays an image of Figure 4.1C showing PF4 (magenta) bound to elongated (yellow
arrows) or not-elongated (green arrows) VWF (cyan) with nuclei stained with Hoescht
(blue) (B) Enlarged examples of PF4 bound to elongated or not-elongated VWF isolated
from (A). (C) The relative colocalization of VWF signal to PF4 signal using Coste’s
colocalization coefficients showing PF4 binds preferentially to elongated VWF compared
with not-elongated VWF. Mean + 1 SEM are shown with N > 12 with N signifying
independent VWF strands analyzed.
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Figure 4.3 A HIT-like monoclonal antibody and HIT patient IgGs bind PF4-VWF
complexes in vitro.
(A) Representative injured area and downstream areas in the microfluidic channels as in
Figure 1C, but staining for VWF and KKO. (B) Comparison as in Figure 1D for total KKO
bound. Abbreviations are as Figure 1D. Mean ± 1 SEM are shown. N ≥ 3 representing
separate microfluidic channels. P values were determined by a one-way ANOVA analysis.
(C) and (D) are similar to (A) and (B) respectively, but showing only the injured areas. In
(C), diluted plasma from patients at high risk of having HIT or low-risk controls (Ctl) were
used. In (D), diluted plasma from these individuals was quantified. Mean ± 1 SEM are
shown. N ≥ 3 separate channels. P values were determined using a one-way ANOVA to
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compare relative binding in the absence of PF4 or in the presence of infused PF4 at 25
µg/ml for each IgG sample.
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Figure 4.4. KKO preferentially binds elongated VWF strands over not-elongated
VWF.
(A) Displays an image of Figure 4.3A showing KKO (red) bound to elongated (yellow
arrows) or not-elongated (green arrows) VWF (cyan) with nuclei stained with Hoescht
(blue). (B) Enlarged examples of KKO bound to elongated or not-elongated VWF isolated
from (A). (C) The relative colocalization of VWF signal to KKO signal using Coste’s
colocalization coefficients showing KKO binds preferentially to elongated VWF compared
with not-elongated VWF. Mean ± 1 SEM are shown with N ≥ 12 with N signifying
independent VWF strands analyzed.
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Figure 4.5. Physical characterization of the PF4-VWF complexes in vitro.
(A) Volume readouts from dynamic light scatter analysis looking at PF4 alone (red, 10
µg/ml) in comparison to VWF alone at varied concentrations (1 µg/ml = black, 5 µg/ml =
blue, 10 µg/ml = green). (B) Volume readouts from dynamic light scatter analysis
evaluating PF4 (10 µg/ml) mixed with the various concentrations of VWF (0 µg/ml = red,
1 µg/ml = magenta, 5 µg/ml = black, 10 µg/ml = blue). Curves are representative of ≥ 4
separate experiments. (C) Confocal images displaying PF4 (red) and KKO binding (green)
in channels in which PF4-VWF-HIT antibody complexes were formed and then infused
with the indicated solution. Original image magnification is x20. (D) Quantification of PF4
and KKO binding showing the flowing a solution containing BSA or VWF does not reduce
the binding of PF4-VWF-HIT antibody complexes within the channel. N ≥ 5.
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Figure 4.6. PF4-VWF-HIT antibody complexes are prothrombotic in vitro.
(A) Representative fields of uninjured (top) and injured (bottom) endothelium after
exposure to a flow of recalcified whole human blood for 10 minutes, demonstrating the
binding of platelets to the VWF strands. The bottom channel displays the edge of injury
showing platelets and an uninjured area that resembles the appearance of the control
uninjured channel (top) (B) Same as in (A), but with the inclusion of PF4 (25 µg/ml) and
the indicated monoclonal antibody (10 µg/ml) and studied at the time points indicated.
Binding of KKO and of platelets are shown. (C) Mean ± 1 SEM are shown. N ≥ 6 separate
studies for the relative level of bound platelets (as quantified by calcein AM) compared to
injured endothelium with added KKO in the absence of PF4. P values were determined
using a one-way ANOVA analysis.
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Figure 4.7. Platelet binding to the PF4-VWF-HIT antibody complexes is dependent
on both the GPIb/IX receptor and FcRIIA.
(A) As in Figure 4.6B, representative fields showing platelet accumulation on injured
endothelium after flowing recalcified whole human blood with or without added PF4 and
KKO and with or without the GPIb/IX-VWF-blocking antibody AK2 or the FcRIIA-blocking
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antibody IV.3. (B) Mean ± 1 SEM for N ≥ 6 separate studies for the relative level of bound
platelets compared to injured endothelium with added KKO, but no PF4. Mean ± 1 SEM
are shown. N ≥ 3 separate studies with N signifying separate channels. P values were
determined using a one-way ANOVA analysis.
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Figure 4.8. Heparin disrupts PF4-VWF-HIT antibody complexes but can be combatted
by elevated levels of PF4.
(A) Complexes with VWF were formed by flowing PF4 (25 µg/ml) and KKO (10 µg/ml) along
the damaged vasculature followed by exposing the channel to a heparin (0-40 U/ml)
containing solution for ten minutes. Means ± SEM are shown with N ≥ 4. P values were
determined by one-way ANOVA analysis. (B) Studies showing how PF4 (25 µg/ml) and
KKO (10 µg/ml) binding in PF4-VWf-HIT antibody complexes changed when washed with
a solution containing heparin (0-0.4 U/ml), PF4 (5-100 µg/ml), and/or KKO (10 µg/ml) for
ten minutes.
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Figure 4.9. Drug interactions with the PF4-VWF-HIT antibody complexes in vitro. (AC) are studies of the effects of ADAMTS13 or NAC on the presence of VWF-PF4 or VWFPF4-HIT antibody complexes. (A) Shows representative images from studies as in Figure
3A with PF4 25 µg/ml infused into each lane. In some studies, KKO (10 µg/ml),
ADAMTS13 (7 nM) and/or NAC (10 mg/ml) was added as indicated. (B) The data shown
are the mean ± 1 SEM of the number of VWF strands present in the channel after exposure
to the indicated solution relative to those present in channels with injury+PF4+KKO. N ≥
4 and P values were determined by one-way ANOVA analysis. (C) Shows the mean ± 1
SEM are shown for the length of VWF relative to the length of the viewing window with N
≥ 4 independent channels. P values were determined by one-way ANOVA analysis.
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Figure 4.10. NAC impedes HIT-exacerbated thrombosis in a rose bengal carotid
arterial injury model.
(A) Displays the time (minutes) to occlusion in a rose bengal photochemical carotid
arterial injury model comparing mice infused with TRA, KKO, and KKO with nacetylcysteine. N ≥ 3. (B) Displays the estimated AUC measured in total milliliters for the
same mice shown in (A).
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CHAPTER 5 – Neutrophil accumulation and NET release contribute to thrombosis
in HIT

This chapter presents work featured in the article that has been submitted:
Gollomp, K., et al., (2018) submitted
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Abstract
HIT is an immune-mediated thrombocytopenic disorder associated with a severe
prothrombotic state. We investigated whether neutrophils and NETs contribute to the
development of thrombosis in HIT. Using an endothelialized microfluidic system and a
murine passive immunization model, we show that HIT induction leads to increased
neutrophil adherence to venous endothelium. In HIT mice, endothelial adherence is
enhanced immediately downstream of nascent venous thrombi, after which neutrophils
migrate retrograde via a CXCR2-dependent mechanism to accumulate into the thrombi.
Using a microfluidic system, we found that PF4 binds to NETs, leading them to become
compact and DNase resistant. PF4-NET complexes selectively bind HIT antibodies, which
further protect them from nuclease digestion. In HIT mice, inhibition of NET formation
through Padi4 gene disruption or DNase treatment limited venous thrombus size. Padi4-/did not effect arterial thrombi or severity of thrombocytopenia in HIT. Thus, neutrophil
activation contributes to the development of venous thrombosis in HIT by enhancing
neutrophil-endothelial adhesion and neutrophil clot infiltration, where incorporated PF4NET-HIT antibody complexes lead to thrombosis propagation. Inhibition of neutrophil
endothelial adhesion, prevention of their chemokine-dependent thrombus recruitment, or
suppression of NET release should be explored as strategies to prevent venous
thrombosis in HIT.
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Introduction
HIT is an immune-mediated thrombocytopenic disorder, characterized by venous
and arterial thrombi154. Even with early recognition and initiation of appropriate therapy,
thromboembolic complications still occur155. The current standard of care for patients with
suspected HIT involves intense anticoagulation that carries the risk of significant bleeding
and only provides partial protection against recurrent thromboembolic events87. While
avoidance of heparin exposure may prevent the development of HIT156, there are clinical
settings where heparin remains irreplaceable157. An improved understanding of the
pathobiology of HIT may help identify targeted therapies to prevent thrombosis without
subjecting patients to the risk of intense anticoagulation. These insights may also be
beneficial in the treatment of other inflammatory, prothrombotic conditions ranging from
antiphospholipid syndrome158 to sepsis159.
HIT is caused by the development of pathogenic antibodies (HIT antibodies) that
recognize complexes of heparin and the platelet-specific human chemokine PF488, which
is released in high concentrations at sites of platelet activation and then binds to surface
GAGs on platelets160, monocytes50, ECs43, and neutrophils161. HIT antibodies cross-react
with PF4-GAG complexes after which their Fc termini engage FcRIIA receptors, leading
to cell activation162. Although the high risk of thrombosis observed in HIT has classically
been attributed to the assembly of PF4-GAG complexes on platelets, these complexes
also form on the surface of other cells types, including monocytes50 and neutrophils122.
Moreover, we recently showed that PF4 and HIT-like antibodies bind predominantly to the
endothelial surface after vessel wall injury, leading to an increase in the extent of
endothelial damage upstream and downstream of the initial site of injury43.
There are multiple factors that suggest neutrophils may contribute to the
pathogenesis of HIT. Human neutrophils express FcRIIA163 and neutrophil activation via
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this receptor promotes increased phagocytosis, degranulation, and generation of ROS164.
PF4 and HIT antibodies have been shown to induce integrin expression on neutrophils122
and enhance the formation of neutrophil-platelet aggregates165. Myeloperoxidase (MPO)
levels have also been found to be elevated in plasma obtained from patients with HIT
compared to plasma from patients with other causes of thrombocytopenia165, suggesting
that HIT is associated with neutrophil activation. In the setting of infection or inflammation,
activated neutrophils can contribute to thrombus formation through NETs released
chromatin that can trap platelets, bind clotting factors, and deactivate natural anticoagulants166.
These findings led us to hypothesize that neutrophils activated by HIT antibodies
may contribute to the prothrombotic nature of HIT. To address this question, we performed
studies using an in vitro microfluidic system43 and a passive murine immunization model
of HIT47. In both systems, we found that exposure to HIT antibodies lead to enhanced
neutrophil adhesion to the venous endothelium. Following cremaster venule laser injury in
the murine passive immunization model of HIT, we observed that neutrophils adhered to
the downstream endothelium and then followed a chemogradient to migrate retrograde
into the growing thrombi. When activated neutrophils undergo NETosis during HIT, their
released NETs are bound by PF4, leading to their physical compaction. These PF4-NET
complexes bind HIT antibodies and become resistant to circulating DNases. Additional
passive murine immunization HIT studies in mice that are resistant to NET formation due
to a deficiency in the gene that encodes peptidyl arginine deiminase 4 (PAD4), an enzyme
that induces chromatin decondensation through the citrullination of histone lysine
residues167, confirm that NETosis plays a role in the murine model of HIT. The results of
a corollary analysis of clinical samples obtained from patients diagnosed with HIT,
suggests that NET formation influences the disease in humans. The relevance of these
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studies to the development of the prothrombotic state in HIT by Step 3 propagation and
potential new targets for therapy based on these studies are discussed.

Methods
Mice and human samples.
HIT mice were transgenic hPF4+/FcRIIA+

. All HIT mice were also on a Cxcl4-/-
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background168, as murine PF4 is not recognized by HIT antibodies103. Genetic alterations
were confirmed by appropriate PCR analyses101. We used the CRISPR-Cas9 genome
editing system169 to disrupt Padi4 exon2 in HIT mice (Padi4-/-/HIT mice, Figure 5.13).
Guide RNA (gRNA) flanking the targeted exon was designed to minimize off-target
interactions170 (5’-CCTAAGGGCTACACAACCTT-3’ and 5’-GCTGGCTGCTTTCACCTGTAC-3’) and injected into harvested embryos at concentrations of 50 ng/μL along with
Cas9 mRNA 100 ng/μL by the CHOP Transgenic Mouse Core. Oligonucleotide primers
designed to amplify the 0.2 kb region of the gene encasing Exon 2 (5’CATCTGTTCTGCTGCTGGCTG-3’,

5’-CTCCTAAGGGCTACACAACCTTC-3’)

were

used to confirm the presence of the desired gene disruption. Functional abrogation of
PAD4 activity was confirmed by stimulating neutrophils isolated from the bone marrow of
Padi4-/- mice and plated on poly-L-lysine-coated slides (Sigma-Aldrich) with 100 nM of
phorbol-12 myristate 13-acetate (PMA, Sigma-Aldrich) overnight at 37°C and then staining
the cells with SYTOX green (1 μM) and anti-histone H3 antibody Ab5103 at a dilution of
1:500 to visualize NET release (Figure 5.13B). Both Padi4+/+/HIT and Padi4-/-/HIT mice
were studied at 10-30 weeks of age. Only male mice were used in the cremaster vessel
injury experiments; however, in previous studies, we have not appreciated any sex
differences in thrombosis in the passive immunization HIT murine model following
photochemical carotid artery injury50.
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Deidentified plasma samples were obtained from patients with suspected HIT104.
All subjects were evaluated with a polyspecific PF4/heparin ELISA (Immucor)47 and a
serotonin-release assay171,172, and classified as having or not having HIT by a panel of
three independent expert adjudicators who based their decision on laboratory results and
clinical findings. Control plasma was obtained from healthy individuals and patients
diagnosed with immune thrombocytopenia (ITP)173. Citrated plasma was stored at -80°C
and MPO concentrations were measured by ELISA (Biolegend). IgG was isolated from
plasma from some HIT patients and healthy donors using protein G agarose (Pierce)50.

Antibodies and other labeled probes.
KKO, an anti-PF4/heparin monoclonal antibody, and TRA, a mouse IgG 2bK
isotype control monoclonal antibody47, were purified from hybridoma supernatants. AntiFibrin 59D8 monoclonal antibody was provided by Harmut Weiler of the Blood Center of
Wisconsin56 PF4 was visualized using a polyclonal rabbit anti-human PF4 antibody
(abcam). A rabbit anti-citrullinated histone 3 (cit-H3, Ab5103, abcam) was used to
visualize citrullinated H3 and rabbit anti-MPO antibody (EMD Millipore), was used to label
NETs. Both of these antibodies were labeled for visualization with a goat anti-rabbit IgG
H&L Alexa Fluor 594 (ab150080, abcam). F (ab′) 2 fragments of the anti-mouse CD41
monoclonal antibody MWReg30 and of the anti-mouse Ly-6G antibody 1A8 (BD
Biosciences) were used to detect murine platelets and neutrophils, respectively, in the
cremaster laser injury model. HIT antibodies purified from patient plasma samples were
visualized with an anti-human IgG Fc secondary antibody (eBioscience). All antibodies
were either labeled using Alexa Fluor antibody-labeling kits according to manufacturer’s
instructions or species-appropriate Alexa Fluor-conjugated secondary antibodies (all from
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ThermoFisher Scientific). Extracellular DNA was visualized using SYTOX green or orange
nucleic acid stain (ThermoFisher Scientific).

NET-lined microfluidic channel studies.
Experiments were performed using a BioFlux 1000 Controller (Fluxion) with an
attached heating stage at 37°C as described108. The BioFlux channels were visualized
with an Axio Observer Z1 inverted microscope (Zeiss) equipped with a motorized stage
and an HXP-120 C metal halide illumination source. The microscope and image
acquisition were controlled by BioFlux Montage software with a MetaMorph-based
platform (Molecular Devices). Isolated human neutrophils (2 x 106 cells/ml) were incubated
with 1 ng/ml TNFα (Gibco) at room temperature for 10 minutes and then flowed through
channels coated with 50 μg/ml of fibronectin (Sigma-Aldrich), to which they adhere, and
then incubated with 100 ng/ml PMA overnight at 37°C. Cell-free DNA (cfDNA) release was
visualized with 1 μM SYTOX green or orange, and the channels were infused with
recombinant PF4 (0-200 μg/ml), expressed and purified as we described174, with or without
unfractionated porcine heparin (0.4 U/ml, BD Biosciences) at 2-5 dynes/cm2. To confirm
that the cfDNA structures adherent to the microfluidic channel walls were NETs, we
performed co-immunolocalization in which channels ± PF4 (25 μg/ml) were incubated with
either anti-cit-H3 at 4°C overnight or anti-MPO at 37°C for 1 hour, and then incubated with
an Alexa Fluor 594 conjugated secondary antibody for 1 hour at 37°C prior to imaging with
a Zeiss LSM 710 laser-scanning confocal microscope. Structures with co-localization of
cfDNA and MPO or citrullinated histones were deemed to be NETs. PF4-NET complexes
were then incubated with 25 μg/ml of KKO or a polyclonal anti-PF4 antibody (abcam) for
1 hour at 37°C. NET digestion studies were carried out by infusing the channels with 100
U/ml DNase I (Sigma-Aldrich) at 2 dynes/cm2 after which the channels were washed with
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phosphate-buffered saline (PBS, Gibco) and fixed with 2% paraformaldehyde (BD
Biosciences). To avoid laser-induced changes to the conformation of DNA175, we
minimized laser exposure during our experiments. To account for this effect when studying
whether KKO binding to PF4/NET complexes increased resistance to DNase I, we
compared NET digestion by analyzing videos in which channels with and without KKO
were included in the same visual field and exposed to UV light for the same amount of
time. Channels were blocked with PBS with 2% BSA, and PF4-NET complexes were
visualized by incubating SYTOX-labeled NETs with a rabbit anti-human PF4 antibody at
37°C for 1 hour, rinsing the channels with PBS flowed at 5 dynes/cm2 for 5 minutes, and
then incubating with an anti-rabbit secondary antibody at 37°C for 1 hour. KKO was
labeled with Alexa Fluor 647 (ThermoFisher Scientific) prior to NET channel infusion. NET
complexes were imaged with a Zeiss LSM 710 laser-scanning confocal microscope.
Similar studies were done using 100 U/ml bacterial-derived micrococcal nuclease (New
England Biolabs). Data were analyzed using ImageJ open source image processing
software176.

Endothelialized channel microfluidic studies.
We used the TNFα inflammatory thrombosis microfluidic model described in
Chapter 2. Briefly, endothelialized microfluidic channels were incubated with TNFα (1-10
ng/ml) to simulate inflammation. Whole blood samples obtained from healthy human
donors were fluorescently labeled with 2 mM calcein AM to visualize leukocytes and
platelets and then incubated with KKO or TRA (25 μg/ml) for 15 minutes. The samples
were then recalcified with CaCl2 (11 mM final concentration) and immediately flowed
through the channels at 5 dynes/cm2. When using ImageJ to count endothelial-adherent
cells, size exclusion thresholds were used to distinguish platelets from leukocytes. To
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assess KKO binding to TNFα-stimulated endothelium, the HUVEC-lined channels were
infused with PBS containing PF4 (10 μg/ml) and KKO (25 μg/ml) conjugated with Alexa
Fluor 488 (Invitrogen) at 5 dynes/cm2. Following the infusion, the channels were washed
with PBS and fixed with 2% paraformaldehyde (BD Biosciences). KKO binding was
quantified based on fluorescent measurements obtained from a Zeiss LSM 710 laser
scanning confocal microscope. Levels of KKO-endothelial binding were compared to
those observed after the whole blood samples containing PF4 and KKO were infused
through HUVEC channels that had been subjected to hematoporphyrin (50 µg/ml, SigmaAldrich) photochemical injury, as our group has previously described43.

Femoral vein neutrophil rolling studies.
HIT mice were anesthetized with nembutal and a skin flap extending from the ankle
to thigh was removed to expose the femoral vein. SYTOX orange (2 nM) and F(ab′)2
fragments (0.2mg/g mouse) directed against Ly6-G and CD41 were infused as 100 μL
boluses via a catheter placed into the jugular vein to detect cfDNA, neutrophils, and
platelets respectively. Confocal microscopy was used as described previously98 to obtain
videos of neutrophil rolling and adhesion in the femoral vein at baseline and 10 minutes
after 1 μg/g of KKO was infused via the jugular catheter. Data were collected and confocal
time-lapsed images were analyzed using Slidebook 6.0 to compare neutrophil behavior
before and after KKO exposure.

Isolated human neutrophils.
Human blood was collected after informed consent from healthy aspirin-free
volunteers through a 19-gauge butterfly needle into 4 ml vacutainers coated with 7.2 mg
of ethylenediaminetetraacetic acid (Becton Dickinson). Blood samples were stored at
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room temperature and used within 1 hour. Neutrophils were isolated with negative bead
selection using the MACSxpress Neutrophil Isolation Kit (Miltenyi Biotec). The supernatant
was collected and centrifuged at 300g for 10 minutes, and the cell pellet was resuspended
in 2 ml ammonium-chloride-potassium (ACK) lysing buffer (ThermoFisher Scientific) for 5
minutes to lyse erythrocytes, after which the cells were washed with 10 mLs of Hank’s
balanced salt solution (HBSS, ThermoFisher Scientific), and then resuspended in HBSS
containing calcium chloride (1.3 mM) and then manually counted, with trypan blue dye
exclusion (Gibco) for cell viability.

Bioassay for NET digestion.
PF4-induced NET resistance to digestion was quantified using a modified version
of a previously described assay98. Isolated human neutrophils resuspended in HBSS,
were stimulated with TNFα (1ng/ml) for 5 minutes and transferred to a fibronectin-coated
(50 μg/ml) 96 well plate with 2 x 105 cells placed in each well. The samples were incubated
with 100 nM of PMA ≥ 4 hours at 37°C to stimulate NET release. NETs were incubated
with PF4 (0-50 μg/ml) ± KKO (25 μg/ml). Released cfDNA was labeled with SYTOX green
(1μM), and a baseline reading was obtained with fluorescence spectrometry, excitation
485 nm and emission 537nm (SpectraMax M2, Molecular Devices). The samples were
then incubated with 1U/ml DNase I (Sigma-Aldrich) for 30 minutes at 37°C and a repeat
fluorescence reading was obtained. The percent original fluorescent intensity was
measured for each well with higher values reflecting increased DNase I resistance.

Glass slide NET compaction and digestion studies.
To assess NET behavior without exposure to fibronectin, isolated human
neutrophils resuspended in HBSS at a concentration of 2 x 106 cells/ml were allowed to
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settle on uncoated microscope cover glass slides (Fisherbrand) placed in a 24 well tissueculture plate (Falcon) for 30 minutes at 37°C. The supernatant was aspirated and 500 μL
of HBSS containing PF4 (0-50 μg/ml) was added to the wells and incubated at 37°C for 1
hour. The supernatant was again aspirated and 500 μL of DNase I (100U/ml) was added
to the wells and incubated on a standard analog rocker (VWR) at 37°C for 1 hour. Images
of the NETs before and after compaction and digestion were obtained with Axio Observer
Z1 inverted wide field microscope (Zeiss) and data were analyzed using ImageJ
opensouce image processing software176.

Cremaster laser injury studies.
Intravital microscopy was performed as described154 using Padi4+/+ and Padi4-/HIT mice. Arterioles and venules of 20-40μ diameter were studied, and injury was induced
with an SRS NL100 pulsed nitrogen dye laser (440nm) focused on the vessel wall and
pulsed until the vessels were perforated as indicated by the release of a small number of
erythrocytes. Prior to injury induction, SYTOX green or orange (1μM) and F(ab′)2
fragments (0.2 mg/g mouse) were infused as 100 μL boluses via a catheter placed into
the jugular vein. After 1-3 injures were made, 1 μg/g of KKO or TRA was infused, and an
additional 3-4 injuries were made with maximum experimental time per mouse being 2
hours. In some studies, the mice were treated with the CXCR2 antagonist SCH527123
(10 mg/kg, Apexbio) resuspended in distilled H20 with 5% dimethyl sulfoxide (SigmaAldrich). In other studies, the mice were treated with an IV bolus of bovine pancreasederived DNase 1 (100U/mouse, Sigma-Aldrich) immediately prior to KKO injection and
laser injury. Widefield and confocal microscopy were performed. Data were collected and
confocal time-lapsed images of platelet and neutrophil accumulation were analyzed using
Slidebook 6.0. Confocal Z-stacks were obtained immediately following injury at 5 minutes
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and again 60 minutes following KKO or TRA infusion. Data were analyzed with Slidebook
6.0 to measure platelet thrombus volumes.

Statistical analysis.
Differences between 2 groups were compared using a 2-sided Student’s t test with
Welsh’s correction or a Mann-Whitney U test. Normal distribution was tested using the
D’Agostino & Pearson normality test. Differences between >2 groups were determined by
one- or two-way ANOVA (as appropriate) and a Kruskall-Wallis test was performed when
data was not normally distributed. Multiplicity corrected p values are reported for multiple
comparisons. Statistical analyses were performed using Microsoft Excel 2011 and
GraphPad Prism 7.0 (GraphPad Software). Differences were considered statistically
significant when P values were ≤0.05.

Study approval.
Animal procedures were approved by the Institutional animal care and use
committee (IACUC) of the CHOP and in accordance with NIH guidelines and the Animal
Welfare Act. Anonymized human blood was collected after signed, informed consent was
provided by healthy donors, and approval for studies using human blood was obtained
from CHOP’s Human Review Board in accordance with Declaration of Helsinki principles.
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Results
Enhanced neutrophil adhesion to the venular endothelium in HIT.
Neutrophils are activated when exposed to PF4 and HIT antibodies122. To
determine if this activation might impact neutrophil-EC interactions, we infused calceinAM labeled whole blood through HUVEC-lined microfluidic channels and quantified cell
adhesion over time. We observed scant leukocyte-endothelium adhesion in unstimulated
channels that was unchanged by the addition of the HIT-like monoclonal antibody KKO or
the isotype control TRA (data not shown). However, when the HUVEC cells were pretreated with TNFα, there was a two-fold increase in the number of adherent leukocytes in
samples incubated with KKO, which induces the release of endogenous PF4 from
platelets47, compared to samples treated with the isotype control TRA (Figures 5.1A,
5.1B, and 5.1C). We did not observe that TNFα treatment led to an increase in KKO
binding to the HUVECs (Figure 5.2) supporting that the increase in leukocyte adhesion
seen in vivo was at least in part a result of leukocyte rather than endothelial activation. We
then asked if these findings could be recapitulated in vivo using a murine HIT model
following injection of KKO56. Within 30 minutes of KKO infusion, we observed increased
neutrophil rolling and adhesion to uninjured cremaster muscle venules, but no neutrophil
rolling or adhesion occurred in uninjured cremaster arterioles before or after the animals
were exposed to KKO (Figures 5.1D and 5.1E). We similarly observed an increase in
neutrophil adhesion in the femoral vein 10 minutes following treatment with KKO (Figures
1F and 1G).

Enhanced neutrophil involvement in venular thrombosis in HIT.
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We next asked whether exposure to HIT antibodies influences neutrophil
incorporation into thrombi in vivo in the murine model of HIT. Cremaster vessels were
injured at time 0 and adherent neutrophils and platelets were quantified at 5 minutes. The
mice were then infused with KKO or TRA, and the thrombi were reexamined at 60 minutes.
While there was an increase in platelet accumulation in arterioles following HIT induction,
only a small number of neutrophils were incorporated into arteriolar thrombi, with a small
but significant increase following treatment with KKO (Figure 5.3). At sites of venular injury
prior to HIT-induction, there was platelet and fibrin accumulation (Figure 5.3B and Figure
5.4, respectively) but only a small number of neutrophils adhered to these thrombi (Figure
5.3A and 5.3C). In contrast, following HIT induction, there was marked increase in
neutrophil accumulation within venular thrombi (Figure 5.3C) with a minimal change in
fibrin accumulation (Figure 5.4) and platelet volume (Figure 5.3B). The rise in neutrophil
accumulation was not observed following TRA infusion (Figure 5.3A through 5.3C).

A CXCR2-dependent retrograde migration of neutrophil into venular thrombi in HIT.
To better understand the process of neutrophil accumulation in venular thrombi in
HIT, we induced laser injuries in venules following KKO infusion, and monitored platelet
and neutrophil accumulation in these lesions over 5 minutes. While platelets quickly
adhered directly to the site of venous injury, most neutrophils initially bound to the
endothelium 30-40 microns downstream of the injury (Figure 5.5). This finding is likely
due to a combination of increased neutrophil adhesiveness induced by KKO exposure,
documented in Figure 5.1, in addition to activation of the endothelium downstream of
cremaster laser injuries in HIT that we have previously described43. These neutrophils
subsequently migrated in a retrograde direction into the evolving thrombus (Figure 5.5A)
and 60 minutes following the initial injury, a significantly higher number of neutrophils were
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present in venular thrombi in mice exposed to KKO compared to those infused with the
isotype control TRA (Figures 5.5A and 5.5B). We hypothesized that retrograde migration
of adherent neutrophils into the thrombi was induced by a chemoattractant released by
activated platelets in the clots. Activated platelets release several chemokines from their
 granules that cause neutrophil migration by engaging neutrophil surface CXCR2177. To
test whether the retrograde recruitment of neutrophils to venular thrombi in HIT was
chemokine-dependent, we treated the mice with the CXCR2 antagonist SCH527123177
prior to the induction of HIT. We observed that thrombi in mice treated with SCH527123
before KKO infusion contained significantly fewer neutrophils within their thrombi (Figure
5.5). Furthermore, these neutrophils were located at the periphery of the platelet-rich
thrombi and not embedded within them.

In vitro studies of PF4-NET interactions.
After observing marked HIT-induced neutrophil infiltration in venular thrombi, we
hypothesized that adherent neutrophils contribute to venous thrombi in HIT, in part,
through the release of NETs, as described in deep venous thrombosis178. Moreover,
platelet activation, one of the hallmarks of HIT, can initiate NETosis in inflammatory
states179,180. Activated platelets release high levels of PF4, which forms high-molecular
weight aggregates with various polyanions, producing antigens that are recognized by HIT
antibodies141. We postulated that when PF4 is released in HIT, due to its cationic charge,
it will bind to cfDNA present in NETs and impact NET biology. To investigate PF4-NET
interactions in real time, we studied neutrophils adherent to fibronectin-coated microfluidic
channels stimulated with PMA to release NETs. We confirmed that these cfDNA structures
were NETs by using co-immunofluorescent staining to show that they contained
citrullinated histones and MPO (Figure 5.6). The NET-lined channels were then infused
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at venular flow rates with buffer containing PF4 at concentrations readily attained at sites
of platelets activation (5-100 µg/ml)122. Prior to exposure to PF4, NETs labeled with
SYTOX were round and transparent, with a cloud like appearance that we termed “fluffy”.
When infused with HBSS or human plasma, the NETs extended, and when flow was
stopped they rebounded to their former shape. Following treatment with either buffer or
plasma containing PF4, the NETs became opaque and narrow with a sharply tapered tail
that did not change shape when flow was stopped. (Figure 5.7A, Figure 5.6). Maximum
compaction, with a 50% reduction in NET area, was achieved when the NETs were flowed
with HBSS containing PF4 concentrations of ≥10 µg/ml (Figure 5.7B, left, for PF4 ≤25
µg/ml and not shown for >25 µg/ml). Confocal imaging of the compacted NETs, labeled
with an anti-PF4 antibody and a fluorophore-conjugated secondary antibody, confirmed
that PF4 bound to these structures (Figure 5.7A). Total NET DNA content measured by
fluorescence intensity was preserved following PF4 infusion, excluding the possibility that
the compacted NET appearance was due to the dissolution of DNA (Figure 5.7B, right).
Co-immunofluorescent studies of NETs following PF4 infusion demonstrated that
compaction does not lead to displacement of citrullinated histones or MPO (Figure 5.6).
We next asked whether PF4-induced changes in NET morphology could impact
NET behavior. While PF4-free NETs were highly susceptible to DNase I at a concentration
of 100U/ml, with near complete digestion in <2 minutes, PF4-bound NETs were resistant
to DNase I, with near-complete protection at PF4 concentrations of ≥10 µg/ml (Figure
5.7C and 5.7D). The infusion of human plasma containing PF4 was also found to confer
resistance to DNase I-mediated digestion (Figure 5.8) and similar results were observed
with the use of bacterial-derived micrococcal nuclease (Figure 5.9). Comparable nuclease
resistance was also observed in a static system not coated with fibronectin, showing that
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fibronectin, which has a DNA binding domain and is known to interact with NETs181, is not
the cause of the observed changes in NET behavior (Figure 5.8).
Previous in vitro studies reported that NETs are degraded by exposure to
heparin182, suggesting that NETs should be reduced in patients with recent heparin
exposure. We found that at a therapeutic concentration of 0.4U/ml147 or at a
supratherapeutic concentration of 5000U/ml, heparin did not degrade NETs in our
microfluidic system; however, we observed that exposure to heparin, reversed compaction
with restoration of fluffy morphology (Figure 5.10A and 5.10B). Confocal imaging of NETs
labeled with a polyclonal anti-PF4 antibody confirmed that heparin treatment removed PF4
from the NETs (Figure 5.10A), and DNase I infusion studies confirmed that decompaction
of NETs restored their susceptibility to endonuclease digestion (Figure 5.10C and 5.10D).
However, when NETs were exposed to a 25 µg/ml instead of 10 µg/ml of PF4, a
concentration still within the range typically observed at sites of thrombosis88, NET
compaction and DNase resistance were maintained during co-infusion with therapeutic
concentrations of heparin (Figure 5.10C and 5.10D).

In vitro effects of HIT antibodies on PF4-NET complexes
PF4 has previously been shown to form complexes with DNA aptamers that are
HIT antigenic targets124. We, therefore examined whether PF4-NET complexes are also
recognized by KKO and IgG isolated from HIT patient plasma using the microfluidic
chambers to assess binding and function. We found that KKO and HIT IgG suspended in
HBSS did not interact with non-compacted NETs, but both bound to PF4-NET complexes
(Figure 5.11A and Figure 5.12A). KKO dissolved in human plasma also bound
specifically to PF4-NET complexes. (Figure 5.12A). Antibody binding did not induce
greater NET compaction, but it enhanced resistance to DNase I digestion (Figure 5.11B).
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This effect was found to be specific to HIT antibodies, as incubation with a polyclonal antiPF4 antibody at 25 μg/ml did not provide similar protection from endonucleases (Figure
5.11C and 5.11D). Similar results were seen using NETs immobilized to fibronectin-coated
96-well plates (Figure 5.11E)183.

Thrombosis in the HIT murine model in the presence or absence of PAD4.
We then asked whether enhanced NET endonuclease resistance and the
formation of PF4-NET-HIT antibody complexes, observed in vitro, contribute to in vivo
thrombus development in the murine model of HIT. We hypothesized that the release of
NETs by thrombus-adherent neutrophils and their subsequent modification by PF4 and
HIT antibodies may play a role in the prothrombotic state that develops in these animals.
To better understand the way in which NETosis may contribute to thrombosis in HIT, we
studied Padi4-/-/HIT mice that are incapable of releasing NETs (Figure 5.13). Previous
studies have shown that Padi4 knockout mice do not release NETs and are protected from
venous thrombosis178. Following KKO injection, severity of thrombocytopenia in Padi4-//HIT mice was comparable to that seen in Padi4+/+/HIT controls. (Figure 5.14A) The size
of arteriolar thrombi following laser injury was unaffected by PAD4 deficiency (Figure
5.14B) and neutrophil incorporation into venule thrombi following TRA injection was similar
in Padi4-/- and Padi4+/+ HIT mice. However, after KKO injection, the Padi4-/-/HIT mice
developed smaller venular thrombi following injury (Figure 5.14C and 5.14D) with
incorporation of fewer neutrophils (Figure 5.14E). This difference became more
pronounced with the passage of time (Figure 5.14C). Consistent with these studies in
Padi4-/- HIT mice, Padi4+/+ HIT mice treated with DNase I prior to KKO infusion, had a
significant decrease in platelet thrombus volume 60 minutes following injury (Figure
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5.14C), suggesting that NETs play a role in thrombus growth and stabilization in this
model.

Clinical indication of NETosis in HIT
It has been reported that circulating MPO levels are elevated in HIT165, potentially
implicating neutrophils and NETosis in the pathobiology of HIT. We confirmed this clinical
finding comparing cfDNA and MPO levels in samples from patients at high- or at lowlikelihood of having HIT44, healthy controls, and patients with immune-thrombocytopenia
(ITP). Both MPO levels (Figure 5.15A) and cfDNA (Figure 5.15B) were significantly
higher in individuals diagnosed with HIT compared to healthy controls and patients with
an alternative cause of immune thrombocytopenia. However, we did not observe a
significant difference in MPO or cfDNA concentrations between patients diagnosed with
HIT compared to ill patients evaluated for HIT, but found to have a low probability of having
the disease. These findings demonstrate that neutrophil activation and NETosis occur in
multiple proinflammatory/prothrombotic states that commonly occur in hospitalized
patients.

Discussion
Over the past several years, it has become increasingly clear that the
pathophysiology of HIT extends beyond platelet activation in Step 2. It has previously been
shown that HIT antibody interaction with other cells types including the endothelium43 and
monocytes50, leads to cell activation and a prothrombotic state as described in Step 2.
Others have also demonstrated that HIT antibodies activate PF4-exposed neutrophils
through their FcRIIA receptors, leading to increased expression of Mac-1 on the cell
surface and enhanced neutrophil aggregate formation122. In this paper, we explore specific
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pathways by which neutrophils may contribute to thrombosis in Step 2, and propose that
they do so through multiple steps including the stimulation of neutrophil adhesion to
inflamed endothelium, the promotion of neutrophil migration into venular thrombi, and the
formation of antigenic PF4-NET-HIT antibody complexes that contribute to propagation
via Step 3.
The basis for enhanced binding of HIT-activated neutrophils to the endothelium in
large vessels and the microcirculation requires further exploration. Prior studies have
shown that HIT antibody exposure increases neutrophil surface expression of Mac-1122.
ECs are also activated by PF4 and HIT antibodies, increasing surface expression of Pand E-selectins93. Our finding of enhanced in vitro neutrophil binding parallels the
increased adhesion seen in vivo in the setting of our murine model of HIT, with or without
EC injury. We speculate that neutrophil adhesion immediately downstream of growing
venular injury may be due to increased turbulent flow around larger thrombi, that is known
to enhance neutrophil adhesion to the endothelial lining184. It may also be due to the
release of PF4 from activated platelets within the thrombus that results in increased
assembly of antigenic complexes on the downstream endothelium, leading to more HIT
antibody binding and endothelial activation43. The role of each of these mechanisms in the
accumulation of neutrophils in injured venules requires additional investigation to identify
opportunities for intervention.
After adhering to the endothelium downstream of thrombosis, many neutrophils
migrate in a retrograde manner and are incorporated into the venular clots. Retrograde
migration may occur in response to a chemotactic gradient emanating from degranulating
platelets. A similar process termed “directed intravascular migration” has been described
in ischemia-reperfusion injuries, in which degranulating platelets release CXCL7
(neutrophil activating peptide 2 (NAP2)) and CXCL5 (epithelial-derived neutrophil112

activating peptide 78 (ENA-78)), leading to CXCR2-dependent neutrophil recruitment185.
The retrograde migration we observed in venular HIT thrombi is also similar to “neutrophilswarming,” a process in which large numbers of neutrophils rapidly accumulate at sites of
infection or sterile injury where they release NETs186. In support of this hypothesis, we
show that the retrograde migration of neutrophils into venous thrombi can be abrogated
with the blockade of CXCR2. Whether NAP2 and/or ENA-78, both released from platelets
and bound by CXCR2187, contribute to the chemogradient remains to be determined.
Further investigation needs to be done to ascertain if this pattern of adhesion occurs in
other prothrombotic disorders associated with venous thrombosis.
Many groups have proposed that NET release links neutrophil accumulation to
thrombus progression178,188,189. We posit that NETs released in HIT are uniquely
prothrombotic because the binding of PF4 and HIT antibodies causes them to become
immunogenic. Previous studies have shown that nucleic acid binding leads to the
exposure of the same antigenic epitopes present on PF4/heparin complexes124. Mice
injected with PF4/nucleic acid complexes develop antibodies that cross-reacted with
PF4/heparin complexes124. Our microfluidic channel experiments support that PF4 forms
complexes with chromatin DNA in the same way as PF4 binds heparin to form
macroaggregates190. Our studies showing that HIT IgG isolated from human plasma binds
to these PF4-NET complexes, confirms that they contain HIT antigenic epitopes.
In addition to producing HIT antigenic complexes, we have observed that PF4
binding leads to chromatin compaction that causes NETs to become DNase resistant. It
has previously been shown that NET binding to the cationic peptide LL-37 leads to
enhanced protection from nuclease digestion191, in a manner similar to what we have
observed with PF4. While DNase-resistant NETs may have increased antimicrobial
activity, impaired NET degradation has been implicated in the pathogenesis of
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autoimmune diseases, including anti-phospholipid antibody syndrome and lupus192,193. In
these disorders, DNase resistance is thought to occur due to the development of anti-NET
immunoglobulins that interfere with DNase binding to cfDNA183. In HIT, PF4 forms
complexes with NETs that are bound by HIT antibodies that provide additional protection
from DNases. These stable, compacted PF4-NET-HIT IgG aggregates then serve as a
Fc-rich surface that can recruit and activate circulating hematopoietic cells via their
FcRIIA receptors and activate the complement cascade163.
To test this hypothesis, we generated Padi4-/- HIT mice that do not undergo
NETosis167,178,194. In these animals, venular thrombi generated after HIT induction are
markedly smaller than those observed in animals capable of NET release, with fewer
incorporated neutrophils and decreased platelet volumes. This suggests that NETs
contribute to the early stages of venule thrombus growth, enhancing both platelet
accumulation and neutrophil recruitment. This effect was not observed in laser injuryinduced arteriole thrombi, which have little neutrophil infiltration irrespective of PAD4
activity. Moreover, the loss of PAD4 activity – and likely NET formation – did not affect the
severity of thrombocytopenia in HIT mice, suggesting that the development of venular
thrombi is unrelated to the mechanism underlying the development of thrombocytopenia.
In vivo NET visualization is technically difficult, and most in vivo studies rely on
functional analysis. We therefore treated HIT mice with DNase prior to cremaster laser
injury and found that this led to a significant decrease in cremaster venule thrombus
platelet volumes. This finding further supports our hypothesis that NETs play a role in
thrombus growth and stabilization in this model. However unlike in the Padi4-/-/HIT mice,
the number of thrombus-adherent neutrophils did not fall in accordance with the decrease
in platelet volumes. This difference may occur because Padi4-/- mice never release NETs,
whereas PF4-compacted NETs are incompletely degraded by DNase and may still expose
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PF4-NET-HIT IgG aggregates that can recruit circulating neutrophils. Nonetheless, the
decrease in venular thrombus size raises the possibility that DNase treatment may be
effective in preventing the venular prothrombotic state in HIT.
In summary, we demonstrate that neutrophils contribute to the prothrombotic state
in Step 2 of HIT (Figure 1.5) through enhanced adhesion to the endothelium downstream
of venous thrombi and subsequent retrograde migration into these thrombi. There,
activated neutrophils release NETs that form complexes with PF4 that are subsequently
bound by HIT antibodies. These PF4-NET-HIT antibody complexes are protected from
DNases and may contribute to thrombus propagation in Step 3 by exposing an Fc-rich
surface. Thus, our studies extend the range of PF4-bound HIT antigenic polyanionic
targets beyond heparin, GAGs, and polyphosphates. This would implicate that neutrophilderived NETs, are a key figure in the venular thrombus propagation in HIT (Figure 1.5).
HIT mice that have neutrophils unable to undergo NETosis have smaller venous thrombi,
but still develop enhanced arterial clots and thrombocytopenia. Further work is required to
understand whether neutrophils contribute similarly to the development of venous thrombi
in other immune/inflammatory prothrombotic states such as the anti-phospholipid antibody
syndrome and sepsis. More investigation is needed to determine if blocking these
pathways will help prevent venous thromboembolic complications in patients with HIT or
other prothrombotic disorders.
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Figure 5.1. Enhanced leukocyte-endothelial adhesion in HIT.
(A) Calcein-AM labeled blood incubated with KKO (red) or TRA (blue) was infused through
HUVEC-lined channels exposed to TNF. Representative widefield image of leukocytes
(white) adhering to the endothelium is shown. Size bar and arrow indicating direction of
flow are included. Image was obtained with an Axio Observer Z1 inverted microscope
using x10 magnification. (B) Leukocyte-endothelial adhesion was quantified for KKO (red)
and TRA (blue). Six channels were studied in each TNFα-exposed arm (lighter colors) and
3-5 channels in the unexposed arms (darker colors). (C) The final number of adherent
leukocytes at 15 minutes is shown as mean ± 1 standard deviation (SD). Comparative
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analysis was performed by Student’s t-test. (D) Representative confocal image of
neutrophils rolling in a venule before and after KKO infusion. Neutrophils were stained
using anti-Ly-6G F(ab′)2 fragment (green). Size bar and arrow indicating direction of flow
are included. Images were obtained with an Olympus BX61WI microscope with a x40/0.8
numeric aperture water-immersion objective lens. (E) Neutrophil adhesion to cremaster
arterioles and venules was studied in the HIT murine model prior to and 30 minutes after
exposure to KKO. Adhesion was defined as neutrophil immobilization for ≥30 seconds.
Seven and four animals were studied in the venular and arteriole arm, respectively.
Statistical comparison of binding was preformed using a Kruskall-Wallis one-sided
ANOVA. (F) Representative confocal image of neutrophil rolling and adhering to the
femoral vein before and 15 minutes after the infusion of KKO. Images are as in (D). Size
bar and arrow indicating direction of flow are included. (G) Graph representing neutrophil
adhesion to the femoral vein ± KKO infusion as in (F). N = 4 per arm. Statistical comparison
was performed by Student’s t-test.
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Figure 5.2. TNFα stimulation does not enhance KKO binding to HUVECs.
(A) Graph showing the mean ± 1 SD of KKO adhesion to microfluidic channels coated
with a confluent layer of HUVECs after infusion of whole blood or PBS containing PF4 (25
μg/ml) and Alexa Fluor 488-conjugated KKO. Two fluorescent measurements were
obtained from each channel. The number of channels per arm is indicated on the graph.
The channels were either unstimulated, treated with TNFα prior to infusion, or subjected
to photochemical hematoporphyrin injury. When whole blood was flowed through TNFαtreated channels, the channels clotted, leading to interference with fluorescence
measurements. Therefore, we only infused these channels with PBS. Comparative
statistical analysis was done with a Kruskal-Wallis one-way ANOVA. (B) Representative
confocal images of an unstimulated channel infused with PBS, an uninjured channel
infused with whole blood, a TNFα stimulated channel infused with PBS, and a whole blood
infused channel subjected to photochemical injury on the right half of the presented field.
In this image, KKO only adheres to the injured portion of the channel to the right of the
gray dotted line. Scale bar and arrows showing direction of flow are indicated.
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Figure 5.3. Effect of HIT of neutrophil accumulation in cremaster vessels pre- and
post-injury.
(A) Representative confocal images from cremaster arteriole and venule laser injuries
showing platelets labeled with anti-CD41 (dark blue) and neutrophils labeled with anti-Ly6G (green). Paired images from the same vessel taken at 5 and 60 minutes following laser
injury. KKO or TRA were infused intravenously beginning at minute 5 after injury. Size bar
and arrow indicating direction of flow are included. Same microscope and acquisition
software as in Figure 5.1D. (B) and (C) are graphs quantifying adherent neutrophils and
platelets in the same thrombi, respectively. Twenty-eight injuries were made in twelve
KKO-treated mice. Sixteen injuries were made in four TRA-treated mice. Twelve arteriole
injuries were made in three untreated and three KKO-treated mice. Individual data points
and mean ± 1 SD are shown. Comparative statistical analysis between 3 or more groups
was performed by Kruskall-Wallis one-way ANOVA and comparisons between two groups
was performed with a Student’s t-test.
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Figure 5.4. Fibrin generation occurs in cremaster laser injuries.
(A) Cremaster venule thrombus at 5 minutes after injury but prior to KKO exposure in HIT
mice. Scale bar and arrows showing direction of flow are indicated. Fibrin and platelet
accumulation are shown alone at the right. A composite image including the neutrophil
stain is shown on left. (B) The same injury 60 minutes following KKO administration.
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Figure 5.5. Chemokine-dependency of neutrophil accumulation into venous
thrombi in HIT.
(A) Representative confocal images of cremaster venule injuries showing platelet (blue),
neutrophil (green) and KKO staining (red) at 1-60 minutes following laser injury. Typical
injuries are shown from mice infused with TRA, KKO, and KKO + SCH527123, a CXCR2
antagonist195. Size bar and arrow indicating direction of flow are included. Same
microscope and acquisition software as described in Figure 5.1D. (B) Graphs quantifying
adherent neutrophils in venule thrombi 5 and 60 minutes following laser injury. Thirty-two
injuries were made in 12 KKO-treated mice. Seventeen injuries were made in 3 TRAtreated mice. Eleven injuries were made in 3 KKO + SCH527123-treated mice. Individual
data points and mean ± 1 SD are shown. Comparative statistical analysis was performed
by Kruskall-Wallis one-way ANOVA.
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Figure 5.6. PF4-cfDNA complexes contain both MPO and citrullinated H3.
(A) Representative confocal image of channel adherent NETs incubated with SYTOX
green and an anti-citrullinated H3 antibody before (above) and after (below) a 30-minute
infusion with PF4 (25 µg/ml). Scale bar and arrows showing direction of flow are indicated.
(B) As in (A), but representative confocal image of channel adherent NETs incubated with
SYTOX green and an anti-MPO antibody before (above) and after (below) a PF4 infusion.
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Figure 5.7. Microfluidic studies illustrating PF4-NET interactions.
(A) Representative confocal images of NETs exposed to PF4 or buffer, demonstrating
change in morphology. PF4 specifically adhered to the NET DNA, visualized by labeling
with a polyclonal anti-PF4 antibody (-PF4 Ab), causing the NETs to become compact.
Side bar and arrow indicating direction of flow are included. (B) Mean ± 1 SD of area
covered by NETs exposed to the indicated PF4 concentration is shown on the left.
Simultaneously measured mean fluorescent intensity (MFI) of SYTOX-labeled cfDNA is
shown on the right. For both, N = 3-6 channels per PF4 concentration, with visualization
of 30-60 NETs per channel. Comparative statistical analysis was performed by KruskallWallis one-way ANOVA. (C) Representative widefield images of NETs ± PF4 (10 µg/ml),
simultaneously infused with DNase I (100U/ml). Near complete digestion of NETs not
exposed to PF4 occurred within two minutes, whereas NETs compacted with PF4
remained intact. Size bar and arrows indicating direction of flow are included. (D) Graph
showing representative changes in NET fluorescent intensity observed over a 5-minute
infusion of DNase I (100U/ml) in the presence of 0-10 µg/ml PF4. These studies were
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based on analysis of 3-4 channels for each condition with 30-60 NETs observed in each
channel. (E) Confocal images were taken of 3 channels per condition following digestion
and the residual mean volume ± 1 SD of 30-100 NETs per channel was measured.
Comparative statistical analysis was done by Kruskall-Wallis one-way ANOVA.
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Figure 5.8. PF4 induces NET compaction and DNase I resistance without
fibronectin and in the presence of human plasma.
(A) and (B) are microfluidic channels lined with NETs infused with human plasma ± PF4.
In (A) on the left is a graph showing the mean NET area ± 1 SD after plasma infusion.
NET area was measured in 3 channels per condition with > 150 NETs measured per
condition. Comparative statistical analysis was performed with a Mann-Whitney U-test.
On the right are widefield representative images showing PF4-induced changes in NET
morphology. Scale bar and arrows showing direction of flow are indicated. (B) Same as in
(A), but after a 30-minute infusion of DNase I. NET area was measured in 2 channels per
condition with >150 NETs measured per condition. (C) and (D) Studies of PF4 binding and
effects of PF4 incubation on NETs on uncoated glass slides. In (C), the graph represents
the mean ± 1 SD of NET area following incubation with the indicated concentrations of
PF4. Two slides were incubated with each PF4 concentrations, and 75-150 NETs were
measured per slide. Comparative statistical analysis was performed with a Kruskal-Wallis
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one-way ANOVA. On the right are representative widefield images of NETs incubated with
buffer containing 0 - 50µg/ml PF4. A scale bar is included. In (D), after the PF4 treatment,
the NETs were incubated with DNase I and total NET area was measured. On the left, is
a graph showing the mean ± 1 SD of NET area post-DNase I exposure. Three slides were
incubated with each concentration of PF4 and comparative statistical analysis was
performed with a Student’s t-test. On the right, are representative widefield images of
NETs as in (C), but after DNase digestion. A scale bar is indicated.
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Figure 5.9 Studies showing NET susceptibility to digestion with micrococcal
nuclease.
Microfluidic channel adherent NETs were incubated with PF4 (0-25 µg/ml) and then
infused with micrococcal nuclease (MNase) at concentrations of 100U/ml for 5 minutes.
The graph depicts residual area of the NETs incubated with increasing concentrations of
PF4 following MNase digestion ± 1 SD. These studies were based on analysis of 3
channels for each condition with 50-100 NETs observed in each channel. Comparative
statistical analysis was done with a Kruskal-Wallis one-way ANOVA.
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Figure 5.10. Studies of heparin-mediated NET decompaction and restoration of
nuclease susceptibility.
(A) Representative confocal image showing a comparison of two PF4-compacted NET
channels, following a simultaneous 20-minute infusion with a therapeutic concentration of
heparin at 0.4U/ml (top) or no added heparin (bottom), after Sytox and anti-PF4 antibody
staining. Scale bar and arrow showing the direction of flow in the channel are included.
Same microscope and acquisition software as described in Figure 5.1A. (B) Graph
demonstrating the mean ± 1 SD of the area occupied by the cfDNA of PF4/NET complexes
with and without heparin infusion. Six channels with 30-60 visualized NETs per channel
were studied in each arm and comparative statistical analysis was done with a Student’s
t-test. (C) Graph showing representative changes in NET fluorescent intensity observed
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over a 5-minute infusion of DNAse I (100U/ml) in NETs infused with heparin 0.4U/ml and
the indicated concentrations of PF4. (D) Graph showing the final mean fluorescent
intensity ± 1 SD of channels as in (C). These studies were based on analysis of 3-7
channels for each condition with 30-60 NETs observed in each channel. Comparative
statistical analysis was done by a Kruskal-Wallis one-way ANOVA.
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Figure 5.11. Microfluidic studies examining HIT-antibody PF4-NET complex
interactions.
(A) Representative confocal images of activated neutrophils adherent to fibronectincoated channels and stained for cfDNA (white) and KKO binding (red) in the absence and
presence of 6.5 µg/ml PF4. Size bar and arrow indicating direction of flow are included.
Same microscope and acquisition software as described in Figure 5.1A. (B)
Representative widefield images of adherent neutrophils as in (A), but in the presence of
100U/ml DNase1 and 6.5 µg/ml PF4 ± 25 µg/ml KKO over 2 minutes. Size bar and arrow
indicating direction of flow are included. (C) Representative graph showing the decrease
in NET area over a 3-minute DNase I digestion. (D) Mean ± 1 SD of the final area of NETs
following a 5-minute infusion of DNase I (100 U/ml) in the presence of 6.5 µg/ml PF4 and
KKO or an anti-PF4 antibody (PF4), each at 25 µg/ml. N = 12 in the PF4 and the
PF4+KKO treated arms. N = 3 in the PF4 treated arm. Comparative statistical analysis
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was performed by Kruskall-Wallis one-way ANOVA. (E) PF4-induced resistance to DNase
digestion under static conditions was measured using a previously described NET
degradation assay183. The graph shows the mean percent original fluorescent intensity ±
1 SD. N = 9-10 per arm. Comparative statistical analysis between 3 or more groups was
performed by Kruskall-Wallis one-way ANOVA and comparisons between two groups was
performed with the Student’s t-test.
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Figure 5.12. IgG isolated from HIT patient plasma binds PF4-NET complexes.
(A) Representative confocal image of PF4-NET complexes incubated with IgG (25 µg/ml)
isolated from a healthy control patient plasma for 1 hour, stained with SYTOX and antihuman IgG, showing no human IgG adhering to cfDNA present in NETs. Scale bar and
arrows showing direction of flow are indicated. (B) Representative confocal image of PF4NET complexes incubated with IgG (25 µg/ml) isolated from the plasma of a patient with
a confirmed diagnosis of HIT, stained with SYTOX and anti-human IgG, showing human
IgG binding specifically to NET cfDNA. (C) Representative confocal image of PF4-NET
complexes, stained with SYTOX green, infused with plasma containing KKO, showing that
KKO still binds specifically to PF4-NET complexes when added to plasma rather than
buffer. Scale bar and arrows showing direction of flow are indicated.
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Figure 5.13. CRISPR/Cas9 gene-editing generation of Padi4-/- mice.
(A) At the top, is a schematic showing the first three exons of the murine Padi4 gene and
the binding of CRISPR gRNAs designed to disrupt a 0.2 kb region (red) of the Padi4 gene
encompassing Exon 2. Below the schematic are electrophoresis gels demonstrating the
disruption of Exon 2 PCR amplification in 4 clones, and below the gels is the DNA
sequence analysis from a wildtype mouse with the portion of Exon 2 deleted in clone 18
represented in grey, lower-case letters. At the bottom is the normal murine PAD4 amino
acid (aa) sequence in red with caps indicating sequence preserved in Clone 18, and small
letters indicating the aa sequence lost in Clone 18. The PAD4 sequence expected in clone
18 is shown below with the preserved first 8 aa in red, followed by a frameshift mutation
(-) leading to 9 altered aa in blue with a premature stop codon (*). (B) Representative
images of bone marrow-isolated neutrophils obtained from clone 18 Padi4-/- mice and
Padi4+/+ siblings, plated on a poly-L-lysine coated slide, incubated with buffer alone or
PMA (100 nM) overnight. Samples were SYTOX green stained to visualize DNA shown in
green, and anti-histone H3 (citrulline R2+R8+R17) to visualize citrullinated histones (cit133

His) shown in red. SYTOX and cit-His staining of unstimulated cells shows intact nuclei
with cit-His staining only observed in Padi4+/+ cells. Staining of PMA stimulated cells shows
extracellular DNA strands and increased cit-H3 in Padi4+/+ cells. The microscope and
acquisition software were as described in Figure 5.1A.
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Figure 5.14. NETosis studies in the passive immunization Padi4-/-/HIT mouse model.
(A) Platelet counts 4 hours after intraperitoneal injection of KKO or TRA in HIT or FcRIIA+,
hPF4-/- mice. Padi4 status is indicated. Mean ± 1 SD is shown. Number of mice studied
per arm is indicated in bars. Comparative statistical analysis was performed by KruskallWallis one-way ANOVA. (B) Same as in (A), but for arteriole thrombus size as measured
on confocal imaging after KKO infusion into HIT mice with Padi4 status indicated.
Statistical analysis performed with a Student’s t-test. (C) and (D) are graphs showing the
number of adherent neutrophils and the platelet volumes in cremaster venule thrombi in
HIT mice 60 minutes after laser injury. Individual data points and mean ± 1 SD are shown.
6 injuries were made in 3 TRA-treated HIT mice, 33 injuries were made in 8 KKO-treated
Padi4-/- HIT mice, 5 injuries were made in 1 TRA-treated Padi4-/- mouse, 22 injuries were
made in 13 KKO-treated HIT mice, and 25 injuries were made in 4 KKO-treated HIT mice
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following infusion of DNase. Comparative statistical analysis was performed with a
Kruskall-Wallis one-way ANOVA. (E) Representative confocal images demonstrating the
extent of platelet and neutrophil accumulation at the site of cremaster venule thrombi
following HIT-induction, 5 and 60 minutes after the inciting laser injury and infusion of KKO
in Padi4-/- mice compared to Padi4+/+ mice ± DNase. Size bar and arrow indicating
direction of flow are included. Same microscope and acquisition software as in Figure
5.1D.
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Figure 5.15. MPO and cfDNA levels in clinical samples.
Measurements of (A) MPO and (B) cfDNA levels in plasma from normal controls (Ctl),
patients diagnosed with ITP, and patients evaluated for HIT that either had a confirmed
diagnosis (“HIT”) or were unlikely to have HIT (“Non-HIT”). Individual measurements and
mean ± 1 SD are shown. Comparative statistical analysis was performed by KruskallWallis one-way ANOVA.
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Chapter 6 – ICAM-1 – targeted thrombomodulin mitigates tissue factor – driven
inflammatory thrombosis in a human endothelialized microfluidic model
This chapter presents work featured in the article:
Greineder, C., Johnston, I., et al. (2017) Blood Advances 1(18): 1452-1465
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Abstract
Diverse human illnesses are characterized by loss or inactivation of endothelial
TM, predisposing to microvascular inflammation, activation of coagulation, and tissue
ischemia. Single-chain antibody fragment (scFv/TM) fusion proteins, previously protective
against end-organ injury in murine models of inflammation, are attractive candidates to
treat inflammatory thrombosis. However, animal models have inherent differences in TM
and coagulation biology, are limited in their ability to resolve and control endothelial
biology, and do not allow in-depth testing of “humanized” scFv/TM fusion proteins, which
are necessary for translation to the clinical domain. To address these challenges, we
developed a human whole-blood, microfluidic model of inflammatory, TF-driven
coagulation that features a multichannel format for head-to-head comparison of
therapeutic approaches. In this model, fibrin deposition, leukocyte adhesion, and platelet
adhesion and aggregation showed a dose-dependent response to TNFα activation and
could be quantified via real-time microscopy. We used this model to compare hTM/R6.5,
a

humanized,

intracellular

adhesion

molecule

1

(ICAM-1)–targeted

scFv/TM

biotherapeutic, to untargeted antithrombotic agents, including soluble human TM (shTM),
anti–TF antibodies, and hirudin. The targeted hTM/R6.5 more effectively inhibited TFdriven coagulation in a PC-dependent manner and demonstrated synergy with
supplemental PC. These results support the translational prospects of ICAM-targeted
scFv/TM and illustrate the utility of the microfluidic system as a platform to study
humanized therapeutics at the interface of endothelium and whole blood under flow.
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Introduction
More than a century after the first description of purpura fulminans in 1884, the
relationship between coagulation and systemic inflammation remains the subject of
considerable interest and study196–198. The thrombotic process that occurs in the setting of
infection or activation of the immune response is recognized as having distinct elements,
which distinguish it from normal hemostasis or even other forms of arterial or venous
thrombosis199. While agents such as antithrombin III and APC initially held promise in
treating sepsis, their clinical utility has been limited by a lack of efficacy and bleeding
risks200,201, and the benefit of more standard anticoagulants such as heparin is
uncertain202,203. Better understanding of the elements of inflammatory thrombosis and
identification of targets for safe intervention represent a significant medical priority.
The PC pathway normally functions to limit excessive activation of coagulation, but
it is suppressed in the setting of systemic inflammation. Inflamed ECs demonstrate loss
of the natural anti-coagulants TM and EPCR from their luminal surface30,204–207.
Conversely, TF expression on a variety of cell types in systemic inflammation promotes
activation of coagulation and is an attractive target for intervention208,209. Existing
pharmacologic approaches intended to intercept inflammatory activation of coagulation
may be limited by their inability to localize to TF-expressing procoagulant surfaces. For
example, soluble human TM (shTM), which is currently being evaluated in a phase 3
clinical

trial

of

patients

with

severe

sepsis

and

coagulopathy

(www.clinicaltrials.govidentifier #NCT0158831), lacks any specific affinity for cellular
surfaces210.
My interest in inflammation and the prothrombotic nature of HIT overlapped with
that in Dr. Vlad Muzykantov laboratory’s interest in pharmacologic approaches to
attenuate inflammation by specifically targeting TM to activated cellular surfaces211. In their
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first report of this strategy, recombinant mouse TM was fused to a single-chain antibody
fragment (scFv) specific for mouse ICAM-1 (CD54). In a murine model of acute lung injury,
ICAM-1–targeted scFv/TM was found to facilitate interaction with endogenous EPCR,
reduce inflammatory markers, and improve transendothelial plasma protein leakage212.
While these studies demonstrated the potential therapeutic benefit of this approach, the
effect on activation of coagulation was not examined.
The challenges in demonstrating the efficacy of ICAM-1–targeted TM in TF-driven
inflammatory thrombosis are several fold. First, there is uncertainty over the clinically
significant sources of TF in sepsis and related disorders213,214. Differences in cellular
sources of TF are particularly relevant to scFv/TM, as its distribution is more controlled
than untargeted “fluid-phase” agents (i.e., soluble TM) and therefore more likely sensitive
to changes in the relative cellular contributions to thrombin generation. It is challenging to
discern the contribution of endothelial TF from other sources such as hematopoietic cells,
epithelium, fibroblasts, pericytes, and smooth muscle215–217. While ECs express TF under
inflammatory stimuli in vitro, studies have failed to demonstrate a definitive role of
endothelial TF in murine models218, which may not fully replicate human biology or be
sensitive to the contribution of endothelial TF to activation of coagulation215–217. TM itself
demonstrates species-specific differences in the balance between anti-inflammatory and
anti-thrombotic activity219,220. Finally, translation to human pathologies has been limited by
the absence of species cross-reactivity of the murine therapeutic.
To address these challenges and provide a model that can begin to close this
translational gap, my efforts at using a commercially available, multichannel microfluidic
system that uses human whole blood perfused through cytokine-activated, human
endothelial–lined flow chambers, with real-time microscopy for visualization of underlying
pathophysiologic events were combined with the Muzykantov’s group. This joint effort
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focused on use of this sytem to study “humanized” scFv/TM therapeutic hTM/R6.5, which
incorporates both human TM and a human-specific anti–ICAM-1 scFv. This approach
allowed testing of ICAM-1–targeted scFv/TM as an intervention in TF-driven inflammatory
thrombosis using an entirely human microfluidic system, employing multiple channels run
simultaneously, allowing for a side-by-side comparison of therapeutic interventions within
a single experiment.

Methods
Venipuncture and whole blood preparation.
All studies involving human subjects were approved by the University of
Pennsylvania institutional review board (protocol 822534). Written informed consent from
healthy volunteer donors was obtained for the use of deidentified blood samples. Whole
blood samples were collected from the antecubital vein using a 19G butterfly cannula
system. The first 5 ml of blood was discarded, followed by collection into vacuum tubes
containing citrate and corn trypsin inhibitor (CTI), a FXII inhibitor, with final concentrations
of 11 mM and 50 μg/ml, respectively.
In experiments involving inflammatory activation of whole blood, 50 ng/ml
lipopolysaccharide (LPS) was added for 90 minutes at 37°C. In experiments involving PCdeficient blood, whole blood samples were centrifuged for 15 minutes at 1500g at room
temperature to isolate platelet-poor plasma. 50% of the original plasma was removed and
replaced with an equivalent volume of PC-immuno-depleted or normal control plasma. CTI
was then added to maintain the final blood concentration at 50 μg/ml.
In all experiments, 5 μg/ml Alexa Fluor 568/anti-fibrin monoclonal antibody was
added to whole blood, along with either calcein-AM (2 μg/ml) or fluorescent anti-leukocyte
and platelet antibodies (Brilliant Violet anti-CD45 and FITC anti-CD41, each 1.5 μg/ml).
142

Whole blood samples were recalcified just prior to infusion into the microfluidic channels,
adding CaCl2 to a final concentration of 11 mM.

Microfluidic model of inflammatory thrombosis.
Endothelialized microfluidic chambers and a TNFα injury were described in
Chapter 2. On the day of experimentation, endothelialized channels were flow adapted for
4 to 6 hours at 5 dynes/cm2 at 37°C using TNFα. To induce inflammatory activation of
ECs, TNFα was added at varying concentrations during the flow adaption period. Fresh
media was allowed to flow through the channels for 30 minutes to “wash out” residual
TNFα prior to introduction of whole blood. In some experiments, EC-targeted antibodies
or recombinant proteins were added during the first 25 minutes of this washout period,
followed by 5 minutes of flow to remove nonspecifically bound protein. In other
experiments, antithrombotic agents were mixed into the whole blood.
While each Bioflux 48-well plate contains 24 flow chambers, whole blood
experiments were run with no more than 8 channels (4 pairs of 2) at once to minimize the
time between imaging of each pair of channels. This setup allowed 2 or 3 replicates for
each of 3 or 4 experimental conditions (e.g., control, TNFα only, TNFα + therapeutic A,
and TNFα + therapeutic B). A computer interface was used to move a motorized
microscope stage (Fluxion Biosciences) rapidly between viewing areas, allowing each pair
of channels to be imaged approximately every 15 to 30 s. Imaging was performed on a
Zeiss Axio Observer microscope under a ×10/0.25 objective. The focal plane was set to
be at the interface of the lower wall endothelial layer and the whole blood. Under this
objective and aperture, we expect the depth of field to be ∼8.5 μm. Fluorescent images
were acquired using identical settings for all channels, while bright-field images allowed
direct visualization of flow.
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Confocal microscopy.
Channels were fixed by flowing 4% paraformaldehyde at 1 dyne/cm 2 into the
channel for 15 minutes. The cells were washed with PBS and blocked with 5% donkey
serum prior to adding primary and secondary antibody and staining with Hoechst reagent.
Imaging was performed using a Zeiss LSM 710 at original magnification ×20.

Data analysis and statistics.
Each figure represents data from a single experiment with means and standard
errors derived from replicate channels within that experiment. For analyses, bright-field
and fluorescence microscopy images were imported into ImageJ and analyzed frame by
frame using identical acquisition parameters for each experiment. Backgrounds were
subtracted using an ImageJ rolling-ball algorithm with a radius of 50 pixels. Preset regions
of interest, covering the entire channel except the areas immediately adjacent to the side
walls, were used to measure MFI in green and red channels or mean signal intensity in
the bright-field channel. Frame “time codes” were used to generate time courses, and
areas under the curve (AUCs) were calculated for statistical comparisons. First-derivative
curves were calculated with GraphPad statistical software and statistical differences were
determined using GraphPad Prism 6.0. One-way analysis of variance was performed,
followed by appropriate multiple comparison (Tukey) test and calculation of multiplicity
adjusted P values. P < 0.05 was considered statistically significant.

Cells and cell lines.
HUVECs were purchased and maintained using EGMTM BulletKitTM (Lonza).
Drosophila S2 cells were maintained in Schneider’s complete medium and transitioned to
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serum free Insect-Xpress (Lonza) supplemented with 0.5 mM CuSO4 for recombinant
protein expression. Anti-human ICAM-1 hybridoma (clone R6.5), CHO-hICAM, and CHOK1 wild type cells were purchased from ATCC.

Antibodies and other reagents.
Human α-thrombin, human PC, CTI, and blood collection tubes containing citrate
and CTI were purchased from Haematologic Technologies. Recombinant human TNFα
was purchased from Corning. Lipopolysaccharides (LPS) from E. Coli 055:B5 and
recombinant hirudin were purchased from Sigma-Aldrich. Anti-human VCAM-1
(polyclonal, BBA19) was purchased from R&D systems. Anti-human TF antibodies were
purchased from R&D systems and eBioscience (clone HTF-1). FITC conjugated-antiCD41 (clone HIP8) was also purchased from eBioscience. Anti-human TM (clone Phx-01)
and Brilliant Violet anti-CD45 (clone 30-F11) antibodies were purchased from BioLegend.
Lyophilized, immunodepleted PC-deficient plasma and normal plasma controls were
purchased from Aniara.

Cloning of R6.5 single chain variable fragment (scFv), soluble human TM (shTM), and the
hTM/R6.5 fusion protein.
PCR using 5’ signal peptide primers was used to isolate full length cDNAs for R6.5
variable heavy chain (VH) and light chain (VL) from hybridoma-derived single stranded
cDNA, as previously described221. The encoded sequence was compared with the
previously published full-length sequence of the R6.5 monoclonal antibody variable
domains and found to be identical222. VH and VL cDNAs were assembled into an scFv
construct in the pMT/Bip expression vector with the triple flag tag appended to the 3’ end
of the VL domain. Likewise, cDNAs encoding shTM (Glu22-Ser515) and the hTM/R6.5
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fusion protein were ligated into the pMT/Bip expression vector (Invitrogen), each with a
triple Flag tag appended to the 3’ end. For the fusion protein, an Spe I site was added to
the 5’ end of R6.5 scFv, and the 3’ end of shTM, along with a 13-amino acid rigid linker
((SSSSG)2AAA).

Recombinant protein expression and purification.
pMT/shTM, R6.5 scFv, and hTM/R6.5 were each co-transfected with pCoBLAST
in S2 cells and selected with blasticidin to generate stable cell lines216. Expression and
purification was performed as previously described216. Briefly, proteins were harvested
from S2 cell supernatant using an anti-FLAG (M2) affinity column (Sigma-Aldrich), and
assessed for purity via sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) and high-performance liquid chromatography (HPLC). The differences in affinity
lead to different flow rates and isolation of components from the mixture.

Results
Production and characterization of human-specific anti-ICAM scFv/TM.
To create the humanized anti-ICAM scFv/TM complementary DNA (cDNA)
construct (hTM/R6.5), cDNA encoding the extracellular portion of human TM (Glu22Ser515) was fused with the R6.5 scFv cDNA, containing VH and VL domains cloned from
the corresponding anti–human ICAM-1 hybridoma121,223. The detailed molecular design of
each construct is shown in Figure 6.1A. Purified R6.5 scFv and hTM/R6.5 migrated as
single bands on nonreducing SDS-PAGE (Figure 6.1B), with sizes (∼35 kDa and ∼120
kDa) similar to those seen for previous scFv and scFv/TM fusion proteins (TM runs
significantly higher than its predicted size due to glycosylation). Similar purity was seen
on size-exclusion high-performance liquid chromatography, although this method
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revealed a dimer form of hTM/R6.5, which accounted for ∼20% of total absorbance
(Figure 6.1C). As shown in Figure 6.1D and 6.1E, hTM/R6.5 demonstrated high affinity,
specific binding to human ICAM-1 in a flow cytometry based assay with stably-transfected
CHO cells (Kd = 24 nM) and a cell-based enzyme-linked immunosorbent assay on TNFα–
activated HUVECs (Kd = 9.7 nM), respectively. The fusion protein was functionally active
when bound to TNFα–activated HUVECs, demonstrating thrombin-dependent PC
activation after binding and washing to remove nonspecifically-bound protein. At
concentrations sufficient to saturate available binding sites on these cells (40-50 nM), the
fusion protein more than compensated for the loss of APC generation caused by activation
of the ECs by cytokine (P < .01; Figure 6.1F).

Establishing a multichannel system of endothelialized flow channels.
To enable testing of hTM/R6.5 at the interface of human whole blood and
endothelium, HUVECs were grown in microfluidic flow chambers until they established 3dimensional, fully confluent, endothelialized channels (typically 2-3 days) as displayed in
Chapter 2. Following 6 hours of flow adaptation at 5 dynes/cm2, a shear stress typical of
postcapillary venules224, cells displayed the qualities described in Chapter 2.

Characterization of inflammatory thrombosis model.
The inflammatory thrombosis model was characterized as described in Chapter 2.
To determine the optimal conditions for testing antithrombotic therapeutics, we defined the
extent of coagulation in the microfluidic model as a function of the dose and time of
cytokine exposure. Both higher concentration of TNFα (Figure 2.5B) and longer duration
of stimulation (Figure 2.5C) led to greater fibrin deposition upon infusion of whole blood.
These experiments also revealed the advantage afforded by the multichannel format,
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which allowed comparison of multiple experimental conditions (with replicates) within a
single experiment. Figure 6.2 shows the relatively small variance within a single
experiment, compared with the variability across experiments with separate EC
preparations and whole blood samples. On the basis of these results, each subsequent
experiment was performed with a single blood sample and EC preparation and 8
microfluidic channels.
Apart from fibrin deposition, other physiologically relevant outcomes were found to
vary with the extent of cytokine activation of the endothelialized channels. In particular,
adhesion of leukocytes and platelets, based on accumulation of green fluorescence, was
seen only after TNFα stimulation (Figure 6.3A). Higher doses of TNFα also demonstrated
earlier disruption and occlusion of blood flow, based on changes in bright-field signal
intensity (Figure 6.3C). Separately tracking platelets and leukocytes using antibodies to
platelet αIIb 3 labeled in green and antibodies to leukocyte CD45 labeled in blue, we found
that while that the number of adherent platelets varied with TNFα concentration in the
range of 1 to 10 ng/ml, the number of adhered leukocytes was similar (Figures 6.3B). We
confirmed this finding using an automated cell counting algorithm to enumerate adherent
leukocytes flowing over TNFα–activated channels and found similar numbers of adhered
leukocytes per channel area in channels treated with either 1 or 10 ng/ml TNFα (Figures
6.4A). Additional experiments performed across a lower range of TNFα doses (0.1-1.0
ng/ml) revealed a dose response of leukocyte adhesion to TNFα stimulation within this
lower range (Figures 6.4B). Finally, flowing whole blood over TNFα–activated channels
resulted in not only adhesion of leukocytes but also an activation of neutrophils that
resulted in deposition of NETs225, which could be visualized in real time with nucleic acid
stains (Figures 6.5)221.
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Inflammatory thrombosis model is TF driven.
We next validated the role of TF in initiating coagulation in this model, noting that
peripheral blood was collected in the presence of CTI, a FXIIa inhibitor222. Figures 6.6A
shows the experimental design, in which TF inhibitory antibody (or media control) was
flowed over TNFα–activated endothelialized channels prior to the infusion of whole blood.
As shown in Figures 6.6B, TF blockade significantly (P = 0.02) reduced fibrin deposition,
confirming the role of endothelial TF as a driver of coagulation in this model. TF antibody
decreased the accumulation of green fluorescence (Figures 6.7A), reflecting the sum of
leukocyte and platelet adhesion. While these cell types were not individually stained in this
experiment, the morphology suggested a decrease in platelet rather than leukocyte
adhesion.

Endothelial TM regulates inflammatory activation of coagulation.
A similar approach was taken to investigate the role of endogenous endothelial TM
in regulating coagulation in the whole blood microfluidic model. Although TNFα stimulation
decreases endothelial TM, some APC generation capacity remains (Figures 6.1F). To
achieve complete inhibition, we used an antibody specific for the fifth epidermal growth
factor–like domain of TM, which blocks thrombin binding and eliminates nearly all APC
generation capacity (Figures 6.1F)226. Treatment of TNFα–stimulated channels with this
antibody prior to the infusion of whole blood significantly increased fibrin deposition (P <
0.001; Figures 6.6C-D).
These results established the microfluidic model as a means to test targeted
therapeutics in a humanized system, with the hypothesis that the ICAM-1 targeted fusion
protein would localize to activated cellular surfaces, reverse the loss of endothelial TM
induced by cytokine activation, and abrogate the TF-driven thrombotic response. Indeed,
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treatment of TNFα–activated endothelialized channels with 50 nM hTM/R6.5, a
concentration chosen based on the prior binding studies (Figures 6.1E), produced the
opposite effect of the TM-blocking antibody, completely eliminating fibrin deposition
(Figures 6.6B-C). As seen previously, effects on green fluorescence mirrored those seen
for fibrin generation, consistent with a reduction in platelet adhesion (Figures 6.7B).

Comparative testing of antithrombotic agents.
Given the effectiveness of hTM/R6.5 in the whole blood microfluidic model, we
next took advantage of the multichannel format to compare its antithrombotic efficacy with
that of other antithrombotic agents. As a first step, the fusion protein was tested against
equimolar concentrations of its individual components, shTM and R6.5 scFv. These
proteins had minimal effects on fibrin deposition when infused during the TNFα washout
period (Figure 6.8). While expected, this confirmed that both domains of the fusion protein
are required for its activity and excluded that ICAM-1 blockade alone might be solely
responsible for the observed anti-thrombotic effect.
Endothelial-bound hTM/R6.5 was next tested against shTM added directly to
whole blood. Figure 6.9A shows the experimental design of these experiments. While
both agents significantly decreased fibrin deposition (Figure 6.9B), the effect of shTM was
less sustained (P = .05), even at a dose far greater than its IC50 in TF-induced thrombin
generation assays227. It should be noted that hTM/R6.5 was limited to the protein bound
to the cells, as the targeted protein was not added to whole blood in these experiments.
Hirudin (5 U/ml) and hTM/R6.5 (50 nM) were also compared and demonstrated similar
results (P = 0.03; Figure 6.9C).
hTM/R6.5 was next compared with shTM following a combination of cytokine
activation of ECs and inflammatory activation of whole blood (Figure 6.10A). The latter
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was induced by 90-minute preincubation of the whole blood with 50 ng/ml LPS, conditions
previously used to induce neutrophil oxidative burst and monocyte TF expression in
human whole blood228,229. LPS was chosen to better simulate human disease states, such
as sepsis, in which activated leukocytes and other blood components may contribute to
inflammatory thrombosis198,199. While both agents demonstrated antithrombotic effect in
this setting, hTM/R6.5 was significantly more effective in inhibiting fibrin deposition than
shTM (P = 0.05; Figure 6.10B).

hTM/R6.5 is at least partially PC dependent.
We next tested the contribution of PC activation to the antithrombotic activity of
hTM/R6.5. A recently reported antibody, HAPC1573, which binds human APC (but not its
zymogen) and inhibits its inactivation of FVa and FVIIIa in a dose-dependent manner230,
was mixed into whole blood (Figure 6.11A). In naive whole blood, HAPC1573 treatment
produced fibrin deposition similar to equimolar isotype control antibody (P = 0.33),
although shortened time to peak-fibrin generation was observed. APC inhibition markedly
increased fibrin deposition in endothelialized channels treated with hTM/R6.5 (P < 0.05),
although a persistent delay was seen in the time to peak-fibrin generation (Figure 6.11BD). This effect, reported in previous TGA studies, has been attributed to direct inhibition
of thrombin by TM227.
These results prompted investigation of hTM/R6.5 in the setting of PC deficiency,
a condition observed in sepsis and other syndromes involving systemic activation of
coagulation231–233. To achieve the levels of PC deficiency similar to patients with these
illnesses, we removed 50% of the plasma from donor whole blood and replaced it with an
equal volume of PC-immuno-depleted (or non-depleted control) plasma (Figure 6.12A).
Like APC inhibition, partial depletion of plasma PC produced fibrin deposition similar to
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control whole blood (P = 0.34), with a slight decrease in time to peak-fibrin deposition234.
PC deficiency dramatically altered the activity of the fusion protein, eliminating its inhibitory
effect on overall fibrin deposition (P = 0.34; Figure 6.12B-D). In contrast, hTM/R6.5
produced a delay in time to peak-fibrin generation in both PC-deficient and control whole
blood, consistent with direct thrombin inhibition by the fusion protein (Supplement Table
10)227. Finally, addition of exogenous, plasma-derived human PC to the PC-depleted blood
restored the full antithrombotic effect of hTM/R6.5 (P < 0.05; Figure 6.12B-D).

Discussion
This is the first report of ICAM-1 targeted fusion proteins as a therapy for TF-driven
inflammatory thrombosis. Affinity targeting to cellular surfaces has the potential to
dramatically alter local concentrations and interaction with binding partners, particularly in
surface-driven phenomena such as coagulation, and the improved efficacy of hTM/ R6.5,
compared with other therapeutics, including sTM, hirudin, and anti-TF, demonstrates the
translational potential of this approach. hTM/R6.5 bound to the surface of activated human
ECs and restored APC generation capacity above that of uninflamed endothelium.
hTM/R6.5 shares a number of desirable features with its mouse-specific analog,
YN1/mTM212, and the use of an scFv fragment enables facile genetic fusion to therapeutic
cargoes and mitigates the Fc and complement-mediated toxicities seen in clinical trials of
the parental antibody, R6.5, or enlimomab235–238.
To demonstrate the therapeutic efficacy of human-specific hTM/ R6.5, a
microfluidic system consisting of entirely human components was developed to model TFdriven inflammatory thrombosis. Sophisticated in vitro systems have been developed that
incorporate multiple cell types and reproduce the architecture of microvascular
networks239–243. Our priority was to establish a comparatively straight- forward model,
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suitable for testing and comparing targeted scFv/TM with other antithrombotic drugs211,244–
246

. Although the model lacks subendothelial components of a true vessel, including

epithelial tissues, it allows for control over endothelial and leukocyte activation,
manipulation and treatment of human WB, and quantification of therapeutic effects with
high spatial and temporal resolution. While the present focus was on abrogation of fibrin
deposition, additional readouts of inflammatory biology such as leukocyte adhesion and
generation of neutrophil extracellular traps were also shown to be possible using this
model system. By calculating first-derivative curves of fibrin fluorescence intensity, we
provide readouts analogous to common TGA assays. Importantly, the multichannel format
of this system allows for parallel testing of multiple therapeutic approaches with a single
blood donor and EC preparation, limiting the impact of these variables, which can
complicate other complex microfluidic model systems.
Several limitations of the model should be highlighted. First, PDMS flow chambers
are rectangular in cross-section and fail to reflect the mechanical compliance of normal
vasculature247. Use of linear channels with fixed dimensions and no branches limits
extrapolation to physiologic vascular beds, where inflammatory, TF-driven thrombosis
may occur heterogeneously248. The important physiologic sources of TF are a matter of
ongoing investigation249, and as currently constructed, this model is limited to
hematopoietic and endothelial sources. In addition, only HUVEC cells were investigated
in the current model, although further optimization to enable culture of and comparison
with other endothelial sources is ongoing. The current conformation does not permit
recirculation, so exposure of endothelialized channels to WB flow was limited in duration
by need to avoid cell settling and activation of the contact pathway (CTI provides ;1 hour
of inhibition222). While our intention was to model TF-driven thrombosis, the use of CTI
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may likewise be viewed as a limitation, as it eliminates any contribution of FXII–dependent
coagulation, believed to play a role in certain systemic inflammatory syndromes250.
These limitations notwithstanding, the data presented provide several insights into
the role of the endogenous PC pathway and the action of scFv/TM therapeutics. First, the
contrasting results with inhibition and augmentation of endothelial TM suggest its
importance in regulating coagulation under systemic inflammation. Second, the benefit of
ICAM-targeted TM over its soluble counterpart supports the hypothesis that localization of
the protein to the cellular membranes enhances its functional activity212,251,252. In fact, the
difference in potency between these 2 agents may be more significant than their relative
concentrations would suggest, as only a fraction of hTM/R6.5 molecules would have
bound to the cell membrane. While ICAM-1 targeting of hTM/R6.5 was limited to
hematopoietic and ECs in these studies, other cell types, such as epithelium, express
ICAM-1, and may be both an important source of TF24 and a valuable target of this
approach253.
There are several reasons why binding of TM to cell membranes may enhance its
antithrombotic activity. Cell-surface localization positions TM in proximity to TF and
prothrombinase complexes assembled on cell membranes, resulting in immediate
inhibition of thrombin and redirection to PC activation as it is produced254,255. Experiments
involving antibody inhibition of APC and plasma PC deficiency suggest that PC activation
is an important mechanism of hTM/R6.5 antithrombotic activity, as the ability of hTM/R6.5
to decrease the peak rate of fibrin generation was PC dependent. EC surface localization
may accelerate activation of PC by partnering with endogenous EPCR, promoting PC
cleavage by the thrombin/TM complex256. Although this was not investigated in the present
studies, previous studies with the murine-specific analog of hTM/R6.5 demonstrated APC
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generation by cell-bound fusion protein was inhibited when binding of PC to endothelial
EPCR was blocked212.
The contribution of PC activation to the antithrombotic activity of hTM/ R6.5
suggests a benefit with combination therapy, as pharmacologic replacement of TM alone
may be insufficient in the setting of PC deficiency (as seen in septic patients231,232). While
human plasma–derived PC concentrate failed to improve outcomes in sepsis or
disseminated intravascular coagulation22,257, the synergy observed with pairing of PC and
hTM/R6.5 suggests that simultaneous PC replacement and targeted delivery of TM may
be an effective clinical strategy. Further investigation using patient specimens in our
microfluidic model and confirmation in preclinical animal models will be necessary to
determine if this combination therapy can surpass numerous previous pharmacologic
attempts to prevent TF-driven inflammatory thrombosis and disseminated intravascular
coagulation in the clinical setting.
These studies present a novel therapeutic approach in sepsis, but that could be
applicable across various Steps 2 and 3 in HIT’s pathogenesis (Figure 1.5). These studies
show that ICAM-1-targeted TM is more effective than its soluble form displaying how
thrombi localization can improve therapeutic efficacy. In reference to HIT, this could be
utilized to localize therapeutics to HIT relevant targets; these targets could include
PF4/GAG (as discussed in Chapter 3), PF4/heparin, PF4-VWF-HIT antibody (as
discussed in Chapter 4), or PF4-NET-HIT antibody (as discussed in Chapter 5)
complexes. TM could potentially combat HIT thrombosis as it provides both antithrombotic and anti-inflammatory components. Alternatively, therapeutics targeting the
glycocalyx, VWF, neutrophils, or NETs could also be affective in a localized structure.
Moreover, by understanding how each target is significant in particular vessels and injury
settings, the therapeutics can be further tailored to patient conditions.
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Figure 6.1. Assembly, characterization, and functional activity of hTM/R6.5
biotherapeutic.
(A) Molecular design of R6.5 scFv and hTM/R6.5. (B) Size and purity of recombinant
proteins based on SDS-PAGE (lane 1, R6.5 scFv; lane 2, hTM/R6.5) and (C) size
exclusion HPLC. hTM/R6.5 has a minor dimer form (indicated by arrow), accounting for
∼20% of absorbance at 280 nm. (D) hTM/R6.5 binds specifically to human ICAM-1expressing CHO cells (CHO-hICAM), but not wild type (CHO wt). Flow cytometry was
performed on each cell type incubated with different concentrations of fluorescently
labeled fusion protein. For each reaction, MFI was calculated for 10 000 events. Each
reaction was done twice, with mean ± SD of the MFI shown. (E) hTM/R6.5 binds strongly
to TNFα-stimulated HUVECs, but only minimally to non-stimulated cells. Cell-based
ELISAs were performed on live cells as previously described19 using anti–FLAG-HRP to
probe for cell-bound fusion protein. Graph shows mean ± SD. (F) In vitro APC generation
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assay by cell-bound fusion protein, as described previously212. TNFα-stimulated HUVECs
show reduced APC generation capacity due to loss of surface TM, although some residual
function is seen in comparison with cells treated with an anti-TM blocking monoclonal
antibody. For testing the functional activity of cell-bound hTM/R6.5, bvg-stimulated cells
were incubated for 30 minutes at 37°C with various concentrations of fusion protein and
then washed to remove nonspecifically bound protein prior to incubation with human
thrombin (1 nM) and PC (100 nM). At saturating concentrations of hTM/R6.5 (40-50 nM),
the fusion protein more than compensates for the reduction in PC activation induced by
TNFα stimulation (*P < .01 versus TNF only). Graph shows mean ± SD, N = 3 for each
condition. EC50, 50% effective concentration; mOD, 1/1000th of an optical density unit.
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Figure 6.2. Intra- versus inter-experimental variability.
Fibrin deposition data from two independent experiments. While some variation is seen
between replicate channels within the same experiment (error bars show mean ± SEM for
N = 2-3 channels), the timing and extent of fibrin deposition is fairly consistent, allowing
meaningful statistical comparisons between experimental groups. In contrast, the MFI
versus. time curve is markedly different between TNFα-stimulated channels run on
separate days, preventing pooling of data or comparisons of groups run on separate days.
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Figure 6.3. Changes in TNFα treatment impact fibrin and platelet accumulation
which impact time to occlusion.
(A) Green fluorescence, representing adhesion of leukocytes and platelets (both labeled
with calcein AM) to the endothelium. Representative image (left panel) shows individual
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adherent leukocytes (arrows) as well as variably sized clusters of various cell types
(arrowheads). Graph (right panel) shows mean fluorescence intensity versus time for
differing TNFα concentrations, mean ± SEM, with N = 2 channels for control and N = 3
channels for each concentration. (B) Three color experiment, in which fibrin (red),
leukocytes (blue), and platelets (green) were tracked with distinct fluorophores. Left panel
shows representative images of endothelialized channels pre-activated with varying doses
(1 ng/ml versus. 10 ng/ml) of TNFα. Quantitation (right panel) shows that platelets and
fibrin vary with TNFα concentration, but the number of adherent leukocytes is unchanged
across doses, ** = P < 0.01, * = P < 0.05, # = n.s. (P = 0.54). (C) Use of brightfield signal
intensity as a marker of partially disrupted or fully occluded flow, following infusion of whole
blood into TNFα-stimulated endothelialized channels. Representative image (left panel)
shows characteristic increase in signal in bottom channel, which had occluded at the time
point shown. Graph shows mean signal intensity (MSI) versus time for differing TNFα
concentrations, mean ± SEM, with N = 2 channels for control and N = 3 channels for each
concentration.

160

A

B

Figure 6.4. Quantification of leukocyte numbers in TNFα-activated channels.
(A) Similar density of adhered leukocytes was observed between channels activated with
either 1 ng/ml (blue) or 10 ng/ml (red) (N =3/dose) (B) A dose-response of adhered
leukocytes was seen in a lower range of 0.1-1 ng/ml of TNFα (n=1/dose). Minimal
leukocyte adhesion was seen in un-activated channels (blue). The density of adhered
leukocytes was calculated using an automated particle counting algorithm (ImageJ).
Images from calcein AM-stained blood were converted to binary masks, and particles
counted using the included “analyze particles” algorithm with a circularity index of 0.5-1.
To minimize interference from large platelet aggregates, blood was not re-calcified prior
to infusion over channels in these experiments.
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Figure 6.5 Exposure of TNFα-activated channels to whole blood results in
deposition of NETs.
(A) Staining of extracellular nucleic acid, often in elongated deposits, was seen in TNFαactivated endothelium (bottom), but not in untreated channels (top). (B) Formation and
growth of NETs could be monitored in whole blood in real time. Whole blood, stained with
1 µM cell-impermeant SYTOX nucleic acid stain (green) and 4 µM Hoeschst cell-permeant
nucleic acid stain (blue), was infused over TNFα (0.5 ng/ml)-activated endothelium.
Neutrophil nuclei could be seen as small, mobile, poly-lobulated forms (arrowhead), while
endothelial nuclei were larger, round, and stationary (asterisk). Extracellular DNA
associated with NETs stained brightly with SYTOX, and dimly with Hoeschst (arrows).
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Figure 6.6. Endothelial TM regulates TF-driven coagulation in inflammatory
thrombosis model.
(A) Schematic showing experimental design. Endothelialized channels were flow adapted
at shear stress of 5 dynes/cm2, stimulated with 1 ng/ml TNFα for 6 hours, and then treated
with antibodies or fusion protein during the first 25 minutes of a 30-minute TNFα washout
period, followed by a 5-minute wash to remove nonspecifically bound protein and, finally,
infusion of whole blood at shear stress of 5 dynes/cm2. (B) Blockade of endothelial TF
delays and markedly reduces fibrin deposition (P = 0.02 for AUC of TNF versus TNF +
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anti-TF antibody). Graph shows mean ± SEM, with N = 2-3 channels per condition. (C)
Blockade of endothelial TM results in significant increase in fibrin deposition (P < 0.001
for AUC of TNF only versus TNF + TM blockade), whereas treatment of TNFα-activated
endothelium with hTM/R6.5 scFv fusion protein completely eliminates fibrin deposition (P
= 0.03 for AUC of TNF only versus TNF + hTM/R6.5). Graph shows mean ± SEM, with N
= 2-3 channels per condition. (D) Representative fluorescent images for panel C show
fibrin deposition within endothelialized channels and demonstrate opposing effects of TM
inhibition and augmentation.
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Figure 6.7. Therapeutic comparison of platelet and WBC accumulation during
inflammatory thrombosis.
Green fluorescence time curves (left panel) and AUC analysis (right panel), mean ± SEM,
from (A) TF inhibition experiment (N = 2 channels per condition, *P < 0.05 versus. TNFα
only), (B) anti-TM versus. hTM/R6.5 experiment (N = 2 channels per condition, *P = 0.03
for hTM/R6.5 versus anti-TM), (C) shTM versus hTM/R6.5 experiment (N = 2 channels
per condition, *P = 0.03 for hTM/R6.5 versus TNFα only, # P = 0.08 for shTM versus TNFα
only), and (D) combined TNF/LPS model (N = 2 channels for TNF/LPS only and N = 3
channels for each treatment group, *P = 0.04 for shTM versus. TNFα/LPS only, **P = 0.02
for hTM/R6.5 versus TNFα/LPS only). The effect of each antibody and/or therapeutic on
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the accumulation of green fluorescence mirrored its effect on fibrin deposition (Figures
6.6A, 6.6B, 6.10, and 6.11, respectively).
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Figure 6.8. Both domains of hTM/R6.5 are required to generate an antithrombotic
effect.
(A) Experimental design. All proteins were infused in equimolar concentrations (50 nM)
during the TNF washout period, followed by a 5-minute wash to remove nonspecifically
bound protein. Flow of media and whole blood was at shear stress of 5 dynes/cm2. (B)
Only hTM/R6.5 inhibited fibrin deposition, confirming that both the ICAM-1 binding and
hTM domains must be present to produce an antithrombotic effect. Left panel shows MFI
versus time, mean ± SEM, with N = 2 channels per condition. Right panel shows AUC
analysis. * = P < 0.05 versus all other conditions.
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Figure 6.9. Comparative testing of antithrombotic agents.
(A) Experimental design, showing distinct timing of treatment with hTM/R6.5 scFv, bound
to ECs during the first 25 minutes of the TNFα washout period versus soluble agents,
which were mixed into whole blood. (B-C) Both 100 nM shTM (B) and 5 U/ml hirudin (C)
inhibited coagulation, but were less effective than hTM/R6.5 (50 nM). Left panels show
MFI versus time, ± SEM, with N = 2 channels for TNFα only and N = 3 channels for each
therapeutic. Middle panels show representative fluorescent images. Right panels show
AUC analyses. * = P < 0.05 versus TNF only; ** = P < 0.05 versus both other conditions;
#, not significant (P = 0.17).
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Figure 6.10 hTM/R6.5 has greater antithrombotic activity than shTM in combined
model of endothelial cytokine activation and endotoxemia.
(A) Experimental design, showing 6-hr stimulation of endothelialized channels with TNFα
and 90-minute preactivation of whole blood with LPS (50 ng/ml). In this case, hTM/R6.5
(50 nM) was infused during the TNFα washout period and mixed into the whole blood. (B)
The fusion protein provided superior antithrombotic effect. Left panels show MFI versus
time, mean ± SEM, with N = 2 channels for TNF/LPS only and N = 3 channels for each
therapeutic. Right panels show AUC analyses. * = P < 0.05 versus TNF/LPS only; ** = P
< 0.05 versus both other conditions.
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Figure 6.11. Antithrombotic activity of hTM/R6.5 is largely reversed by APC
inhibition.
(A) Design of APC inhibition experiments. Anti-hAPC antibody (HAPC1573) or equimolar
isotype control were mixed into whole blood at 300 nM concentration. (B) Inhibition of APC
significantly reduced the antithrombotic effect of hTM/R6.5 while not significantly affecting
fibrin deposition in endothelialized channels not treated with fusion protein. Graph shows
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mean ± SEM, with N = 2 channels for each condition. (C) AUC analysis. * = P < 0.05
versus all other conditions; #, not significant (P = 0.47); ##, not significant (P = 0.72). (D)
Time curves of the first derivative of fibrin fluorescence intensity demonstrate the effects
of various combinations of HAPC1573 and hTM/R6.5 on key parameters: peak-fibrin
generation rate and time to peak-fibrin generation rate. Dotted lines show actual values,
whereas solid lines show Gaussian functions fitted to these data.
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Figure

6.12.

Antithrombotic

activity

of

hTM/R6.5

is

enhanced

by

PC

supplementation in the setting of plasma PC deficiency.
(A) Design of PC deficiency experiments. hTM/R6.5 was infused during the first 25
minutes of the TNFα washout period, followed by infusion of PC-deficient blood versus
control blood. (B) The anti-thrombotic effect of hTM/R6.5 was reduced in PC-deficient
blood and restored with the addition of supplemental PC. Graph shows mean ± SEM, with
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N = 2 channels for each condition. (C) AUC analysis. * = P < 0.05 versus all other
conditions; #, not significant (P = 0.33); ##, not significant (P = 0.28). (D) Time curves of
the first derivative of fibrin fluorescence intensity demonstrate a delay in peak-fibrin
deposition, but not a reduction in peak height by hTM/R6.5 in PC-deficient whole blood.
Full efficacy is restored with the addition of supplemental plasma PC.
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Chapter 7 – Discussion, Impact, and Future Directions
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Discussion
ECs play an important role in the thrombotic complications in HIT.
In Chapter 3, we showed that in a microfluidic photochemical model of endothelial
injury and in the cremaster arteriole laser injury model that PF4 and HIT show extensive
binding to the EC lining upon which platelets accumulate during the process of thrombus
growth. The area targeted by HIT antibodies spreads downstream of the original injury
site. These findings are significant because they emphasize the importance of the
vasculature as a target in HIT and a focus for novel interventions to complement
contemporary antithrombotic therapies. These include therapeutics directed to endothelial
PC receptor (EPCR), that block protease-activated receptors120, modify the glycocalyx
coat258 or inhibit oligomerization of VWF.
APC bound to EPCR activates PAR1 by a noncanonical cleavage259 leading to
improved EC barrier function and resistance to injury by TNF260,261. We have shown that
PF4 binds to TM, enhanced APC generation262. HIT antibodies block this effect, which we
proposed may contribute to thrombus development. To combat or bypass this effect, we
envision utilizing the peptide, Parmodulin-2, which blocks the PAR1/G13/RhoA pathway
and stimulates PAR1/Gq/Rak1 signaling120. This allows for the cytoprotective signaling
of PAR1 on ECs, but blocks the proinflammatory effects. This would allow us to evaluate
how maintaining EC health combats being directly bound by PF4 and HIT antibodies. To
distinguish between Parmodulin’s effects on ECs and its effects on circulating platelets,
we intend to study Parmodulin-2 in the photochemical injury model, incubating the drug
with whole blood prior to infusion and hematoporphyrin injury as a baseline. Parmodulin2 would be used in comparison to wildtype APC, and 2 variants that retain cytoprotective
effects with little anticoagulant effects. These studies will be made possible by obtaining
said parmodulins from Dr. John Griffin at the Scripps Research Institute263,264. The variant
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5A-APC can be used for studies of murine as well as human endothelium265, this allows
us to study the therapeutics in the HIT passive immunization murine model.
We will

modify the glycocalyx

using

heparinase,

chondroitinase,

and

hyaluronidase to cleave heparin sulfate, chrondroitin sulfate, and hyaluronan,
respectively. Treatment with these enzymes reduces the thickness of the glycocalyx layer
by 26-43% when used individually and up to 90% when used in combination12,15,258.
Removal of individual GAGs changes diffusion properties; this would suggest that these
three GAGs are not evenly distributed and differ in their contribution to its permeability.
Heparinase decreased diffusion, whereas diffusion was enhanced by the other two
enzymes258. This may imply that heparin sulfate plays a more important structural role and
its removal causes the collapse of the glycocalyx which compacts surface GAGs and
prevents solute diffusion. How changes in diffusion affects binding of PF4, HIT antigen
formation and the impact of immune injury on endothelial coagulant reactions will be
studied.
We envision HIT mice will be treated with these enzymes individually or in
combination, and then will be subject to injuries to cremasteric vessel as described in
Chapter 3. One key preliminary study will be to determine if removal of the glycocalyx
affects baseline platelet adhesion and activation by allowing blood cells to interact more
freely with the vascular wall. Nevertheless, by tracking PF4 and HIT antigen binding in
these settings as presented in Chapter 3, we will shed light on the significance of the
glycocalyx to the pathogenesis of HIT.

VWF offers a thrombosis-relevant binding site for HIT antigens and contributes to the
propagation of HIT.
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In Chapter 4, we showed that elongated strands of VWF released from EC post
injury generate extensive binding surfaces for PF4 and HIT antibodies. The PF4-VWF-HIT
antibody complexes enhanced platelet accumulation in our in vitro microfluidic model.
These findings are significant for various reasons. First, VWF strands are likely to be found
in arteries and arterioles and be present under high shear132,266. VWF release occurs under
inflammatory conditions that often are found in patients with HIT266,267 and are likely to be
release in response to immune injury. Thus, these new observations suggest that control
of endothelial activation may reduce the prothrombotic risks of HIT.
These findings suggest that HIT antibodies bind along the surface of ECs to
elongated strands of VWF and in doing so enhance platelet accumulation, along with
additional mechanisms that may be revealed in the future. The role of VWF in thrombus
formation in the cremaster laser injury model has been uncertain, but our group has shown
that suppressing ADAMTS13 activity in this model is prothrombotic and results in the
generation of elongated thrombi268. As visualized in Chapter 4, VWF strands from injured
ECs extend downstream along less injured ECs. This quality, in combination with
formation of PF4-VWF-HIT antibody complexes, implies that VWF continually sensitizes
ECs downstream of an injury site, allowing downstream thrombus extension in a process
we called “rolling recruitment” and consistent with thrombus propagation as visualized in
Step 3 (Figure 1.5). VWF also slows down platelets by allowing them to “roll” along the
strands of VWF132,269, where they may deliver PF4 to the adjacent downstream EC surface
extending the area of immune-targeted endothelium. The collective impact of these effects
support the role of endothelial cells injury and formation of extended strands of VWF in
the propagation of thrombi in space and extension of the procoagulant risk in time.
We also demonstrated that at least one proposed VWF-targeted therapeutic, NAC,
attenuated clot extension induced by HIT antibody in an in vivo model of vascular rose
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bengal-induced photochemical injury. NAC increased the time to occlusion and indeed
was completely prevented over the initial two hours following injury. It would be premature
to indicate VWF as a key contributor to all thrombotic events in HIT patients. However, our
findings do indicate that VWF-targeted therapeutics may provide a complement or
alternative to anticoagulants in some settings, e.g. thrombi in arterioles or large arteries,
and thereby increase the efficacy and potentially permit lower doses to be used and
thereby decrease the risks of bleeding.
We propose that the PF4-VWF-HIT antibody complexes contribute to arterial
thrombi because the necessary antigenic site requires oligomerization of VWF and shear
forces that open the individual molecules which exposes the requisite binding site.
Therefore, therapies directed at this complex will be mostly efficacious for arterial thrombi.
We will test this focusing on the use of recombinant ADAMTS13 as recently described in
mice270. We propose that such therapeutic intervention will be effective in arteriolar
thrombi, but not venule thrombi, and therefore, in the rose bengal carotid artery injury
model, but less so in a jugular injury model. This raises the intriguing possibility that VWFdirected therapies may help resolve most limb- or life-threatening thrombi caused by
arterial occlusion.
Additionally, we speculate that PF4 bound to VWF is physiologically relevant.
Binding of PF4 to VWF strands under shear may protect it from premature cleavage by
ADAMTS13 under arterial pressure. This suggests that PF4 might bind near the
ADAMTS13 binding site in VWF A2 domain138. We therefore propose that future studies
should also include a better understanding the 3-D structure of the complex between PF4
and VWF, including identifying the binding site(s). This will include utilizing electron
microscopy or cryo-electron microscopy to visualize PF4-VWF strand complexes to
compare against the prior crystallographic studies of the HIT complex using PF4 and
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fondaparinux137,271. Other studies using small drugs or VWF-derived peptides to compete
for PF4 binding will be tested as well. Finally, generation of VWF with the site of interest
mutated may need to be generated to validate PF4’s binding site within the native
molecule and to study the effect of shear.
To more definitively evaluate the impact of VWF, we will also be breeding VWF -//HIT mice to study vascular injury. This will be achieved by standard breeding to create
the double transgenic hPF4+/FcRIIA+ on the VWF-/- background272, but we will also
perform bone marrow transplant from HIT mice into VWF-/- mice. These mice will still
express platelet VWF, but will specifically lack the contribution of EC VWF to thrombi
development. These mice will be used in the rose bengal carotid artery and jugular vein
injury models, and the cremaster arteriole and venule laser injury models. Formation of
the HIT antigen and the time to occlusion will be studied. This will allow us to evaluate
how VWF impacts vessel occlusion, contributes to the thrombus growth, and alters HIT
antibody binding patterns relative to the site of injury. We believe that both the full VWF
knockout and the EC knock will show decreased arterial thrombi, but little or no change in
venular thrombi.

Neutrophil accumulation and NET release impact venous thrombosis in HIT.
In Chapter 5, we showed that NETs may play a similar role as VWF in propagating
HIT thrombi downstream, but on the venous side. After inducing HIT in the murine HIT
model by infusing KKO, we showed that neutrophils adhered to the venous, but not arterial
endothelial lining, even without additional injury. Additionally, downstream of a venous
laser-injury-induced thrombus, there was a marked increase in adhesion of neutrophils.
These migrated retrograde to be incorporated in the growing thrombus. In an in vitro
microfluidic model, we displayed that PF4 and HIT antibodies can bind NETs and provide
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DNase resistance. These all contribute to venous thrombosis by inducing EC and blood
cell activation, physically contributing to thrombus size, and forming PF4/NET/HIT
antibody complexes, which further propagate thrombosis. These findings provide insight
into how neutrophils selectively contribute to venous thrombosis in HIT.
Moreover, the studies introduce novel avenues for mitigating HIT thrombosis,
which include inhibiting neutrophil-endothelial adhesion, preventing the chemotaxis of
neutrophils to growing thrombi, and suppressing NET release or NET lysis. Future studies
will focus on assessing these therapeutic avenues by using similar models as those
described in Chapter 5. To impede neutrophil-endothelial adhesion and neutrophil
chemotaxis, we also propose that blocking antibodies to neutrophil-relevant selectins
and/or integrins273,274 might decrease the prothrombotic venous risks of HIT. For example,
crizanlizumab, a P-selectin blocking antibody was shown to significantly lower the rate of
sickle cell related pain crises in patients with sickle cell disease274. Alternatively, CL2 is an
antibody that blocks the binding of leukocytes to E-selectin273 and was shown to reduce
the extent of neutrophil transmigration to a site of inflammation during an acute
inflammatory response. Each have potential to combat the enhanced adhesion of
neutrophils seen to the venous lining seen in our studies and to the downstream
accumulation of neutrophils in venous thrombi. Recent studies have also shown a mouse
model which utilizes an adenovirus-mediated expression of endomucin to reduce
neutrophil adhesion275. Endomucin is a membrane-bound glycoprotein that normally
prevents leukocyte-EC interaction, but is downregulated with inflammation (TNFα)
stimulation. This will allow us to evaluate the most effective and therapeutically relevant
means of impeding neutrophil contribution to HIT thrombosis. Additionally, there is an
opportunity to target the rates of NET formation or degradation to limit their effects. Our
future studies will include investigating such agents, which include N-acetylcysteine,
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DNase I, PAD4 inhibitors, and acetylsalicylic acid150,183,189,194,276,277. Despite the fact that
anti-VWF and NET agents are not considered anticoagulants, they may still result in
adverse side effects such as bleeding or immune defects, and therefore, their utility in the
murine HIT model in conjunction with DTIs needs to be examined.

Novel ICAM-1 targeted therapeutics reduce inflammatory thrombosis in sepsis model
In Chapter 6, we showed the potential for using ICAM-1-targeted TM to inhibit or
delay inflammatory thrombosis in an endothelialized microfluidic sepsis model. We were
able to show that this targeted therapeutic was more effective at inhibiting TF-driven
thrombosis than untargeted therapeutics such as soluble human TM and hirudin.
Moreover, we showed this antithrombotic effect was PC-dependent and was
synergistically effective with supplemental PC. This provides significant insight into
potential treatments for the inflammatory-driven side of HIT. The current treatments for
HIT are DTIs, which have limitations in that they have increased risk of bleeding diathesis,
and consequently, require frequent patient monitoring41,44. The advantages of targeted TM
is that it will primarily bind where inflammation has induced increased ICAM-1 levels;
moreover, considering its PC-dependent functionality, the targeted TM will also be
selectively antithrombotic in regions in which there is sufficient FIIa to bind TM leading to
increased APC production. Furthermore, because the therapeutic is TM, the other TM
domains can provide additional anti-inflammatory and anti-activated endothelium effects
not seen with DTIs. A site selective antithrombotic that also combats inflammatory
components could provide a unique solution to the VWF- and NET-associated EC-related
mechanisms of thrombosis seen in HIT. Future studies in this realm will focus on
integrating this therapeutic into cremaster murine models of HIT to determine the feasibility
for preventing and mitigating HIT thrombosis on both the venous and arterial sides. There
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is also interest in utilizing the targeting mechanism used in this therapeutic for other
antithrombotics. An intriguing therapeutic could be an scFv-derived from a HIT antibody
like KKO that binds to the PF4 antigenic site exposed when it is bound to GAGs, VWF and
NETs and that would target a therapeutic to HIT antigen-rich sites.

Impact of the Described Research
Understanding the prothrombotic nature of HIT.
From a broader perspective, this research has the potential to impact our
understanding, research approach, and treatment paradigm around HIT. In gaining a
better understanding of how the endothelium (Chapter 3), VWF (Chapter 4), and NETs
(Chapter 5) can form HIT antigenic complexes, we’ve provided new insights into the
pathophysiology of thrombosis in HIT and the prolonged period of risk for recurrent
thromboembolic complications (Step 3). We envision HIT as developing in three distinct
all be it, overlapping, steps: Step 1: initiation by PF4/heparin complexes; Step 2: activation
of intravascular cells (monocytes, platelets) causing thrombosis; and Step 3: antigen and
thrombus propagation during which additional PF4 binding surfaces as generated that
create a procoagulant positive feedback loop that is entirely independent of heparin.
With these studies, we have opened doors to additional future research questions:
In what situations are these complexes most paramount to the propagation of HIT? How
well do the various polymeric targets compete for PF4 in time and space? How do the
location and affinity of these complexes impact the clinical course of HIT and what are the
implications for response to current therapy? Future research could include in vivo studies
using various injury settings with co-visualization of the EC glycocalyx, VWF, and
neutrophils/NETs. This research could include using microfluidic studies to identify the
binding preference of PF4 under flow in presence of these various polymeric targets in the
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absence and/or presence of heparin. Both endothelial cell heterogeneity within the
vasculature, genetic and epigenetic risk factors remain wide open to exploration as well.
Ultimately, these studies hold the potential to alter diagnosis and treatment in HIT.
Across many healthcare fields, researchers are looking for physiological parameters that
can be used for predictive analytics and predictive diagnosis; these predictive measures
provide a means of knowing and treating a patient’s pathology before it manifests into a
tangible phenotype, which helps reduce medical cost, reduce treatment time, and improve
patient outcomes. Predictive diagnosis would be very valuable in HIT considering its
endpoints and our studies provide additional parameters that could have predictive
significance. Prior studies would have placed patients with prior heparin exposure or
bacterial infections at risk for HIT. But our studies now implicate the composition of the
glycocalyx, levels and glycosylation of VWF, and neutrophil activation as having a higher
propensity for HIT associated endpoints. Preemptive measures taken at the first clinical
sign of HIT could include the use of non-anticoagulant reagents such as blocking
GP1bAK2 antibody), blocking FcRIIA (IV.3 antibody), or removing ultra-large VWF
multimers (NAC or ADAMTS13) which may reduce thrombus extension, permit the
intensity of anticoagulation to be lowered in the setting of thrombocytopenia, and lessen
the risk of recurrent thrombembolism.

New insights into hemostasis and thrombosis in other clinically relevant settings.
These studies may also impact how we should view the relationship between
hemostasis and thrombosis. Hemostasis is viewed as a delicate balance between proand anti-coagulative forces with thrombosis being the tipping of that scale. Consequently,
therapeutics are generally foreign reagents that aim to tip that scale back to balance. This
attempt to balance leads to the risk of under or overshooting hemostasis allowing clotting
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to continue or causing inadvertent bleeds. Alternatively, our studies show that hemostasis
and thrombosis should be viewed as a reestablishment of a standard vascular milieu. As
described in Chapter 6, TM was targeted to ICAM-1; this allowed the therapeutic to
replenish the TM on the surface of ECs that was shed during injury. Treating thrombosis
by replenishing the proteins altered during injury presents a potential avenue to more
precise therapeutics with less side effects. In reference to HIT, reestablishing the
glycocalyx or correcting concentrations of ADAMTS13 could provide unique treatment
strategies with less risk that the currently used DTIs.
These studies have implications for our understanding of other thrombotic
disorders. In lupus, antibodies develop to DNA found in NETs. Studies are in progress to
assess the impact of such antibodies on NET formation and resistance to DNases and the
risk of thrombosis, as are agents that prevent neutrophil accumulation in thrombi and
release of NETs. In the catastrophic antiphospholipid syndrome (CAPS), thrombosis may
involve diffuse endothelial activation which may also involve the release of VWF,
generation of NETs compacted by PF4, similar to the events we describe here in HIT.
Whether therapeutics designed to affect thrombus formation of HIT are also pertinent to
the management of other thrombotic disorders requires additional experimentation.
Lastly, these studies should impact how to study vascular injury ex vivo. One of
the major advances we made was improving the performance of the endothelialized
microfluidic system. The ability to observe intravascular cell binding to the endothelium
and the development of thrombosis under physiological flows in real time provided insight
that would otherwise not be feasible. For example, we observed that the stranded VWF
had higher affinity for PF4, and subsequently, KKO. The elongation and conformational
changes presented by VWF when tethered to an EC would be difficult to replicate in other
ex vivo settings. There are devices that induce shear138,145,150 and may alter VWF
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confirmation, but none provide the environment of an EC monolayer grown to confluency
in 3 dimensions displaying large multimeric VWF fibers. Previously, ELISAs or similar
technologies were the primary means of measuring PF4 and antibody binding. This has
obvious limitations in not allowing for flow, real time imaging, or the overall cellular
environment present in the microfluidic setting. Moreover, when considering in vivo
models, despite providing great insight, they also present certain limitations. Relevant to
studies of HIT, in vivo models make it more difficult to decipher the minute interactions
and contributions as we saw with PF4 binding VWF; in vivo imaging of VWF in thrombi
have historically displayed diffused staining and have not been able to image the strands
of VWF released by ECs. The microfluidic realm gives us the ability to better recapitulate
the in vivo environment while still maintaining more control and specificity of unmodified
or modified cells studied, flow rates and other physical parameters – such as temperature
and oxygen level – and drug exposure. They allow studies of cells from multiple different
species and also allow studies of a cell line and primary cells in 3D.

Summary
This thesis focused on studies of the prothrombotic processes underlying HIT. We
found that PF4 and HIT antibodies predominantly bound to perithrombus endothelium in
the absence of damage and even more so in the setting of HIT. Further investigation led
to the discovery that VWF and NETs participate in the prothrombotic propagation of
thrombi in HIT. We observed the formation of PF4-VWF-HIT antibody complexes that
promoted platelet accumulation that was propagated downstream. These observations
offer potential new therapeutic targets in HIT, which will be a focus of future studies. In
addition to the studies on NETs, we also define how neutrophils contribute to venous
thrombi in HIT. We culminated our studies with an investigation into combatting
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inflammatory thrombosis in a sepsis model, which provides insights into the effect of
inflammation which may precede or accompany HIT. Using a novel ICAM-1 targeted TM
therapeutic, we saw that targeted TM inhibited TF induced thrombosis via a PC-dependent
pathway more efficiently than soluble reagents. Collectively, this thesis work provides a
more defined understanding of the pathogenesis of thrombosis in HIT and related
inflammatory states and provides insights into potential novel therapeutics.
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